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As humans age, specific mental faculties deteriorate even in the absence of dementia. Age 
related cognitive decline affects quality of life, and has significant implications from a socio-
economic perspective; however not everyone declines to equal degrees, at equal rates, or 
from the same baseline. This PhD examined a large sample of community-dwelling older 
adults called the Lothian Birth Cohort 1936, most of whom completed an intelligence test at 
age 11 years, and again around age 73 as part of a detailed assessment that also included 
detailed brain magnetic resonance imaging (N range = 700-866). I investigated the 
independent effects of two linked genetic loci which have been associated with greater risk of 
Alzheimer’s disease – the APOE ε haplotype (commonly ‘genotype’) and a poly-T repeat in 
the TOMM40 gene. Are 'risk' variants in these loci associated with specific measures of 
cognitive ageing and brain structure - specifically white matter microstructural integrity, 
hippocampal volumes, white matter lesions or cerebral microbleeds – in this sample? 
Firstly, a pilot study aimed to replicate significant associations between the ADRB2 
gene and brain imaging/cognitive phenotypes, that had previously been reported in a smaller 
subsample of the cohort that had by that time undergone MRI (n = 132). Previously reported 
significant associations were not significant in the larger, full LBC1936 sample (n = 700-
866), but novel significant associations were found (P < 0.05). Specifically, integrity of the 
left arcuate fasciculus white matter tract significantly mediated part of the association 
between specific genetic variations at ADRB2, and the Digit Symbol Coding task of 
information processing speed. These findings indicated that this approach – testing three-way 
genetic/brain imaging/cognitive associations for mediation - was viable for the main 
APOE/TOMM40 analyses.  
Results in the main APOE/TOMM40 analyses showed that specific variants in the 
APOE and TOMM40 gene loci were statistically significantly associated (at raw P value < 
XIX 
 
0.05) with white matter tract microstructural integrity, but not white matter lesions, 
hippocampal volume or cerebral microbleeds. Inconsistencies with previous, positive reports 
showing significant associations between APOE ε and these latter phenotypes may reflect a 
degree of type 1 error or more study-specific discrepancies (which are detailed throughout). 
APOE ε was significantly associated with average scores on a large proportion of cognitive 
tests, independent of age 11 intelligence (i.e. ‘cognitive ageing’; Deary et al., 2004). These 
associations were partly – but not completely – mediated by white matter tract 
microstructural integrity. TOMM40 poly-T repeat genotype was associated with cognitive 
ageing to a much lesser extent. A range of brain phenotypes may form the anatomical basis 
for significant associations between APOE genotype and cognitive ageing, among which 
includes white matter tract microstructural integrity. 
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On average, there is some age-related decline of specific mental functions in humans. Non-
pathological mental decline – ‘cognitive ageing’ - has significant implications for individuals 
and their families in terms of quality of life, and for society as a whole in terms of financial 
burden (Hofer and Sliwinski, 2000; Mirkin and Weinberger, 2002; Deary et al., 2007). 
Individuals vary in terms of older age cognitive ability, but also vary in terms of baseline 
childhood ability and rate of change. It is important to understand the risk factors, modifiers 
and anatomical substrates of this change (Deary et al., 2007). By examining genetic 
contributions to cognitive ageing and structural brain magnetic resonance imaging (MRI) 
phenotypes in a relatively large sample of community-dwelling older adults, this thesis aims 
to contribute to understanding of these mechanisms.  
The following sections outline the broad context of this PhD thesis (i.e. the ageing 
population), followed by a more specific background to the cognitive, imaging and genetic 
variables investigated, and the aims, dataset and outline of this thesis. 
 
1.2. Context 
1.2.1. An ageing population 
The life expectancy of the world’s population is increasing. In 1950, there were 205 million 
older adults globally, compared with 606 million in the year 2000, and a predicted two billion 
in 2050 (i.e. aged ≥ 60 years; UN World Population Ageing report, 2002). This is due to a 
number of factors including but not limited to: improvements in healthcare, home/working 
environments, health and safety legislation, and dissemination of health information (e.g. 
anti-smoking, pro-exercise advertisements; Whalley and Smyth, 2013).  
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The UN World Population Ageing 1950-2050 report (2002) examined data taken 
from several sources of official worldwide population data.  This report suggests that a range 
of factors (as described above) contribute to two main driving forces behind population 
ageing:  
1. Total fertility rate has decreased, e.g. between the periods 1950-1955 (2.8 children born 
per woman in developed regions) and 2000-2005 (1.5 children).  
2. Life expectancy rates have increased, e.g. between the periods 1950-1955 (average global 
life expectancy = 46.5 years at death), and 2000-2005 (66.0 years).  
This is indicative of a demographic shift where, as the ‘baby boom generations’ age, and with 
fertility rates low, the proportion of older adults relative to other demographics becomes 
significantly greater (UN World Population Ageing report, 2002). Using similar data up to 
2006,  Lutz et al. (2008) predicted  proportionate  increases in the older aged population (i.e. 
≥60 years) in North America from 0.16 (out of 1; relative to the entire population) in the year 
2000, to 0.18 in 2010, 0.23 in 2020, and 0.27 in 2030.  
 
1.2.2. The implications of an ageing population  
The UN World Population Ageing report (2002) describes two major consequences of a 
demographic shift towards an ageing population: 
1. The ratio of individuals that are in some way dependent upon others will increase 
significantly, based on the assumption that all persons under 15 or over 65 years of age 
will require at least some form of support. 




This is likely to impact significantly upon economic growth due to reduced labour and output 
coupled with increased healthcare and general support costs (e.g. out-patient dependency 
programs, disabled access; Zhao et al., 2013).  
 
1.2.3. Cognitive ageing 
Successful ageing extends beyond the absence of mental or physical illness to include 
personal independence and autonomy; this requires relatively intact mental faculties (World 
Health Organisation, 2003; Fiocco and Yaffe, 2010). Specific cognitive abilities such as 
attention and memory are relevant for higher-order skills such as planning and decision 
making, and these are important in terms of maintaining independence and a good quality of 
life – for example, remembering to take medication, prepare meals safely, and manage 
finances (Fiocco and Yaffe, 2010; Burton et al., 2007). Losing mental function is among the 
most feared aspects of ageing (Martin, 2004).  
What factors influence the natural age-related decline in a person’s ability to process, 
manipulate, recall and communicate complex information? Individuals vary along a 
continuum of cognitive ageing, and past studies have examined a range of potential risk 
factors including but not limited to: cardiovascular disease pathologies, specific genetic 
variables, levels of education, and smoking/alcohol/dietary intakes, among other potentially 
important variables (Korczyn and Vakhapova, 2007; Deary et al., 2009; Plassman et al., 
2010). 
Cognitive ability in older age plays a significant role in maintaining independence and 
quality of life. This is important from both compassionate and socioeconomic perspectives, 
and it is therefore critical to understand the risk factors and anatomical brain substrates 




1.3. Thesis background 
1.3.1. Specific cognitive abilities are more sensitive to age 
Cognitive ability can be fractionated into different domains, such as memory or reasoning. 
This observation is based on statistical methods such as factor analysis of different cognitive 
tests (e.g. Carroll, 1993; Salthouse, 2010; Penke et al., 2012), and on patterns of 
neuropsychological impairment in groups of participants with specific brain lesions (i.e. 
preservation of some cognitive abilities, but not others; e.g. Della Sala et al., 2004).  
There is evidence that specific aspects of cognitive ability are more sensitive than 
others to the effects of age. For example, tasks of ‘fluid’ intelligence, e.g. executive 
functions, information processing speed, declarative memory, are more affected by age 
compared with aspects of ‘crystallized’ intelligence (i.e. general semantic information such as 
vocabulary), which are generally relatively resilient to age (Horn & Cattell, 1966; Salthouse, 
2010; 2011). In evidence of this, Wilson et al. (2002) examined 694 older adults in the 
Religious Order Study, a longitudinal assessment of older Catholic nuns, priests and brothers. 
The participants showed no evidence of Alzheimer’s disease (AD), in that they all scored 
above 24 on the Mini Mental State Exam, a common screening tool for dementia (out of 30; 
MMSE; Folstein et al., 1975). Participants were of varying ages (mean age = 75.9 years, 
standard deviation [SD] = 6.9), and they completed a range of tests including declarative 
memory (split into ‘Story retention’ and ‘Word retention’), ‘Word knowledge’ (reflecting 
crystallized intelligence), working memory, ‘Perceptual speed’ (i.e. information processing) 
and visuospatial tasks (21 tests in total). They found greater effects of cross-sectional age at 
time of assessment for fluid-type tests (Story retention r correlation with age = -0.29, Word 
retention r = -0.37, Working memory r = -0.30, Perceptual speed r = -0.42, Visuospatial 
ability r = -0.34), than for Word knowledge (r = -0.10; reflecting crystallized ability; specific 
P value not provided). 
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1.3.2. Cognitive ageing is modified by different variables including specific genetic 
loci 
Cognitive ageing may be modified by a number of variables, including environmental or 
genetic risk factors (Haan et al., 1999). Evidence of a significant role for genetic variation on 
cognitive ageing is provided in a large study by Davies et al. (2012). Davies et al. conducted 
a genome-wide association study on cognitive ageing based on five large discovery cohorts 
(Lothian Birth Cohorts 1921 & 1936 [LBC1921/1936]; Aberdeen Birth Cohort 1936 
[ABC1936]; Manchester and Newcastle Longitudinal Studies of Cognitive Ageing Cohorts 
[the University of Manchester Age and Cognitive Performance Research Centre; ACPRC, 
and North East Ageing Research; NEAR cohorts, respectively]), totalling 3802 participants. 
Significant associations were re-tested in two replication cohorts (total N = 1367). General 
factors of cognitive ability were created for each of the cohorts, using different tests of fluid 
intelligence, by principal components analysis (PCA). Each score was then adjusted for 
premorbid ability; either with measures of childhood intelligence (LBC1936/1921 and 
ABC1936), or with growth curve models based on data from up to four time points, including 
ability at 10 years prior (ACPRC/NEAR cohorts). Older age ability adjusted for prior ability 
was considered ‘cognitive ageing’. Participants in the discovery groups were genotyped for 
549,692 common single nucleotide polymorphisms (SNPs) plus a bespoke assay for 
apolipoprotein (APOE) ε2/ε3/ε4 status. They found that possession of the APOE ε4 allele (vs. 
possessing only ε2 or ε3 alleles) was associated with significantly worse cognitive ageing 
(unstandardised β = -0.22, standard error = 0.04, P = 2.18 x 10
-8
), and that no other SNP 






1.3.3. The anatomical brain substrates of cognitive ageing 
There is evidence that fluid-type intelligence tests tend to be more sensitive to the effects of 
age, compared with more crystallized-type tasks (Wilson et al., 2002; Salthouse, 2011). A 
logical extension of this is that specific brain substrates are more sensitive to age, and 
underpin these significant fluid-type cognitive associations with age. Schretlen et al. (2000) 
examined how frontal lobe volumes underpinned associations with cognitive ability. In 112 
participants (mean age = 54.0, SD = 19.0) detailed cognitive and brain MRI assessments were 
performed. They constructed crystallized and fluid-intelligence ‘factors’ using principal 
components analysis (PCA). Based on eight tests of semantic (e.g. Information) and fluid-
spatial (e.g. Block Design), ability, they generated two factors: a crystallized ability factor 
that accounted for 36.7% of the variance (r with age = 0.64, r with education = 0.66), and a 
fluid ability factor that accounted for 31.1% of the variance (r with age = -0.56, r with 
education = 0.32). They found that frontal lobe volumes correlated significantly with age (r = 
-0.28, P = 0.003), but overall brain volume minus frontal volume did not (r = 0.16, P = 
0.100). Comparing models for the fluid factor, Schretlen et al. found that a model with age (β 
= -0.39, P < 0.001) was improved significantly by adding frontal lobe volume (β = -0.27, P 
<0.001, total variance explained = 61%, an increase of 37%). Therefore the model was 
significantly improved by adding frontal lobe volumes (F [2, 109] = 32.6, P <0.001). This 
was not the case with brain volume minus frontal lobe volume (all P > 0.05), indicating a 
degree of frontal lobe structure-function specificity.  
There are limitations to the above (and similar) studies which investigate anatomical 
substrates to specific cognitive abilities. Each specific brain imaging phenotype is only 
partially informative and a range of brain imaging phenotypes are therefore required to 
elucidate the more precise underpinnings of the specific cognitive abilities tested. This also 
means that only relatively large sample sizes are likely to provide reliable results (Salthouse, 
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2011). Penke et al. (2010a) for example investigated the role of white matter integrity using 
different metrics, one of which was fractional anisotropy (FA). White matter is characterised 
by a fatty myelin layer that permits efficient communication between brain regions, and is 
therefore a plausible substrate of cognitive functioning (Penke et al., 2010a). Penke et al. 
reported that a general factor of white matter tract integrity FA (gFA), constructed with 
principal components analysis (PCA), was significantly associated with a general factor of 
information processing speed (r = -0.24, P = 0.007) in a subsample of the LBC1936 dataset 
that had by that time undergone diffusion tensor MR imaging (DTI; n = 132; aged around 73 
years). In a later study examining a larger sample of the LBC1936 cohort, gFA significantly 
associated with general fluid-type cognitive ability (g; standardized β = 0.13, P < 0.05) 
explaining around 10% of the variance (n = 420; Penke et al., 2012). 
   
1.4. Genetic variables 
To recap, cognitive ageing is affected by a number of variables including genetic factors, one 
of which may be the APOE locus, and it is possible that these associations occur via 
intermediate brain imaging phenotypes. It is possible that other variables – possibly genetic - 
moderate the effects of APOE or exert independent effects. This section details APOE in 
addition to a linked, possibly modifying locus in the translocase of outer mitochondrial 
membrane 40 (TOMM40) gene, and their collective relevance to brain ageing.  
 
1.4.1. Apolipoprotein-e (APOE)  
The APOE gene is located on chromosome 19q13.2 and is 3.7 kilobases (KB) long. The 
APOE ɛ haplotype (commonly and herein referred to as ‘genotype’) is composed of two 
SNPs; rs429358, which causes a Cys130Arg substitution; and rs7412, which causes an 
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Arg176Cys substitution (http://www.ncbi.nlm.nih.gov/gene/348). Different combinations of 
the rs329358/rs7412 SNPs form the ɛ2 (Cys/Cys respectively), ɛ3 (Cys/Arg) and ɛ4 
(Arg/Arg) genotypes (Ringman and Cummings, 2009). Of these, the ɛ3 allele is the most 
common (frequency ~78.3%), followed by ɛ4 (~14.5%) and ɛ2 (~6.4%), although this can 
vary by population (Eisenberg et al., 2010).  
APOE plays a role in the transport and metabolism of lipid in the human body and 
brain (Corder et al., 1994; Bu, 2009). The lipid family includes cholesterols, sphingolipids, 
fatty acyls, glycerolipids, glycerophospholipids, cardiolipids, sterols, triglycerides and 
high/low density lipoproteins, and is important for energy storage and maintaining the 
structure and function of cellular membrane (Fahy et al., 2008). The ɛ4 allele preferentially 
binds to large lipoprotein particles (Bu, 2009), and for several phenotypes is the ‘risk’ variant 
compared with ɛ3 (‘neutral’), and ɛ2 (‘protective’, although less consistently). These 
phenotypes include: risk of Alzheimer’s disease (AD) (Corder et al., 1994); less successful 
cognitive ageing (Deary et al., 2004; Wisdom et al., 2011); differences in brain structure e.g. 
atrophy (Biffi et al., 2010) and functional connectivity (Trachtenberg et al., 2012); and 
cardiovascular pathologies such as hyperlipidaemia, coronary heart disease and stroke 
(Stenset et al., 2006). It is not clear to what extent associations between APOE ε4 and worse 
cognitive ageing reflect preclinical ‘prodromal’ AD or mild cognitive impairment (MCI) 
(Bretsky et al., 2003; Deary et al, 2004). 
The majority of associations between single common candidate gene variants (i.e. 
with minor allele frequencies above 5%) and complex disease traits do not replicate in 
independent samples due to inadequate power, differences in study design/analytic strategy 
and low prior probability of true association; any one candidate gene locus is only likely to 
explain a small amount of total phenotypic variation (~4-5%; Hattersley and McCarthy, 
2005; Munafo et al., 2006). APOE ε4 has been significantly associated with greater risk of 
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AD in a number of independent samples, and is a generally accepted risk factor for AD 
(Corder et al., 1994; Hardy and Higgins, 1992; Hardy, 2006). For example Farrer et al. 
(1997) demonstrated significant association between APOE ɛ4 and AD in several large 
samples. They examined 40 independent samples, including individuals diagnosed with AD, 
and healthy controls, stratified by race into Caucasian (sample N’s = 5107 vs. 6262, 
respectively), African American (N = 235 vs. 240), Hispanic (N = 261 vs. 267), and Japanese 
(N = 336 vs. 1977) analyses. Statistically adjusted for age, gender and cohort membership 
(i.e. research centre), in the Caucasian sample they found significant deleterious effects of the 
ɛ2/ɛ4 (odds ratio [OR] = 2.6, 95% C.I’s = 1.6 to 4.0), ɛ3/ɛ4 (OR = 3.2, 95% C.I’s = 2.8 to 
3.8), and ɛ4/ɛ4 (OR = 14.9, 95% C.I’s = 10.8 to 20.6), vs. the neutral ɛ3/ɛ3 genotype. These 
results were similar in different ethnicities, reflecting deleterious effects of the ε4 allele.  
The APOE ɛ4 allele may contribute to phenotypic differences through different and 
possibly interactive mechanisms: 
1. By promoting the build-up and inhibiting the clearance of amyloid-beta plaques in the 
brain. Accumulations of amyloid-beta disrupt synaptic transmission, and along with 
high levels of neurofibrillary tangles (NFT) this pathology is most characteristic of 
clinical AD (Martins et al., 2006; ‘Amyloid Cascade Hypothesis’, Hardy and Higgins, 
1992). 
2. Through secondary association with cardiovascular pathology. This could be by 
hindering communication between the heart and brain (specifically known as 
cerebrovascular disease e.g. atherosclerosis; Erkinjuntti, 2007; De la Torre, 2010). 
Cardiovascular diseases such as hypertension are common risk factors for 
cerebrovascular disease (De la Torre, 2010) 
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3. Disrupting the effective transport of cholesterol. This is essential for the development 
and maintenance of neurons and the myelin sheaths that characterise white matter 
(Ringman and Cummings, 2009; Martins et al., 2006; Hooijmans and Kiliaan, 2008). 
It is thus generally agreed that APOE ε4 genotype is a significant risk factor for AD 
pathology, yet the association with clinical AD or cognitive decline is far from perfect 
(Johnson et al., 2011). There is heterogeneity in cognitive decline that APOE genotype does 
not account for, and which may be explained by other factors (Crenshaw et al., 2013). Other 
genetic variants aside from APOE may play a role.  
 
1.4.2. Translocase of Outer Mitochondrial Membrane 40 (TOMM40)  
Mitochondrial dysfunction may play a significant role in cognitive decline and AD pathology 
(“mitochondrial cascade hypothesis”; Swerdlow et al., 2010).  The mitochondrial cascade 
hypothesis is based on the observation that the amyloid cascade hypothesis fails to account 
for physiological changes in people diagnosed with AD, that are not limited to the brain – 
such as reduced cytochrome oxidase activity, greater free radical production and evidence of 
greater oxidative stress (Kish et al., 1992; Parker et al., 1990). The amyloid cascade 
hypothesis also fails to consider that amyloid precursor protein and amyloid-beta 
accumulations that are similar to those found in clinical AD can also be found in people with 
traumatic brain injury, suggesting they are actually a secondary reaction or response to 
separate, more primary deleterious changes in the brain (Reitz, 2009).  
The mitochondrial cascade hypothesis is based on certain core assumptions (adapted 
from Swerdlow et al., 2010):  
1 Baseline mitochondrial function, viability and rate of natural decline are determined by 
nuclear genetic and environmental variables. 
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2 Decline in mitochondrial function drives age-related change in a number of biological 
phenotypes, but is compensated for throughout the lifespan through changes in cell 
physiology. 
3 Histological changes typical of AD such as amyloid-beta pathology begin to manifest 
during the compensatory phase.  
4 This compensation fails at a certain point, and histological changes that more closely 
resemble clinical AD begin to manifest as a consequence, including tau phosphorylation, 
synaptic loss, cell cycle re-entry and latent neurodegeneration. 
5 The above assumptions explicitly consider common factors to be underlying age-related 
changes and also AD. In terms of the pathological processes leading to AD, the 
mitochondrial cascade hypothesis considers mitochondrial dysfunction to occur earlier 
than the amyloid-beta accumulations found in clinical AD (Ferencz et al., 2012). 
TOMM40 encodes the channel-forming subunit of the translocase of outer mitochondrial 
membrane (TOM) complex (http://www.ncbi.nlm.nih.gov/gene/10452; Humphries et al., 
2005). This complex imports precursor proteins into mitochondria (Koehler et al., 1999). 
Specifically, precursor proteins in the cytosol first bind to import receptors Tom-20 and Tom-
70 on the mitochondrial surface. The channel-forming Tom-40 is then the basis of a ‘core 
complex’ (together with the smaller receptors Tom-22, -7, -6 and -5), which creates a protein-
conducting pore that transports precursors across the outer membrane, into mitochondria 
(Rapaport, 2005). It has been suggested that APOE and TOMM40 may interact to affect 
mitochondrial dynamics although mechanistically it is unclear exactly how this may occur 
(Roses et al., 2010).   
The rs10524523 locus (hereafter ‘523’) in TOMM40 is characterised by a variable 
number of T residues (poly-T repeats) that can be grouped into ‘Short’ (<20; ‘S’), ‘Long’ 
(20-29; ‘L’), and ‘Very-Long’ (≥30; ‘VL’) (Lutz et al., 2010). Roses et al. (2010) plotted 
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histograms showing the distributions of poly-T repeat lengths in different APOE genotypes; 
ɛ3/ɛ3, ɛ3/ɛ4 and ɛ4/ɛ4. The poly-T repeat was strongly linked with the APOE ɛ haplotype; ɛ4 
is linked to L, with ɛ3 linked to either S or VL alleles (Roses et al., 2010; Figure 1.1). The 
rarer ɛ2 allele appeared to show similar linkage to S or VL alleles in TOMM40 523 - as per 




Figure 1.1. Frequencies of TOMM40 ‘523’ poly-T repeat lengths stratified by APOE ε3 
(top) and ε4 alleles (taken from Roses et al., 2010). 
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The TOMM40 523 repeat is of particular interest because a large number of SNPs in 
the APOE/TOMM40 region are in significant linkage disequilibrium (e.g. rs429358 and 36 
SNPs within ±1.17 KB of the APOE region including 15 TOMM40 SNPs; average D’ = 0.91, 
r
2
 = 0.22, N = 1262; Takei et al., 2011). This means that it is difficult to extrapolate effects of 
SNPs in the region that are truly independent from APOE ɛ4 (Hong et al., 2010; Davies et al., 
2012). In contrast, recent studies have reported effects of TOMM40 523 independent of 
APOE ɛ genotype. An illustrative example comes from Crenshaw et al. (2013). They 
examined 508 generally healthy, non-demented older adults (mean age = 74.0, SD = 9.5; 
baseline MMSE score mean = 29.0, SD = 1.3) that were cognitively assessed prospectively 
on fluid-type cognitive tasks considered sensitive to the effects of age (Weintraub et al., 
2009; Morris et al., 2006). They examined how TOMM40 523 genotype influenced the 
prospective onset of cognitive impairment (i.e. marked decline in performance based on a 
range of cognitive abilities; conversion events = 106). They stratified the sample by APOE ε; 
keeping this constant allowed Crenshaw et al. to test for biologically independent effects of 
TOMM40 523. Crenshaw et al. observed marked variation in the onset of impairment with 
age, according to TOMM40 523 genotype. Specifically, note that in APOE ε3/ε3 genotype 
subgroup, the S/S group has proportionally greater and earlier onset of cognitive impairment 
compared with the VL/VL genotype group, with S/VL intermediate. Although Crenshaw et 
al. did not test for significance, Figure 1.2 demonstrates the heterogeneity that may exist 









Recent studies have shown relatively consistent, significant associations between 
TOMM40 523 genotype and brain-related phenotypes such as age of AD onset (Roses et al., 
2010), and brain phenotypes such as medial temporal lobe gray matter volumes (Johnson et 
al., 2011), independent of APOE. These reports are detailed in Table 1.1. Reports vary in 
showing protective, null or deleterious effects of the S allele (e.g. Johnson et al., 2011; Chu et 
al., 2011 & Cruchaga et al., 2011 respectively). These conflicting reports suggest that 
investigations of the TOMM40 523 poly-T repeat should not make a-priori predictions 
regarding direction of association.  
Figure 1.2. Fractions of older individuals (baseline N = 508) that are classified as 
having cognitive impairment, stratified by APOE genotype groups, to illustrate the 
independent effect of TOMM40 ‘523’ poly-T repeat length (S = Short; L = Long; VL = 
Very-long). Taken from Crenshaw et al. (2013) 
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The exact functional significance of TOMM40 523 poly-T repeat length is a matter of 
ongoing research. Bekris et al. (2011; N = 32) conducted functional analysis of different 
poly-T repeat haplotypes on reporter assay expression levels in SHSY5Y, HepG2 and U118 
neuronal cell lines. Results indicated that specific TOMM40 523 haplotypes were associated 
with lower TOMM40 – but not APOE – gene expression in SHSY5Y neuronal cell lines only, 
indicating a role for this locus in TOMM40 promoter silencer/enhancer activity, but that the 
direction of its effect on expression depends on the cell type and specific haplotype content. 
Hedskog et al. (2012) assessed the biochemical properties of different poly T repeat lengths 
in fibroblast cell cultures taken from APOE 3/4 carriers (S/L vs. VL/L only, n = 8). They 
observed no significant differences between groups in terms of: i) TOMM40 gene mRNA 
splicing, stability or expression, ii) protein expression levels of APOE, TOMM40 or 
Presenilin-2 (PSEN2; linked to familial AD), or iii) transcription/translation of the TOMM40 
protein. Additionally, they found no evidence of poly-T repeat lengths affecting 
mitochondrial function (assessed by ‘ΔΨm’, reflecting depolarization of transmembrane 
potential), morphology or biogenesis (indicated by mitochondrial volume density per 
fibroblast cell). Similarly, in a sample of healthy (n = 39) and AD participants (n = 82), 
Cruchaga et al. reported that poly-T repeat length was not significantly associated with 
protein expression as measured using complementary DNA obtained from the parietal lobe. 
(Further study of poly-T repeat function and significance – beyond these detailed studies - is 
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Notes & limitations 




Neurofilament light protein 
levels in CSF (ng/l); a 
marker of neuronal damage 
where ↓ = possible axonal 
loss. 
(S+ vs. S-, stratified by 
APOE ε4+ & ε4-). 
 
Healthy older adults 
(67.1 years ±6.2 
years*). 




In ε4+: a deleterious effect of S- (S+ M [Mean] 
= ~550, range = 270-1400, S- M = ~900, range = 240-
1740, P = 0.033). 
In S-: protective effect of ε4 ↑ (ε4+ M = ~900, 
range = 240-174, & ε4- M = ~450, range = 180-820, P 
= 0.018) (data estimated from figures. 
Fishers LSD Very small sample; S+ n = 30, 
S- n = 17. Protective effect of 




Cortisol levels   in CSF 
(ug/dL) where ↑ = can 
contribute to hippocampal 
damage. 
(S+ vs. S-, in  ε4+ &  ε4-) 
 
Healthy older adults 
(67.1 ±6.4*). 
57 Age, Education, MMSE, 
gender, major depressive 
disorder (controlled). 
In S-; deleterious effect of ε4 (ε4 + M = ~0.6,  
ε4- M = ~0.45, P = 0.028), but no effect of ɛ4+ 
overall, or in S+ group. 
Fishers LSD TOMM40 523 poly-T repeat 
may modulate the toxic effects 




Age of AD onset in years 
(In ε3/ε4 carriers only; VL+ 
vs. VL-). 
Older adults with AD 
(age of onset 71.2*; 
SD unclear). 
34 None. VL+; earlier onset of AD (VL+ M years = 70.5 
±1.2, VL- M = 77.6 ±2.1, P = 0.02). 
Bonferroni Very small sample. VL 
genotype was ≥27 poly-T 
repeats unlike more recent 




Gray matter volume  
1. whole-brain comparison  
2. age-by-523 VL allele 
dose interaction on volumes 
(In ε3/ε3 carriers only, VL 
dose contrast: 0 vs. 1 vs. 2). 
Healthy older adults 
(55.3 ±6.0*; APOE 
3/3 genotype only). 
117 Age, intracranial volume, 
gender (controlled), 
Family history of AD, 
hypertension (sig. higher 
in S/VL group). 
1. volume ↓ in left ventral posterior cingulate 
(t = 4.10, voxel cluster size = 796, P = 0.001) and 
cuneus (T = 3.43, cluster = 376, P = 0.042) 
2. age-by-523 interaction for volumes in 
retrosplenial area (t = 3.21, cluster = 35, P = 
0.001) and right anterior mesial temporal lobe 






Sig. increased hypertension 
and family history of AD in 
S/VL group. Deleterious 
effects of VL allele.  
Caselli et 
al. 2012 
Verbal memory scores. 
(Auditory verbal learning 
test). 
Healthy older adults 
longitudinally 
assessed every 1-2 
years (58.2 ± 12.3*). 
639 Age, gender, education 
(n.s.; P > 0.05 between 
groups). 
Significant difference in memory change 
between S/S and VL/VL (deleterious) groups 
in APOE ε3/ε3 group only (P = 0.04). 
None  
 






Chu et al. 
2011 
Age of AD onset; years 
(number of L alleles). 
Older adults with 
probable/diagnosed 
AD (age of onset = 
73.0 ±6.3) 
 
892 None. Association between L allele dose and age of 
onset (standardised β = -0.077, P = 0.002) 
attenuated to n.s. when ɛ4 dose controlled. 
None The largest sample investigating 
523 poly-T repeat. Poly-T 





et al. 2012 
Cognitive tasks - Verbal 
Fluency, Logical Memory 
and Ravens Progressive 
Matrices. Age 79 scores 
where ↑ = better, and decline 
across ages 79-87 where 
↑ =  worse. 
(1. 523 genotype; main 
effects) 
(2. L+ vs. L-).  
 
 
Healthy older adults;   
(79.1 ±0.6*). Re-
tested at around 83 & 
87 years. 
187 MMSE (n.s), age 11 IQ, 




history (controlled).  
1. L/VL carriers (vs. other genotypes); ↓ 
Logical Memory (baseline) (parameter estimate 
= -5.06, 95% C.I’s -9.39 to 0.74, P = 0.013), ↑ 
Logical Memory decline (estimate = -0.69, 95% 
C.I’s -1.37 to -0.01), ↑ Ravens Progressive 
Matrices decline (estimate = -0.39, 95% C.I’s -0.77 
to -0.01).  
2. L+; ↓ Logical Memory decline (M = -4.18 
vs. 1.06, P = 0.006). 
All n.s. when controlled for ε4 alleles. 
None Greater decline in Logical 
Memory for L/VL vs. S/S, but 
smaller decline when stratified 




Amyloid β1-40/1-42 & brain 
tau concentrations in CSF, 
where ↑ can interfere with 
synaptic function 
(S+ vs. S-, stratified by ε4+ 
& ε4-). 
Healthy older adults 
(67.1 ±6.2). 
47 Age, education, gender, 
MMSE, Hamilton 
depression scale scores 
(controlled).  
No effects of 523 status; either by S+ vs. S-, 
or S/L/VL genotype. Main effects of APOE 
only. 













Note APOE = apolipoprotein-E gene, TOMM40 = translocase of outer mitochondrial membrane 40 gene, S = Short allele, L = Long Allele, VL = Very-Long allele, +/- = carrier/non-carrier, 
AD = Alzheimer’s disease, CSF = cerebrospinal fluid, n.s. = not statistically significantly different between groups at P > 0.05, N/A = not available/applicable, SD = standard deviation, M = 
mean, C.I. = confidence interval, OR = odds ratio, MMSE = mini mental state exam, BMI = body mass index. Tau = neurofibrillary tangles. All significant findings (P < 0.05) survived 
correction for multiple testing unless otherwise stated. All ages are in years. * = weighted estimates.  
 
Deleterious effects of Short allele 
 
Cruchaga 
et al. 2011 
1. age of onset  
2. risk of AD diagnosis 
Tested overall sample first, 
and then  ε3/ε3 carriers only 
(overall 523 genotype & 
then APOE-ε/523 phased 
haplotype). 
Healthy older adults 
(75.6 ±8.7*), and also 
older adults with AD 







Age, gender (controlled), 
ethnicity (n.s.). Clinical 
Dementia Ratings 
healthy group score = 0, 
AD score > 1. 
i. VL allele; later age of onset in whole 
sample (P = 1.03 x 10-19, but n.s when APOE-ɛ4 
controlled, and no effect in ε3/ε3 or ε3/ε4 carriers). 
Phased haplotype;  ε3/clade A (reflecting VL 
allele) had later age of  onset AD (ɛ3-clade A M 
= 73.31 vs. ɛ3-clade B M = 72.93, P = 0.057) 
ii. L allele in whole sample; trend ↑ risk of 
AD (case freq = 0.41, control freq = 0.16, P = 0.08 
controlling for APOE). VL allele in  ε3/ε3; ↓ risk 
of AD (case freq = 0.41, control freq = 0.48, P = 
0.004;VL & AD risk OR = 0.89). 
 
Bonferroni Reported significant protective 
effect of VL allele in terms of 
AD risk. The largest 
investigation of 523 repeat & 
AD phenotypes. Effects all in 
the opposite direction to those 
reported by Roses et al. 2010. 
Hayden et 
al. 2012 
Broad cognitive test battery 
(17 tests). 
Healthy older adults 
(80.6± 6.0).  
127 Age, gender, APOE, 
education, depression 
(controlled). 
No significant effects in whole sample. 
Several significant deleterious effects of S/S 
vs. S/VL alleles presence for several tasks 
(in APOE ε3/ε3 subgroup only, n = 82; 
detailed in Chapter 7; all P < 0.05).  
 
 
Bonferroni Deleterious effect of S allele in 
‘neutral’ APOE genotype group 
only; hence, small sample. Also, 
S/VL performed much better 
than S/S and VL/VL, who 
performed similarly. This is 
surprising. No associations 
survived bonferroni correction. 
No markers of prior ability. 
 
Cruchaga 
et al. 2011 
(above 
report) 
AD-related phenotypes; CSF 
amyloid β-42 & tau  
(overall 523 genotype). 





See above. Whole sample & ε3/ε3 carriers; no effect of 
523 on Aβ42 or tau levels independent of 
APOE. 
See above Indicates that the mechanisms 
underlying any 523/AD 
association are not APOE routes 
such as Aβ42 levels. 
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1.5. Approach and aims of this thesis 
To recap, the APOE ε gene locus is a risk factor for AD, and the ε4 allele has been 
significantly associated with worse cognitive ageing in large samples of older adults; it is 
possible that these associations occur via intermediate brain imaging phenotypes. However 
other genetic variants - such as the TOMM40 523 poly-T repeat - may modify this association 
and exert influence on brain phenotypes, independent of APOE ε (e.g. Crenshaw et al., 2013; 
described above).  
Few studies have attempted to elucidate the anatomical brain substrates of APOE ε-
cognitive ageing associations. This is because there are few datasets with detailed genetic, 
brain MRI and cognitive data, however these are available in the Lothian Birth Cohort 1936 
(LBC1936; detailed below), a relatively large sample of community-dwelling older adults. 
Additionally, few studies have investigated the effects of TOMM40 523 genotype on brain 
imaging or cognitive phenotypes, independent of APOE ε. 
 
This PhD thesis intends to expand upon the current literature through three specific aims: 
1. Contribute a relatively large amount of data on the association between APOE ε and brain 
imaging/cognitive ageing phenotypes, in generally healthy community-dwelling older 
adults. 
2. Elucidate the effects of TOMM40 523 genotype in brain imaging/cognitive ageing 
phenotypes, and tests whether they are independent of APOE ε.  
3. Elucidate the anatomical substrates of significant associations between APOE ε and 
cognitive ageing phenotypes, with detailed structural brain MRI (statistically tested for 
mediation). 
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Before each analysis, each chapter will provide an overview and critique of relevant previous 
research.  
 
1.6. Dataset used in present thesis: the Lothian Birth Cohort 1936 
For the purposes of this thesis, data was examined from the LBC1936, a large sample of 
generally healthy, community dwelling older adults with detailed genetic, brain MRI, 
cognitive and sociodemographic/medical information available (Deary et al., 2007; 2012). 
Most of the participants completed the Moray House Test (MHT no. 12; an 
intelligence-type test) around the age of 11 years as part of the Scottish Mental Survey 1947 
(Deary et al., 2007). Around the age of 70 years, 1091 participants repeated the MHT in 
addition to a range of assessments related to cognitive and other phenotypes (as described 
above, excluding brain MRI; ‘Wave one’). Later, around the age of 73, participants repeated 
this assessment and also received detailed brain MRI (Deary et al., 2007; 2012; Wardlaw et 
al., 2011; ‘Wave two’). The data collected around the age of 73 – Wave two – are those used 
in the present thesis, in addition to the described measure of childhood intelligence.  
An unusual and valuable aspect of the LBC1936 sample is that most participants have 
a measure of childhood intelligence (i.e. MHT scores) from age 11. Scores on cognitive tests 
completed around age 73, statistically adjusted for age 11 ability - before the effects of age-
related variables such illness – therefore to an extent reflect cognitive ageing (Deary et al., 




1.7. Thesis outline 
The present thesis includes four empirical reports detailing relevant previous research 
(Chapters 4 to 7), preceded by an empirical proof-of-concept study (Chapter 3) and a 
methodology chapter (Chapter 2). Chapters 4-6 examine the genetic contributions of the 
APOE ɛ and TOMM40 523 loci to specific brain imaging phenotypes. Chapter 7 examines the 
effects of these loci on cognitive ageing, and then formally tests whether significant gene-
cognitive associations are mediated by associations with brain imaging phenotypes (as 
reported in Chapters 4-6) which are also associated with the cognitive variables (i.e. in 
situations where the three-way associations all have raw P < 0.05). This ‘Causal steps’ model 
investigates mediation where all variables are significantly associated as this is where 
mediation could be expected the most (Hayes, 2009; Salthouse, 2011). Chapter 3 provides an 
empirical proof-of-concept for this. Chapter 2 provides the methodology common to Chapters 
4-7, and also partly to Chapter 3 (which examines a different genetic locus). Chapter 8 
provides a discussion and overview of the findings. 
Chapter two introduces the sample used in subsequent chapters - the Lothian Birth 
Cohort 1936, and describes methodology common to subsequent chapters. This chapter 
details the genotyping and analytic strategy for APOE ɛ and TOMM40 523 (relevant to 
Chapters 4-7 but not Chapter 3), and phenotyping in terms of brain MRI, cognitive, medical 
and sociodemographic information. Because subsequent chapters examine different 
imaging/cognitive phenotypes, a number of methodological details are study-specific, and 
therefore reported in each respective chapter.  
Chapter three examines the role of two SNPs in the adrenergic beta-2 receptor gene 
(ADRB2). Penke et al. (2010b) reported - in a smaller subsample of the dataset used in this 
thesis - that two SNPs were significantly associated with performance on specific cognitive 
tests, and these significant associations were mediated by white matter microstructural 
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integrity, as assessed with diffusion-tensor MRI. This chapter aims to replicate these 
mediating relationships in the larger, full sample of LBC1936 participants with MRI data, 
and expand analysis to a broader range of cognitive and white matter microstructural 
phenotypes. Chapter 3 is a proof-of-concept study in that it demonstrates the effects of 
specific, common genetic variants on cognitive ageing, mediated by brain MRI metrics; 
suggesting feasibility for subsequent chapters.  
Chapter four examines associations between variation in APOE ɛ/TOMM40 523 and 
white matter microstructural integrity (again assessed with DT-MRI). This sensitive 
phenotype has been significantly associated with changes in AD (Sexton et al., 2011); the 
vast majority of previous reports of APOE are relatively small (Gold et al., 2012), and no 
study has investigated the effects of the TOMM40 523 locus on this phenotype.  
Chapter five examines APOE ɛ/TOMM40 523 variation and hippocampal volume. 
This phenotype is of interest because the hippocampus is the earliest site of neurofibrillary 
AD pathology including amyloid-beta, neuropil and ‘tau’ tangle accumulations (Price and 
Morris, 1999), and is associated with a major symptom of AD; episodic memory impairment 
(Lind et al., 2006). Previous large studies of APOE ɛ/TOMM40 523 (and hippocampal 
volume) in older adults are critiqued. 
Chapter six examines APOE ɛ/TOMM40 523 variations in terms of brain markers of 
cerebrovascular burden; white matter lesions and brain microbleeds. There is evidence that 
the presence of cardiovascular or more specifically cerebrovascular disease pathology can 
increase the future risk of AD and cognitive decline (Debette and Markus, 2010), perhaps 
through promoting accumulations of amyloid-beta, and/or by increasing vulnerability of the 
brain to such pathology (Brickmann et al., 2011). Previous large studies of APOE ɛ and these 
phenotypes in older adults are critiqued. No study has examined TOMM40 523 and white 
matter lesions/brain microbleeds.  
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Chapter seven examines APOE ɛ/TOMM40 523 variation in terms of cognitive 
ageing, on a wide range of phenotypes including executive function, declarative memory and 
information processing speed. Based on Chapters 4-6, three-way significant raw nominal 
associations at P < 0.05, between genetic/imaging/cognitive variables are examined for 
mediation formally with bootstrapping (Preacher and Hayes, 2008). Relatively few samples 
have the requisite data to conduct such analyses, and Chapter 7 is therefore rare in this regard.  
Chapter eight provides an overview of the PhD thesis; it integrates the findings with 
the literature, highlights limitations to the approach described here, and suggests directions 













Chapter 2: Methodology  
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2.1. Recap and overview 
The APOE gene locus is a significant risk factor for Alzheimer’s disease (AD) diagnosis, and 
worse cognitive ageing (Corder et al., 1994; Deary et al., 2004). Specifically, the ε4 allele is 
purportedly the ‘risk’ variant, compared with the neutral ε3 allele and possibly protective ε2 
allele (Wisdom et al., 2011; Eisenberg et al., 2010).   
There is heterogeneity in associations between APOE genotype and different brain 
phenotypes (e.g. cognitive ability), which suggests that other variables – including genetic – 
have a modifying or independent effect. The rs10524523 locus (hereafter ‘523’) in TOMM40 
is characterised by a variable number of T residues (poly-T repeats; Lutz et al., 2010). The 
TOMM40 523 poly-T repeat genotype was identified by Roses et al. (2010) as having a 
significant effect on age of AD onset in a small sample of older adults diagnosed with AD (n 
= 34, mean age = 69.3 years, standard deviation [SD] = 8.3). In individuals with the ε3/ε4 
genotype, longer poly-T repeat lengths (≥27) were associated with an earlier age of onset 
(70.5 years vs. 77.6, P = 0.02). Because APOE genotype was constant, it could be said that 
the effect of TOMM40 523 was biologically independent; i.e. that any significant effect 
cannot be attributed to variation in APOE genotype. Poly-T repeat lengths are commonly 
grouped into ‘Short’ (<20; ‘S’), ‘Long’ (20-29; ‘L’), and ‘Very-Long’ (≥30; ‘VL’; Lutz et al., 
2010; Linnertz et al., 2012). 
 As described in Chapter 1 (‘Introduction’), this thesis aims to investigate the 
independent effects of the APOE ε4 and TOMM40 523 gene loci on structural brain MRI 
(Chapters 4-7) and cognitive ageing (Chapter 7) phenotypes in an existing dataset, the 
Lothian Birth Cohort 1936 (LBC1936). Here, the sample recruitment as well as cognitive, 
brain imaging and genotypic assessment methodologies are described, followed by a 
description of the analytic approach taken. Relevant statistics for the LBC1936 dataset are 
described in Table 2.1 (e.g. mean ages in years, allele frequencies), and the final analytic 
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strategy is detailed in Table 2.2. This chapter provides the core methodology and analytic 
strategy for Chapters 4-7 and most of Chapter 3, although there are study-specific 
methodological details provided in each specific chapter. Chapter 3 is a proof-of-concept 
study for subsequent Chapters 4-7 that uses the same LBC1936 cognitive and brain MRI data 
from around age 73, but investigates a different genetic locus. All of the relevant 
genetic/analytic information for that study is therefore reported in Chapter 3.  
 
2.2. Dataset used in the present thesis  
2.2.1. Ethical statement  
Ethics permission for the study protocol was obtained from the Multi-Centre Research Ethics 
Committee for Scotland (MREC/01/0/56) and from the Lothian Research Ethics Committee 
(LREC/2003/2/29), in accordance with the Declaration of Helsinki, and all participants gave 
written, informed consent.  
 
2.2.2. The Lothian Birth Cohort 1936 (LBC1936) 
The LBC1936 is a sample of 1091 generally healthy, community-dwelling and non-demented 
older adults, 1028 of whom completed a test of intelligence at around age 11 years. All of the 
LBC1936 participants were born in 1936 and most resided in the Edinburgh (Lothian) area of 
Scotland when recruited for a range of cognitive, physical and sociodemographic assessments 
in older adulthood. The recruitment and assessment of this sample is described in the 




2.2.3. Sample recruitment 
On June 4
th
 as part of the Scottish Mental Survey 1947 (SMS1947), all children attending 
school in Scotland that day that were born in 1936 (hence around 11 years old) completed an 
assessment of intelligence called the Moray House Test no. 12 (simply ‘MHT’); a paper-and-
pencil test including a variety of reasoning, visuospatial and mathematical questions. This test 
was validated against the Terman-Merrill revision of the Binet scales, and 70,805 children 
completed the test (Deary et al., 2007; Scottish Council for Research in Education, 1949).  
            In 2003, individuals from the Lothian area that were born in 1936 and may have 
completed the SMS1947 were identified. Upon receiving ethical approval (above), 
participants born in 1936 were identified from Community Health Index (CHI) numbers held 
by the Lothian Health Board, providing date of birth and contact details. Potentially eligible 
individuals (3686) were mailed information on the research project and the nature of 
participation, with a reply slip stating interest and confirming initial eligibility. This was 
supplemented with adverts in relevant media seeking participants who may have been 
assessed on June 4
th
. Excluding individuals medically unable to participate or otherwise 
ineligible, this yielded 1226 participants. Participants who later withdrew, could not be 
contacted or could not undergo assessment before the end of testing were excluded, resulting 
in 1091 individuals (548 male) that made up the LBC1936. This process is detailed in Figure 
2.1, taken from Deary et al. (2007). 
 
2.2.4. Assessment in older age 
In the first wave of the LBC1936 study (‘Wave 1’), at around age 70 years, participants were 
retested on the MHT in addition to other detailed cognitive, genotypic, sociodemographic, 
and physical assessments (N = 1091) at the Wellcome Trust Clinical Research Facility 
(WTCRF; Western General Hospital, Edinburgh). The sample was generally healthy, 
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community-dwelling and non-demented. Around three years later, 866 members of the cohort 
returned for re-testing in the second wave of the study (‘Wave 2’). The main reasons for 
attrition were death, chronic incapacity and general withdrawal (Deary et al., 2012). At this 
point, in addition to repeating the Wave 1 assessments, the majority of participants also 
underwent detailed structural brain MRI, on the same day or around the same time, at the 
Brain Research Imaging Centre (BRIC; also Western General Hospital, Edinburgh).  
At both waves, participants were screened for cognitive impairment with the Mini 
Mental State Examination (MMSE; Folstein et al., 1975), with scores under 24 used to 
indicate possible dementia. Medical history was elicited via interview, including high blood 
pressure or hypertension, diabetes, stroke, hypercholesterolemia, and history of any other 
cardiovascular disease (e.g. heart attack).  
 
2.2.5. Current sample 
Of the 1091 total LBC1936 participants that attended Wave 1, 866 attended Wave 2 also, 
where they underwent repeat cognitive/physical assessments in addition to brain MRI; it is 
this latter dataset that is primarily examined in this thesis (age ~73 years; Wave 2). 
Individuals who reported dementia (n = 1), who had MMSE scores below 24 (n = 7; possibly 
indicative of dementia; Folstein et al., 1975), or did not complete the MMSE at Wave 2 (n = 
1) were excluded. Overall, this left 857 participants, of which 811 and 823 participants had 
successful genotyping for APOE and TOMM40, respectively. Note that the specific numbers 
of participants examined in each chapter vary slightly because not every participant had every 
cognitive and brain imaging phenotype successfully assessed, segmented or processed (Deary 
et al., 2007; Wardlaw et al., 2011). 
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Figure 2.1. Flowchart of recruitment for LBC1936 up to around age 70 years (‘Wave 
1’). Note that this thesis primarily uses data from around age 73 (‘Wave 2’; n = 866).  
Taken from Deary et al. (2007).  
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2.3. Genotyping 
The APOE ɛ haplotype (commonly known as ‘genotype’) is composed of two single 
nucleotide polymorphisms (SNPs); rs429358, which causes a Cys130Arg substitution; and 
rs7412, which causes an Arg176Cys substitution (http://www.ncbi.nlm.nih.gov/gene/348). 
Different combinations of the rs329358/rs7412 SNPs form the ɛ2 (Cys/Cys respectively), ɛ3 
(Cys/Arg) and ɛ4 (Arg/Arg) genotypes (Ringman and Cummings, 2009).  
Genotyping for APOE was completed at the Wellcome Trust Clinical Research 
Facility Genetics Core, Western General Hospital, Edinburgh. For APOE, DNA was isolated 
from whole blood, and the target sequences for the each of the rs7412 and rs429358 single 
nucleotide polymorphisms (SNPs) were genotyped with TaqMan technology. Genotype 
frequencies were relatively similar to those reported in independent samples; the ɛ3 allele is 
the most common (typical frequency ~78.3%), followed by ɛ4 (~14.5%) and ɛ2 (~6.4%), 
although this can vary by population (Eisenberg et al., 2010). In the Wave 2 sample (N = 
811), frequencies were ɛ3 = 76.9%, ɛ4 = 15.8% and ɛ2 = 7.3%, and these were in Hardy-
Weinberg equilibrium (P = 0.44; specific genotype frequencies are shown in Table 2.1; 
online Hardy-Weinberg calculator, 2012). 
TOMM40 523 poly-T repeat length was genotyped by the laboratory of Dr. Ornit 
Chiba-Falek (Duke University). Each genomic sample was amplified by polymerase chain 
reaction (PCR) using fluorescently labelled forward 5’FAM-
TGCTGACCTCAAGCTGTCCTG-3’ and reverse 5’-GAGGCTGAGAAGGGAGGATT-
3’primers. Genotypes were determined on an ABI 3730 DNA Analyzer, using GeneMapper 
version 4.0 software (Applied Biosystems, Foster City, California) for fragment analysis by 
the amplified fragment length polymorphism method (Linnertz et al., 2012).  
Roses et al. (2010) plotted histograms showing the distributions of poly-T repeat 
lengths in different APOE genotypes; ɛ3/ɛ3, ɛ3/ɛ4 and ɛ4/ɛ4. The poly-T repeat was strongly 
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linked with the APOE ɛ haplotype; ɛ4 is linked to L, with ɛ3 linked to either S or VL alleles 
(Roses et al., 2010). As can be seen in Figure 2.2, the ɛ3/ɛ3 genotype was associated with a 
relatively bimodal distribution with mainly ‘Short’ or ‘Very-Long’ repeat lengths, whilst the 
ɛ4/ɛ4 has an almost entirely unimodal distribution reflecting its linkage with the ‘long’ 
genotype. The rarer ɛ2 allele appeared to show similar linkage to S or VL alleles in TOMM40 
523 - as per ɛ3 - although further research is required (Roses et al., 2010). 
The distributions of TOMM40 523 poly-T repeat lengths in the whole sample 
(LBC1936 Wave 2 dataset), and in APOE ɛ3/ɛ3, and ɛ3/ɛ4 genotypes, are displayed in Figure 
2.3. Generally, the distributions in the LBC1936 sample are as would be expected on the 
basis of Roses et al. (2010); a relatively bimodal distribution in the ɛ3/ɛ3 genotype for both 
alleles 1 and 2 (i.e. either Short or Very-Long repeat lengths), and for ɛ3/ɛ4, a similar 
bimodal distribution in Allele 1 (reflecting linkage with APOE ɛ3), and a unimodal 
distribution for Allele 2 (reflecting linkage with APOE ɛ4; Roses et al., 2010).  
The allele frequencies for TOMM40 523 were S = 41.0%, L = 15.4%, VL = 43.6% (N 
= 823; in Hardy-Weinberg equilibrium; P = 0.06). These are similar frequencies to those 
reported in independent laboratories, for example Linnertz et al. (2012) report frequencies of 
S = 45%, L = 11% and 44% in a sample of 177 Caucasian adults.  
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Figure 2.2.  TOMM40 523 poly-T repeat length distributions in APOE ε3/ε4, and 





Figure 2.3. TOMM40 523 poly-T repeat lengths in a) APOE ε3/ε3 (n = 467) and, b) APOE ε3/ε4 genotypes (n = 205; note that the central 
distribution in ‘Allele 2’ most likely reflects linkage between ‘Long’ allele and APOE ε4 allele; Lutz et al., 2010). 
a) b) 
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2.4. Brain imaging 
The brain MRI protocol is described by Wardlaw et al. (2011), which states that participants 
underwent whole brain structural MRI, acquired using “a GE Signa Horizon 1.5 T HDxt 
clinical scanner (General Electric, Milwaukee, USA) equipped with a self-shielding gradient 
set (33 mT m
-1
 maximum gradient strength) and manufacturer supplied 8-channel phased-
array head coil” (pp. 549), lasting around 70 minutes (N = 700 completed scans; mean 
interval between WTCRF and MRI scan appointments = 65.1 days). In addition to standard 
structural T2-, T2*- and FLAIR-weighted MRI, the imaging protocol included a high-
resolution T1-weighted volume sequence acquired in the coronal plane with field-of-view 
256  256 mm, imaging matrix 192  192 (zero-filled to 256  256), 160 1.3mm thick slices 
giving 1  1  1.3 mm voxel dimensions (Wardlaw et al., 2011). The repetition, echo and 
inversion times were 10, 4 and 500 milliseconds respectively. Participants also underwent 
diffusion tensor and magnetization transfer sequences (Wardlaw et al., 2011).  
The specific protocol and methodologies for each imaging phenotype used in 
subsequent chapters (white matter tract integrity; hippocampal volumes; white matter 
lesions/brain microbleeds) are briefly outlined in each chapter and detailed in the protocol 
paper by Wardlaw et al. (2011). Image processing for each of these phenotypes (e.g. 
segmentation with FSL tools) was completed by staff at BRIC (Wardlaw et al., 2011).  
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2.5. Cognitive assessment 
2.5.1. Moray House Test no.12 (age 11)  
This was completed in 1947 at a mean age of 11 years. This assessment has a 45-minute time 
limit and includes 76 questions with a predominance of verbal reasoning items, with some 
numerical and visuospatial items also included (Deary et al. 2007). MHT scores were 
adjusted for age in days at time of assessment, and standardised to an IQ score with a mean of 
100 and a standard deviation of 15 for the LBC1936 sample.  
 
2.5.2. Age 73 cognitive assessments 
Participants completed a broad battery of cognitive assessments including fluid-type tasks 
that may be more sensitive to the effects of age compared with more crystal intelligence-type 
tasks such as the National Adult Reading Test. These tasks assess cognitive ability on a 
number of domains including working memory, declarative memory, visuospatial ability, 
executive function and information-processing speed (Deary et al., 2007; 2012). Genetic 
contributions to age 73 cognitive ability were examined in Chapter 3 and Chapter 7.  
 
Working Memory (Wechsler, 1998a). In the Digit Span Backward task, participants recalled 
(in reverse order) increasingly long lists of numbers as read by an experimenter. If 
participants recited the sequence in the correct reverse order, a positive score was given. The 
length of each digit list increases by one after every second sequence, recited at a regular rate 
by the experimenter. The first sequence is two digits, increasing ultimately to eight. If two 
consecutive failures occurred during the same sequence length, the test was discontinued. 
Digit Span Backward scores were out of a maximum 14.  
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For the Letter-Number Sequencing task, participants listened to sequences of letters 
and numbers, as recited by the experimenter.  Participants then repeated the sequence to the 
experimenter, first reciting the numbers in numerical order, and then the letters in 
alphabetical order. An accurate response for each sequence was required for a positive score, 
with a maximum score of 21. These sequences became increasingly long, starting with one 
number and one letter, increasing by one of each (in turn) until the final sequence of four 




; Wechsler, 1998a). 
 
Processing speed (Wechsler, 1998a). In the Digit Symbol Coding task, participants were 
presented with a single piece of paper from the WAIS-III
 UK
. At the top of the page were 
small reference boxes containing symbols with corresponding numbers beneath them. Below 
this were several lines of numbers, spanning the page with empty boxes beneath them. With 
the reference still visible at the top of the page participants were asked to correctly draw as 
many corresponding symbols as possible within two minutes (Wechsler, 1998a). Participants 
could score a maximum of 133 on this task, with one point for each accurate symbol drawn.  
The Symbol Search task from the WAIS-III
UK
 required participants to determine if a 
row of symbols on the right-hand side contained one of a pair of targets presented to the left-
hand side. Participants indicated this by ticking one of the relevant “yes” or “no” boxes. 
Participants have two minutes to complete as many trials as possible, with a maximum score 
of 60. Positive scores were given for accurate identification or rejection of each target symbol 
on each row (Wechsler, 1998a).   
The Simple and Choice-Reaction time (RT) tests provided measures of information 
processing speed via a self-contained device (Cox et al., 1993). Participants were presented 
with a rectangular box with a screen, and five numbered response keys numbered left to right 
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as 1-2-0-3-4. In the Simple RT condition, participants were asked to rest a finger over the 0 
button, pressing this button as quickly as possible whenever a zero appeared on the screen. 
Participants received 8 practice and 20 test trials. In the Choice-RT condition participants 
placed the second and third fingers of their left and right hands on numbers 1-2 and 3-4 
respectively. After each number appeared on the screen, participants pressed the 
corresponding key as quickly as possible. Each number appeared 10 times in random order. 
Mean reaction times (in seconds) for correct trials were included. In both Simple and Choice-
RT conditions, a one to three second interval occurred between a response and presentation 
of the next trial (Deary et al., 2007).  
The Inspection Time task assessed speed of basic visual processing. Participants were 
asked to discriminate which of two vertical parallel lines was longer, and were given no time 
pressure. Participants completed this task on an E-prime programme, with stimulus lines of 
5cm and 2.5 cm at 1.6 mm length. Participants completed ten trials at 15 durations from 6 to 
200 milliseconds inter-trial interval. Participants indicated which of the two lines were longer 
by pressing “1” or “2” on a keyboard. The number of correct trials rather was used to score 
this task (Deary et al., 2007). 
 
Memory (Wechsler, 1998b). The logical Memory (I and II) tests assessed verbal declarative 
recall for two prose stories at immediate and delayed (around 30 minutes) intervals. 
Participants were told a short story and asked to recall as much specific content as possible. 
This was scored by the experimenter for content-specific accuracy as well as less specific 
thematic recall. This process was then repeated with a second story. Participants were warned 
they will be asked to recall as much as possible of the two stories at 30 minutes delay. After 
the delay, recall was again scored for specific and thematic accuracy. Logical memory stories 
contained 25 elements, with one point for each specific accurate detail.  
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During the Verbal Paired Associates (I and II) memory task, participants were read a 
list of unrelated two-word pairs. Participants were then read the first word of each pair and 
attempted to recall the corresponding paired word. This occurred four times with lists of eight 
pairs presented, yielding an overall score of 32. At 30 minutes delay, participants attempted 





; Wechsler, 1998b).  
Visuospatial ability (Weschsler, 1998a). The Block Design subtask from the WAIS-III
UK
 
assessed visuospatial ability. Individuals were asked to reconstruct pictorial designs from 
three-dimensional blocks placed in front of them, with two minutes permitted for each trial. 
For the first two trials, participants are given either zero, one or two points depending on 
whether they complete the task on the first or second trial (or not at all). Thereafter 
participants were given up to 7 points for each accurate reconstruction, depending on the time 
to completion. Block Design scores could reach a maximum of 68. This task was taken from 
the WAIS- III
UK 
(Wechsler, 1998a).  
The Spatial Span subtest assessed non-verbal working memory. The examiner tapped 
increasingly long sequences onto small cube blocks. The participant was asked to re-tap each 
sequence afterwards. This task was then repeated with participants retapping sequences in 
reverse order. For each task, a positive score was given if tapping was repeated accurately, 
with a maximum of 16 for both forwards and backwards yielding an overall total of 32. 
Spatial Span was taken from the WMS-III
UK 
(Wechsler, 1998a).  
 
Abstract Reasoning (Wechsler, 1998a). The Matrix Reasoning subtest of the WAIS-III 
(Wechsler, 1998a) displays patterns arranged in a matrix with one section missing and five 
options available. After five practice trials, participants attempted to identify the underlying 
rule relating the other three pieces and used this to determine what the missing section should 
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be. A positive score was given for identification of each correct missing pattern. Participants 
could score a maximum of 26 on this task.  
 
2.5.3. Age 73 general cognitive factors  
Data reduction was applied to the cognitive test scores using principal components analyses 
(PCA) which produced the following summary cognitive variables. First, ‘general 
intelligence’ (g) included the six non-verbal Wechsler subtests of Digit Span Backwards, 
Matrix Reasoning, Letter-Number Sequencing, Block Design, Symbol Search and Digit 
Symbol Coding. Second, ‘processing speed’ (gSpeed) included Symbol Search, Digit Symbol 
Coding, Simple RT, Four-Choice RT and Inspection Time. The derivation of these was 
described by Luciano et al. (2009a). Third, a ‘memory’ factor (gMemory) was formed from 
Logical Memory, Spatial Span, Verbal Paired Associates, Letter-Number Sequencing and 
Digit Span Backwards. The derivation of this variable was described by Houlihan et al. 
(2010). Strictly speaking PCA does not generate latent underlying ‘factors’, but this usage is 
common and is adopted here. In each case, analysis tested for the existence of a large first 
unrotated component that could be used to form scores for the three variables. Inspection of 
eigenvalues and scree-plots suggested that a single component should be extracted from the 
data in each of the three analyses.  The first unrotated principal component scores in each 
domain accounted for 50-54% of the variance for g, gSpeed, and gMemory, and all individual test 
scores had moderate to high loadings on their respective first unrotated principal components.  
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2.6. Demographic information 
Genotype frequencies, mean/standard deviation ages in years at time of assessment at the 
WTCRF, MMSE scores, self-reported cardiovascular disease history prevalence rates and age 
11 IQ age data (means and standard deviations) are displayed in Table 2.1, based on the 
whole sample of 866 participants that completed cognitive testing around the age of 73 years.  
Significant differences between genotypes in terms of demographic statistics (outlined 
in Table 2.1) were tested for with one-way analysis of variance (ANOVA). A significant 
effect of APOE genotype was found for prevalence of self-reported high cholesterol (F [5, 
805] = 2.38, P = 0.037) due to significantly higher prevalence rates in the ɛ2/ɛ3 genotype (vs. 
ɛ2/ɛ4 and vs. ɛ3/ɛ4; P < 0.05), and age at time of testing at the WTCRF (F [5, 805] = 2.89, P 
= 0.014) due to significant differences for the ɛ2/ɛ2 genotype vs. all others (P < 0.05). A 
significant effect of TOMM40 523 genotype was found on prevalence of self-reported high 
blood pressure (F [5, 817] = 2.27, P = 0.046), due to significantly higher prevalence rates in 
S/S genotype vs. L/L, and S/L vs. VL/VL (both comparisons P <0.05). No other effects of 





Table 2.1. Descriptive age data (mean/standard deviation; SD) for the Lothian Birth 
Cohort 1936 (‘Wave 2’). 
 APOE genotype 
 ε2/ε2 ε2/ε3 ε2/ε4 ε3/ε3   ε3/ε4   ε4/ε4 
N 3 95 18 472 208 15 













































































































TOMM40 ‘523’ poly-T repeat genotype 
 S/S S/L S/VL L/L L/VL VL/VL 
N 125 123 302 18 95 160 












































































































Note. SD = standard deviation, TOMM40 523 ‘S’ = ‘Short’ allele, ‘L*’ = pooled ‘Long’ and ‘Very-long’ alleles. These data are based on 
the sample once people with reported dementia, MMSE scores ≤24 or missing at Wave 2 are removed; detailed in the text body. APOE 
total n = 811, TOMM40 total n = 823.  
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2.7. Analytic strategy: APOE ε 
The APOE ε locus includes the ε4 allele (generally accepted as the ‘risk’ variant), ε2 
(possibly ‘protective’, but not consistently) and neutral ε3 allele. Each person has any two 
alleles, resulting in six possible combinations (ε2/ε2; ε2/ε3; ε3/ε3; ε3/ε4; ε2/ε4; ε4/ε4). There 
are a number of ways of analysing this genetic locus, statistically. The final strategy used in 
this thesis for Chapters 4-7 is detailed in Table 2.2. Tests of significant differences were 
tested with general linear models (GLM; analysis of variance or simply ANOVA). 
 
2.7.1. Presence vs. absence of the ε4 allele (‘Step 1’) 
Studies of APOE ε commonly test the effects of ε4 ‘risk’ allele presence versus absence (i.e. 
ε2/ε2; ε2/ε3; ε3/ε3 vs. ε3/ε4; ε2/ε4; ε4/ε4; Wisdom et al., 2011; Deary et al., 2004). 
Frequency of the ε4/ε4 genotype is often low, and pooling ε4/ε4, ε3/ε4 and ε2/ε4 participants 
can improve power (Luciano et al., 2009a).  
Some studies exclude the ε2/ε4 genotype from analysis because it includes 
‘protective’ and ‘risk’ alleles which could potentially cancel one another out and reduce 
power of the ε4 presence effect (Wisdom et al., 2011). Here, analyses included the ε2/ε4 
genotype because:  
1) The suggested protective effect of the ε2 allele is much less consistent, compared with the 
deleterious effect of the ε4 allele (Ashford, 2002; McCarron et al., 1999). For example, in 
a large meta-analysis of 20 independent Caucasian samples (N = 4, 946), Bertram et al. 
(2007) reported a significant deleterious effect of ε3/ε4 (vs. ε3/ε3; odds ratio [OR] = 2.7, 
95% C.I.’s = 2.2-3.2) and ε4/ε4 (OR = 12.5, 95% C.I.’s = 8.8-17.7), but no effect of ε2/ε3 
(OR = 0.9, 95% C.I.’s = 0.4-2.5), statistically adjusted for age and study centre.  
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2) The APOE ε2 allele has occasionally been associated with deleterious effects. For 
example, Berlau et al. (2009) examined neuropathology in 85 very-older adults that had 
died (mean age = 97.3, SD not provided) in terms of Braak plaque staging (reflecting the 
degree of neurofibrillary burden including amyloid plaque and ‘Tau’ tangles; detailed in 
Chapter five; Braak and Braak, 1991). They reported that ε2 carriers showed significantly 
increased Braak plaque staging (OR = 8.2, 95% C.I.’s = 2.2-30.4), increased neuritic 
plaques (OR = 4.4, 95% C.I.’s = 1.3-15.2; vs. ε3/ε3 genotype). The ε4 and ε2 alleles 
showed similarly deleterious effects, therefore (see also Trachtenberg et al., 2012; Farrer 
et al., 1997).  
 
2.7.2. APOE ε single point mutation test: ε3/ε4 vs. ε3/ε3 (‘Step 2’) 
The APOE ε4 allele may have dose-response deleterious effects where the ε4/ε4 genotype is 
more strongly associated with brain imaging or cognitive phenotypes, compared with ε2/ε4 or 
ε3/ε4 (e.g. Bertram et al., above). The ε4/ε4 genotype is rare, however, which makes analysis 
of this locus less reliable (Eisenberg et al., 2010; Hattersley and McCarthy, 2005). To account 
for this, studies have previously tested for a significant effect of ε3/ε4 vs. ‘neutral’ ε3/ε3 
(Deary et al., 2004; Wisdom et al., 2011; See Table 2.2). 
 
2.7.3. Presence vs. absence of the ε2 allele (‘Step 3’) 
Although the ε2 allele ‘protective’ effect is less consistent compared with the ε4 ‘risk’ effect, 
independent studies have previously tested for the effects of ε2 allele presence vs. the neutral 






The APOE  genotype is composed of any two of the 2 (protective), 3 (neutral) and 4 
(risk) alleles. The first analytic step tested the effects of APOE 4 allele presence vs. absence, 
i.e. pooled 2/4, 3/4 and 4/4 genotypes versus pooled 2/2, 2/3 and 3/3 (‘Step 1’). 
The second analytic step tested the effect of a single point mutation and removed carriers of 
the ‘protective’ 2 allele: 3/4 vs. 3/3 genotypes only (‘Step 2’; Deary et al., 2004). The 
third and final analytic step tested genotypes which may be protective for neurodegenerative 
pathology, compared with the neutral genotype; i.e. pooled 2/3 and 2/2 versus 3/3 
(Deary et al., 2004; Luciano et al., 2009a; ‘Step 3’). This is detailed in Table 2.2.  
 
2.8. Analytic strategy: TOMM40 ‘523’ poly-T repeat genotype 
The TOMM40 523 genetic locus includes the ‘S’, ‘L’, and ‘VL’ alleles. There are a number 
of ways of analysing this genetic locus, statistically. The final strategy used in this thesis for 
Chapters 4-7 is detailed in Table 2.2.  
On the basis of findings by Roses et al. (2010; see Figure 2.2), studies that investigate 
the TOMM40 523 locus usually group repeat lengths into categories, to improve power; 
namely ‘Short; S’ (<20 T residues), ‘Long; L’ (≥ 20) and ‘Very-long; VL (≥ 30) (Lutz et al., 
2011; Linnertz et al., 2012). This results in six different genotypes (S/S; S/L; S/VL; L/VL; 
VL/VL). In the first analytic step, in the whole sample, a GLM tested for a significant effect 
of TOMM40 523 genotype (i.e. S/S; S/L; L/L; L/VL; VL/VL; ‘Step 1’), followed by post-hoc 
contrasts if a main effect is found (i.e. P < 0.05). 
To investigate the effects of TOMM40 523 repeat length independent of biological 
variation in APOE genotype, analysis then focussed separately on two different APOE ε 
genotype subgroups; firstly participants with the 3/4 genotype (‘Step 2’; e.g. Roses et al,. 
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2010). Devi et al. (2012) reported that this genotype had the highest accumulation of amyloid 
precursor protein (APP) in AD brain mitochondria (vs. 3/3 and 4/4 genotypes; assessed 
by immunoblot analysis), and this correlated strongly with two indicators of mitochondrial 
dysfunction (cytochrome C oxidase activity and reactive oxygen species hydrogen peroxide; 
‘H2O2’). In terms of a possible interaction between APP accumulation and mitochondria 
translocase processes, it is not known if the TOMM40 523 genotype may offset or interact 
biologically with the 3/4 genotype (Devi et al., 2012). Finally, analysis focussed on 
participants with the neutral APOE genotype (3/3) (‘Step 3’), because this eliminates 
variance associated with putatively protective and risk APOE alleles (Johnson et al., 2011; 
Roses et al., 2010).  
In large sample of Caucasians, linkage between the APOE  genotype and TOMM40 
523 length (i.e. 4 links primarily to ‘L’, 3 primarily to ‘S’ or ‘VL’) is such that in the APOE 
3/3 genotype, relatively few L carriers would be predicted whereas in the 3/4 genotype 
typically one L allele would be predicted in addition to either an S or VL allele. Slight errors 
in poly-T repeat length measurement may occur through PCR ‘slippage’ and this may result 
in repeat lengths that are close to the L/VL boundary being incorrectly classified (Linnertz et 
al., 2012). To attempt to control for this, in Steps 2 and 3 the L and VL alleles were pooled 
into an ‘L*’ group; participants with the S/S genotype were compared with those carrying 
only one S allele (pooled S/L and S/VL; hereinafter S/L*), and also against participants 
carrying no S alleles (pooled L/L, L/VL and VL/VL; hereinafter L*/L*). This thesis therefore 
tested for significant effects of TOMM40 523 genotype (S/S; S/L*; L*/L*) on 
cognitive/imaging variables in Steps 2 and 3 (APOE 3/4 and 3/3 subgroups respectively).  
The analytic strategy for TOMM40 523 is described in Table 2.2.  
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2.9. Covariate models 
Three statistical models were tested to investigate the effects of the APOE ɛ and TOMM40 
523 loci on cognitive/brain imaging variables. First, all models controlled for gender and age 
in days at neuroimaging to account for general sex-differences in brain morphology, and the 
huge confounding effect that increasing age can have on brain-related and fluid-type 
cognitive variables; (‘Model 1’; Wardlaw et al., 2011; Hofer and Sliwinski, 2001).  
Second, statistically significant effects (P < 0.05) were re-tested additionally 
controlling for age 11 IQ (‘Model 2’). This allows the current study to partly account for 
differences in childhood intelligence and its subsequent possible influence on health-related 
variables throughout the lifespan, such as disease management (Batty et al., 2007). Finally, 
significant associations that survived correction for age 11 intelligence were then re-tested 
additionally controlling for the following covariates: self-reported history of high blood 
pressure/hypertension, stroke, type-2 diabetes, high cholesterol, and other cardiovascular 
diseases. This reduces the chance that any significant associations occur as secondary to 
genetic associations with cerebrovascular pathology (‘Model 3’; Schiepers et al., 2012; Zade 
et al., 2010).  
Models were additive, meaning that Model 3 included age 11 IQ when significant in 
Model 2. An additive stepwise approach to modelling was taken because running the final 
‘age + gender + age 11 IQ + cardiovascular disease history’ model alone was considered 
overly restrictive a-priori. 
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2.10. Additional analytic details  
An online calculator was used to perform tests of Hardy-Weinberg equilibrium and determine 
minor allele frequencies (http://www.had2know.com/academics/hardy-weinberg-equilibrium-
calculator-3-alleles.html). Data were otherwise analysed with the Predictive Analytics 
SoftWare (PASW, version 17) statistics programme. Specifically, univariate general linear 
models (GLMs) tested the effects of separate APOE and TOMM40 genotypes upon 
cognitive/brain imaging variables. Outliers of more than 3 standard deviations from mean 
values were removed from age 11 intelligence (N = 7). Outliers were not removed from 
imaging variables. Where appropriate, to protect against type 1 errors, the false discovery rate 
(FDR) was used to estimate the number of significant findings controlling for multiple testing 
(Benjamini and Hochberg, 1995). An Excel program (Pike 2011) was used to conduct 
classical one-stage FDR based on associations with white matter integrity. All P values are 
raw unless stated as being FDR-adjusted, and P-values < 0.05 are considered significant. 
 
2.10.1. Power analyses 
Wardlaw et al. (2011) conducted power estimation for the LBC1936 sample using the nQuery 
Advisor (www.statistical-solutions-software.com). With a sample size of n = 650, they 
calculated 80% power (at P <0.05) to find: 1) an r correlation with a value of 0.11, and 2) a 
variable that contributed 0.72% explained variance to a model, additional to four prior 
covariates that explained an initial 40% of the variance. These effect sizes are typical for 
associations between specific genetic variations (e.g. APOE) and brain imaging/cognitive 
phenotypes (Penke et al., 2010a; Wisdom et al., 2011). The current LBC1936 dataset would 
therefore seem sufficiently powered to find significant associations in subsequent analyses 
(Wardlaw et al., 2011). 
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2.11. Final analytic strategy 
The final analytic strategy is displayed in Table 2.2, including APOE/TOMM40 523 analysis 
and stepwise inclusion of covariate models. 
 
Table 2.2. Final analytic strategies for APOE ε and TOMM40 ‘523’ poly-T repeat 
gene loci for Chapters 4-7.  
 APOE ε TOMM40 ‘523’ 
Gene locus: rs7412 + rs429358 









ε4 present (vs. ε4 absent) 
Overall effect of genotype? 
(S/S; S/L; VL/L; L/L; VL/VL) 






ε3/ε4 (vs. ε3/ε3) 
S/S; S/L*; L*/L* 






ε2 present (vs. ε3/ε3) 
S/S; S/L*; L*/L* 






Model 1: Age + Gender 
Model 2: Age + Gender + Age 11 IQ 
Model 3: Age + Gender + Age 11 IQ + Cardiovascular disease history 
 
Note. The term ‘ε4 present’ includes participants with ε3/ε4; ε2/ε4; ε4/ε4 genotypes pooled together, 
while ‘ε4 absent’ includes all other genotypes. ‘ε2’ present includes participants with ε2/ε3 and ε3/ε3 












Chapter 3: ADRB2, cognitive ageing and brain white matter 
integrity 
 
A version of this chapter has been published as: Lyall, D.M., Lopez, L.M., Bastin, M.E., 
Maniega, S.M., Penke, L., Valdés Hernández, M.C., Royle, N.A. et al. (2013). ADRB2, brain 
white matter integrity and cognitive ageing in the Lothian Birth Cohort 1936. Behavior 








The non-synonymous mutations arg16gly (rs1042713) and gln27glu (rs1042714) in the 
adrenergic β-2 receptor gene (ADRB2) have previously been significantly associated with 
cognitive function and brain white matter integrity. The current study aimed to replicate these 
findings and expand them to a broader range of cognitive and brain imaging phenotypes. The 
sample used is a community-dwelling group of older people, the Lothian Birth Cohort 1936. 
They had been assessed cognitively at age 11 years, and undertook further cognitive 
assessments and brain diffusion MRI tractography in older age. The sample size range for 
cognitive function variables was n = 686 to 765, and for neuroimaging variables was n = 488 
to 587. Previously-reported findings with these genetic variants did not replicate in this 
cohort. Novel, nominally significant associations were observed; notably, the integrity of the 
left arcuate fasciculus mediated the association between rs1042714 and the Digit Symbol 
Coding test of information processing speed. No significant associations of cognitive and 
brain imaging phenotypes with ADRB2 variants survived correction for false discovery rate. 
Previous findings may therefore have been subject to type 1 error. Further study into links 
between ADRB2, cognitive function and brain white matter integrity is required.  This chapter 
provides proof of concept for subsequent chapters 4-7, by demonstrating a mediating 
relationship between genetic, brain imaging and cognitive phenotypes in LBC1936 (based on 







3.2.1. The ADRB2 gene locus 
The adrenergic biologic pathway stimulates catecholamine-induced activation of adenylate 
cyclase, which catalyzes the conversion of adenosine triphosphate (ATP) to 3’,’-cyclic AMP 
(cAMP), a secondary messenger that influences cellular replication, differentiation and 
survival; the adrenergic pathway is therefore important for brain development and function 
(Kulminski et al., 2010).  
The adrenergic β-2 receptor gene (ADRB2) is widely expressed in the brain where it 
plays many roles including signal transduction of adrenaline, noradrenaline and to a lesser 
extent dopamine (Brodde 2008; Dohlman et al., 1991). Two single nucleotide polymorphisms 
(SNPs), rs1042713 which causes an Arg16Gly amino acid substitution, and rs1042714 which 
causes a Gln27Glu amino acid substitution, affect adrenergic receptor sensitivity (Cagliani et 
al., 2009; Green et al., 1994). Arg16Gly and Gln27Glu polymorphisms have been 
significantly associated at P < 0.05 (hereafter simply ‘associated’) with increased risk of 
neurodevelopmental disorder (Cheslack-Postova et al., 2007, N = 331, e.g. odds ratio for 
rs1042714 Glu/Glu = 1.66, 95% confidence intervals = 1.07–2.58; vs. Gln/Gln) and, 
separately, with differences in cardiovascular phenotypes such as diastolic blood pressure 
(Snieder et al., 2002; N = 395, e.g. mean mmHg for rs1042714 Gln/Gln = 56.3 vs. Glu/Glu = 
58.0, r
2 
= 2.6%, P <0.01).   
Bochdanovits et al. (2009) tested rs1042713 and rs1042714 in two Dutch samples of 
391 young (mean age 12.7 years) and 409 adult (36.7 years) participants assessed on Dutch 




). For rs1042713, the 
16Gly (G allele) was associated with lower performance IQ scores in the young Dutch 
sample only (χ2 statistic = 6.42, P = 0.01). They also assessed the Lothian Birth Cohort 1936 





Moray House Test No.12 (MHT; a general intelligence-type test) at two ages, namely 11 and 
70 years, and the Matrix Reasoning subtask from the standard WAIS-III
UK
 also at age 70 
years. Matrix Reasoning was significantly associated with both rs1042713 (standardised β = 
0.07; hereafter β; P = 0.025) and rs1042714 (β = 0.08, P = 0.014) positively and additively in 
the direction of the 16Gly and 27Glu (G) alleles, respectively. The rs1042713 SNP was also 
associated with age 70 MHT (β = 0.07, P = 0.025), and rs1042714 with age 11 MHT (β = 
0.07, P = 0.023).  
 
3.2.2. ADRB2, brain white matter tract integrity and cognitive ability 
Diffusion tensor MRI (DTI) and quantitative tractography allow examination of brain white 
matter microstructure in vivo in specific white matter tracts thought to relate to cognitive 
functions (Behrens et al., 2007; Pierpaoli et al., 1996). DTI measures the magnitude and 
directional coherence of water molecule diffusion and, because water molecule diffusion is 
preferentially constrained along  the principal fibre direction by axonal membranes and 
myelin sheaths, this property can be used to assess white matter structural integrity (Behrens 
et al., 2007; Pierpaoli et al., 1996). Fractional anisotropy (FA) and mean diffusivity (MD) are 
examples of common DTI-derived metrics, and reflect the magnitude and level of directional 
coherence of water molecule diffusion (Pierpaoli et al., 1996). Specifically, FA measures are 
high in healthy, structurally intact, coherently organised white matter, but fall in diseased 
tissue, with MD measures the inverse (i.e. lower values in intact tissue). 
In a subsample consisting of 162 LBC1936 participants who had by that time 
undergone diffusion MRI tractography as well as cognitive assessments (Penke et al., 2010b), 
the rs1042714 G allele was significantly associated with reduced FA (β = -0.19, P = 0.008) in 
the left arcuate fasciculus indicating lower white matter integrity. In the splenium of corpus 





0.026), indicating greater integrity. This allele was associated with higher age 70 MHT and 
age 73 Matrix Reasoning performance, both with (β = 0.24, P = 0.003 and β = 0.23, P = 
0.003) and without (β = 0.19, P = 0.008 and β = 0.23, P = 0.003) controlling for childhood 
intelligence as assessed by the MHT. These data therefore indicate that variation in the 
ADRB2 gene may have an effect on the change in cognitive function between childhood and 
older age. In addition, Penke et al. (2010b) found that the integrity of the splenium correlated 
positively with Matrix Reasoning and MHT performance. These neuroimaging and cognitive 
variables were each associated with the G allele of rs1042714. Penke et al. (2010a) further 
reported that controlling for splenium integrity attenuated the relationship between rs1042714 
and both MHT and Matrix Reasoning adjusted for age 11 cognitive ability, indicating that 
this tract partially mediated the SNP-cognitive ageing associations (Sobel mediation test P 
values = 0.058 and 0.077). Penke et al. reported relatively large effect sizes (β) for an 
association study of common SNPs, and it is important to attempt replication in a larger 
sample.  
 
3.2.3. Current study 
Bochdanovits et al. (2009) suggested that the G alleles of rs1042713 and rs1042714 could 
have been under positive selection for higher cognitive ability in humans, whereas Penke et 
al. (2010b) noted that the G allele of rs1042714 appears to be protective against age-related 
cognitive decline (Deary et al., 2009). In the current study it is investigated: i) whether the 
results of Penke et al. (2010b) can be replicated in the larger, full LBC1936 sample; while ii) 
extending the number of cognitive domains and white matter tracts tested for association with 
ADRB2 SNPs, in further exploratory analyses. By formally testing for a mediating 
relationship between genetic, brain imaging and cognitive variables in the LBC1936, this 






3.3.1. Sample and procedure 
The recruitment and testing of the LBC1936 sample used here is described in Chapter 2 
(‘Methodology’; Deary et al., 2007; 2012).  
 
3.3.2. Cognitive assessment 
The cognitive tests completed by members of the LBC1936 sample are described in Chapter 
2 (‘Methodology’), as well as the protocol paper (Deary et al., 2007). Data reduction was 
applied to the cognitive test scores using principal components analyses (PCA) which 
produced summary cognitive variables, as detailed in Chapter 2 (‘Methodology’).  The first 
unrotated principal component scores in each domain accounted for the variance as follows: 
50.1% for g, 49.8% for gSpeed, and 53.6% for gMemory. All individual test scores had moderate 
to high loadings on their respective first unrotated principal components for g (r range = 0.64 
to 0.75), gSpeed (r range = -0.51 to 0.78) and gMemory (r range = 0.54 to 0.82). 
 
3.3.3. Childhood intelligence 
The Moray House Test no.12 (MHT) completed at around age 11 years is described in 
Chapter 2 (‘Methodology’). 
 
3.3.4. Diffusion MRI and tractography analysis 
The core brain MRI procedure is described in Chapter 2 (‘Methodology’; see also the 
protocol paper by Wardlaw et al., 2011).  
Diffusion MRI data acquisition and pre-processing with FSL is detailed in the 





of water diffusion tensor parameters MD and FA. These biomarkers measure the magnitude 
and directional coherence of water molecule diffusion in vivo, and since water molecules 
diffuse preferentially along the principal fibre direction, can be used to assess white matter 
structural integrity (Pierpaoli et al., 1996). Specifically, MD takes low and FA high values in 
healthy, structurally intact white matter, but rise or fall respectively in diseased tissue. Further 
details are provided by Wardlaw et al. (2011). 
 Twelve tracts-of-interest were identified using probabilistic neighbourhood 
tractography, a novel approach for automatic and reproducible tract segmentation (Clayden et 
al., 2007), as implemented in the TractoR package for fibre tracking analysis (Clayden et al., 
2011; http://www.tractor-mri.org.uk). Tracts assessed were the genu and splenium of corpus 
callosum, and bilateral anterior thalamic radiations, rostral cingulum bundles, arcuate, 
uncinate and inferior longitudinal fasciculi. Tract masks generated by this method were 
overlaid on the MD and FA parametric maps and tract-averaged values of these biomarkers, 
weighted by the connection probability, determined for each tract in every subject (Wardlaw 
et al., 2011). In general, probabilistic neighbourhood tractography was able to segment the 
twelve tracts-of-interest reliably (see Wardlaw et al., 2011 for more details). 
PCA was conducted on the tract-averaged water diffusion parameters for these twelve 
pathways, giving clear single-factor models for FA (gFA) and MD (gMD) that accounted for 
38.8% and 39.4% of the overall variance respectively. The ventral cingulum was not included 
in the PCA because the rostral and ventral cingula are subdivisions of the same tract. All 
individual tracts had moderate to high loadings on their respective first unrotated principal 
components (FA r range = 0.33 to 0.70; MD r range = 0.19 to 0.71). This indicates that the 
integrity of white matter tracts is to a substantial degree shared among different tracts 





white matter integrity factors have been found to be associated with cognitive abilities in this 
sample (Penke et al., 2010a; Penke et al., 2012).  
 
3.3.5. ADRB2 genotyping  
ADRB2 SNPs rs1042713 and rs1042714 were genotyped from DNA isolated from whole 
blood by KBiosciences (http://www.kbioscience.co.uk) using their proprietary genotyping 
assay, KASPar.  
 
3.4. Statistical analyses 
Analysis first attempts to replicate the results reported by Bochdanovits et al. (2009) and 
Penke et al. (2010b) using the same cognitive measures and covariates. In a second step, 
exploratory analyses are conducted on a broader range of cognitive measures and white 
matter tracts to test further associations between ADRB2 SNPs, neurostructural indicators, 
and cognitive ability as well as lifetime cognitive change. 
All associations were controlled for gender in addition to age in days at time of 
cognitive and neuroimaging assessment. Penke et al. (2010b) reported that associations that 
controlled for age and gender were unchanged when cardiovascular disease histories were 
entered as covariates. Any influence of cardiovascular pathologies such as high blood 
pressure on genotype-brain imaging/cognitive phenotype associations may have been 
different in the larger sample used here (n = 866) compared with the smaller sample used by 
Penke et al. (n = 162). The current study therefore included associated cardiovascular 
covariates in exploratory analyses as part of the final model in this larger sample unless 
otherwise specified. To examine the effects of ADRB2 upon lifetime cognitive change, 





In the current study, PLINK (Purcell et al., 2007; 
http://pngu.mgh.harvard.edu/~purcell/plink) provided summary statistics for minor allele 
frequencies and was used to perform tests of Hardy-Weinberg equilibrium. Haploview 
provided linkage disequilibrium statistics (Barret et al., 2005; 
http://www.broadinstitute.org/scientific-community/science/programs/medical-and-
population-genetics/haploview/haploview). Data were otherwise analysed with the Predictive 
Analytics SoftWare (PASW, version 17; http://www-01.ibm.com/software/uk/analytics/spss) 
statistics programme.  
Mediation analysis was used to test the indirect effect of the predictor variable 
(ADRB2) upon the outcome (cognitive function), through the hypothesised mediator (white 
matter integrity). Mediation analysis was run using the INDIRECT bootstrapping macro 
(Preacher and Hayes, 2008). In a simple example mediation model (see Figure 3.1), variable 
X’s effects on variable Y can be either direct or indirect via variable M. Path A represents the 
effect of X on M, while path B represents the effect of M on Y, partialling out the effect of X.  
The direct effect of X on Y is represented by path C. The indirect effect can then be 
quantified as the combined product of paths A and B. The bias-corrected bootstrapping point 
estimate coefficients that are reported here each reflect this indirect product (Preacher and 
Hayes, 2008). These point estimate coefficients are unstandardised and averaged over 5000 
bootstrap estimates (Preacher and Hayes, 2008). Bias-corrected bootstrapping has an 
advantage over percentile bootstrapping in that it corrects for any skew in the population, 
including the bias created by the central tendency of the estimate (Efron and Tibshirani, 
1993; Fritz and MacKinnon, 2007).  
To protect against type 1 error, the false discovery rate (FDR) was used to estimate 





1995). An Excel macro (Pike, 2011) was used to conduct classical one-stage FDR based on 
ADRB2 associations with white matter integrity and cognitive function.  
All initially-reported P-values are raw (and then FDR-adjustment is applied),  
coefficients are standardised (and are equivalent to semi-partial r correlations), and P-values 
< 0.05 are considered nominally significant. Linear regression analyses tested the additive 
effects of ADRB2 rs1042713 and rs1042714 SNP G alleles upon white matter and cognitive 





Figure 3.1. Schematic showing a standard mediation model, where variable X’s effects on variable Y can be either direct or indirect via variable 
M. Path A represents the effect of X on M, while path B represents the effect of M on Y, partialling out the effect of X.  The direct effect of X on Y 


































Of the 866 members of the cohort who returned for cognitive testing in Wave 2, participants 
were excluded if they reported being ambidextrous or left-handed at either wave (n = 57; 
reflecting asymmetries in white matter tract connectivity that have been associated with 
handedness; Buchel et al., 2004), had MMSE scores below 24 (n = 7) or not completed at 
Wave 2 (n = 1), reported diagnosis of dementia (n = 1), or failed/refused genotyping for 
rs1042713 (n = 34) or rs1042714 (n = 36). One participant was removed from analysis 
because of a discrepancy between their directly genotyped ADRB2 data (as described above) 
and genome wide association study (GWAS) data which were also available for the current 
sample. Removing this participant did not affect any final results and this chapter reports only 
directly genotyped data as performed by KBioscience. Cognitive and SNP data were 
ultimately obtained from 765 (rs1042713) and 762 (rs1042714) individuals, and 
neuroimaging data were obtained from 650 and 647 subjects, respectively. Outliers of more 
than 3 standard deviations from mean values were removed from all cognitive variables. 
Minor allele frequencies in the sample for rs1042713 were A = 34%, and for 
rs1042714 G = 48%. Genotype frequencies for rs1042713 were AA = 11%, AG = 46% and 
GG = 43%, and for rs1042714 GG = 23%, GC = 50% and CC = 27%. These frequencies are 
relatively similar to those reported in other large independent samples (Snieder et al., 2002). 
Exact tests performed in PLINK confirmed that rs1042713 (P = 0.52) and rs1042714 (P = 
0.91) were individually in Hardy-Weinberg equilibrium. Both SNPs were in high linkage 







3.5.1. Attempted replication of previous findings 
Replication of previous results by Bochdanovits et al. (2009) and Penke et al. (2010b) was 
attempted first. Bochdanovits et al. examined Matrix Reasoning scores at age 70 and MHT 
scores at ages 11 and 70, while Penke et al. examined MHT at age 70 and Matrix Reasoning 
at age 73 both adjusted and unadjusted for age 11 cognitive ability. For comparison, Table 
3.1 shows association statistics ( coefficients and P values) as reported by Bochdanovits et 
al., and Penke et al. and also when re-tested in the present sample. 
In a larger number of the LBC1936 tested at mean age 70 years (n = 1063; Wave 1), 
Bochdanovits et al. (2009) reported associations between ADRB2 SNPs and abstract 
reasoning tasks, controlling for age and gender. When tested again in the current subsample 
of participants that underwent repeat cognitive testing in Wave 2, there were no significant 
associations between rs1042713 or rs1042714 with MHT or Matrix Reasoning at age 70, or 
MHT at age 11 years (all P > 0.05; see Table 3.1). The effect sizes were similar to those 
found by Bochdanovits et al. but non-significant. The current study included right-handed 
participants only. To test for this as a source of discrepancy, the original data (Wave 1) of 
Bochdanovits et al. were re-analysed in right-handed participants only (n = 954). With an 
otherwise identical analytic strategy, the findings by Bochdanovits et al. remained at or very 
close to statistical significance except for one association; namely rs1042714 and age 11 
MHT (β = 0.05, P = 0.165). Another source of discrepancy may be selective attrition of more 
cognitively impaired individuals from Wave 1 to Wave 2 of testing in old age. Independent 
samples t-tests showed that in right-handed participants, those who attended both Waves 1 
and 2 (n = 866)—compared with those who attended Wave 1 only—had higher scores on age 
11 MHT (mean = 50.16, SD = 11.00 vs. mean = 47.62 SD = 10.53, t = -2.89, P = 0.004, 





3.59, P < 0.001, Cohen’s d = 0.30) and age 70 Matrix Reasoning (mean = 13.92, SD = 5.03 
vs. mean = 12.27, SD = 5.14, t = -4.15, P <0.001, Cohen’s d = 0.32).  
The previous pilot study on the subsample of the present cohort that had been brain 
scanned at that time (n = 162) reported seven significant associations (Penke et al., 2010b), 
which are shown here in Table 3.1. In the current full sample, all seven associations were 
markedly reduced in effect size. Only the one between rs1042714 and left arcuate fasciculus 
FA (β = -0.12, P = 0.006) was still significant and the one between rs1042714 and age 73 
Matrix Reasoning (β = 0.07, P = 0.053) showed a statistical trend. This trend attenuated 
when age 11 MHT score was added as a covariate (β = 0.05, P = 0.116). Because there were 
no significant associations with splenium of corpus callosum FA or MD, replicating the 

















Present sample (n = ~765) 
 β (p) 
 









  Moray House Test (age 70) 0.07 (0.025) 0.04 (0.240) 
 rs1042714 Matrix Reasoning (age 70) 0.08 (0.014) 0.06 (0.124) 
  Moray House Test (age 11) 0.07 (0.023) 0.06 (0.109) 
 









  Adjusted for age 11 IQ 0.19 (0.008) 0.00 (0.982) 
  Matrix Reasoning (age 73) 0.23 (0.003) 0.07 (0.053) 
  Adjusted for age 11 IQ 0.23 (0.003) 0.05 (0.116) 
  Left arcuate fasciculus FA -0.19 (0.013) -0.12 (0.006)* 
  Splenium corpus callosum FA 0.16 (0.043) 0.01 (0.803)* 
  Splenium corpus callosum MD -0.17 (0.026) -0.02 (0.567)* 






3.5.2. Exploratory analyses: vascular risk factors 
Controlling for age and gender, linear regression analyses showed an association between 
rs1042713 and self-reported diagnosis of high blood pressure (β = 0.09, P = 0.019), and a 
trend toward an association with rs1042714 (β = 0.07, P = 0.067). Neither SNP was 
associated with self-reported diabetes, stroke, high cholesterol or any other cardiovascular 
disease (all P > 0.05). The following analyses therefore controlled for high blood pressure in 
addition to age, gender and (where applicable in cognitive analyses only) age 11 MHT score.  
 
3.5.3. Exploratory analyses: ADRB2 and white matter tract integrity 
Fifty-two separate tests of association between ADRB2 SNPs and white matter integrity 
variables were conducted (see Table 3.2), of which four were nominally significant at the P < 
0.05 level. For rs1042713, there were associations with lower FA of the left arcuate 
fasciculus (β = -0.10, P = 0.021) and right anterior thalamic radiation (β = -0.09, P = 0.025). 
For rs1042714 there were associations with lower left arcuate fasciculus FA (β = -0.11, P = 












White Matter Tract 
 
rs1042713 (G allele) 
 

























General factor (gMD or gFA) -0.08 (0.072) 531 0.02 (0.638) 531 -0.07 (0.086) 529 0.03 (0.554) 529 
Genu of the corpus callosum  -0.06 (0.152) 570 0.01 (0.773) 570 -0.05 (0.284) 568 0.01 (0.774) 568 
Splenium of the corpus callosum  0.01 (0.837) 586 0.01 (0.836) 586 0.01 (0.772) 584 -0.02 (0.582) 584 
Left arcuate fasciculus  -0.10 (0.021) 562 0.06 (0.148) 562 -0.11 (0.007) 560 0.09 (0.037) 560 
Right arcuate fasciculus -0.06 (0.211) 512 -0.01 (0.913) 512 -0.08 (0.079) 509 0.04 (0.359) 509 
Left uncinate fasciculus -0.03 (0.528) 502 -0.05 (0.305) 502 -0.03 (0.531) 500 0.00 (0.938) 500 
Right uncinate fasciculus -0.05 (0.210) 555 0.06 (0.198) 555 -0.06 (0.146) 553 0.07 (0.124) 553 
Left anterior thalamic radiation  -0.05 (0.285) 488 0.02 (0.641) 488 0.00 (0.929) 486 0.02 (0.603) 486 
Right anterior thalamic radiation  -0.09 (0.025) 567 0.07 (0.102) 567 -0.06 (0.123) 564 0.01 (0.793) 564 
Left rostral cingulum  -0.08 (0.073) 567 0.04 (0.357) 567 -0.07 (0.100) 565 0.02 (0.716) 565 
Right rostral cingulum  -0.02 (0.589) 574 0.00 (0.983) 574 -0.04 (0.346) 572 -0.03 (0.495) 572 
Left inferior longitudinal fasciculus  0.03 (0.540) 586 -0.06 (0.134) 586 -0.06 (0.150) 584 0.01 (0.867) 584 
Right inferior longitudinal fasciculus  -0.07 (0.072) 587 0.02 (0.610) 587 -0.07 (0.072) 587 0.02 (0.610) 587 
Note. Gender, diagnosis of high blood pressure and age at time of MRI statistically controlled. All beta values are standardized. Associations significant at P <0.05 are printed in bold-face. All 





3.5.4. Exploratory analyses: ADRB2 and cognitive performance 
In exploratory analyses, analyses examined a range of cognitive phenotypes at age 73, as well 
as MHT performance at ages 11 and 70 only, at first unadjusted and then adjusted for age 11 
ability. The attempted replication of findings reported by Bochdanovits et al., and Penke et al. 
(above) controlled for age, gender and (where applicable) age 11 intelligence. Controlling for 
age, gender and additionally for high blood pressure, no significant associations were evident 
in the present analyses between ADRB2 SNPs and g, gSpeed and gMemory. Table 3.3 shows the 
associations between ADRB2 SNPs and specific cognitive task scores, not adjusted for age 11 
MHT scores. There was no evidence of association between ADRB2 and specific memory or 
visuospatial tasks.  The ADRB2 SNP rs1042713 showed a nominally significant association 
with better performance on Simple RT, in the direction of the G allele (β = -0.09, P = 0.010). 
The rs1042714 polymorphism was also associated with better Simple RT (β = -0.08, P = 
0.035) and Matrix Reasoning performance (β = 0.07, P = 0.041), in the direction of the G 
allele.  
Additionally controlling for age 11 MHT scores in order to test for associations with 
lifetime cognitive change, Table 3.4 shows that the ADRB2 SNP rs1042714 showed a 
nominally significant association with poorer processing speed (gSpeed; β = -0.07, P = 0.045). 
When tests of association were conducted with specific processing speed tasks, rs1042713 
was associated with faster Simple RT (β = -0.09, P = 0.025) but worse Symbol Search 
performance (β = -0.07, P = 0.044). The rs1042714 polymorphism was associated with worse 
performance on Digit Symbol Coding (β = -0.09, P = 0.010) and Symbol Search (β = -0.08, 
P = 0.022) tests. Note that when age 11 MHT scores were controlled for, the nominally 
significant associations between rs1042714, Matrix Reasoning and Simple RT in Table 3.3 





Table 3.3. Linear ADRB2 SNP associations with cognitive abilities, not adjusted for age 11 cognitive ability. 
 
Cognitive measure 
rs1042713 (G allele) rs1042714 (G allele) 
β (p) N β (p) N 
 











































































































































































Note. Age at time of testing, gender and high blood pressure statistically controlled. All beta values are standardised. Associations significant at P < 0.05 are printed in bold-face. 
a
Controlling 





Table 3.4. Linear ADRB2 SNP associations with cognitive abilities, adjusted for age 11 cognitive ability. 
 
Cognitive measure 
rs1042713 (G allele) rs1042714 (G allele) 
β (p) N β (p) N 
 
Moray House Test: age 70  
 


































































































Four Choice Reaction Time (seconds) 
 

























































Note. Age at time of testing, gender, high blood pressure and age 11 Moray House Test score statistically controlled. All beta values are standardised. 





Linear regression models were used to explore associations between white matter tracts and 
cognitive measures that both showed nominally significant associations with ADRB2 
variants. As shown in Table 3.5, Simple RT was associated with FA of the right anterior 
thalamic radiation (β = -0.10, P = 0.024). The rs1042713 G allele was associated with both of 
these variables. Of the measures associated with the rs1042714 G allele, FA of the left 
arcuate fasciculus was associated with Digit Symbol Coding (β = 0.12, P = 0.001) and gSpeed 
(β = 0.012, P = 0.004). With FDR correction for all reported tests, the association between 
left arcuate fasciculus FA and Digit Symbol Coding remained statistically significant (FDR-
adjusted P = 0.048). None of the other associations between white matter integrity and 
cognitive function survived FDR correction.  
Neuroimaging and cognitive variables that both showed nominally significant 
associations with ADRB2 SNPs were examined further (see Figure 3.2). Note that all 
genotype-phenotype associations attenuated to non-significance when corrected for FDR and 
this mediation analysis is therefore only exploratory. Bootstrapping statistics indicated that 
the association between rs1042713 and Simple RT was significantly mediated by right 
anterior thalamic radiation FA (bootstrapping point estimate coefficient i.e. indirect effect: 
<0.001 [95% C.I.s: <0.001 to 0.002]), because the bootstrapping confidence interval span did 
not contain zero (Preacher and Hayes, 2008). Left arcuate fasciculus FA was found to 
significantly mediate the association between rs1042714 and Digit Symbol Coding (indirect 














Digit Symbol Coding 
 
Simple Reaction time 
 









































































Note. Age at time of testing, gender, high blood pressure and age 11 Moray House Test score statistically controlled. All beta values are standardised. 
Associations significant at P < 0.05 are printed in bold-face. 
a









Figure 3.2. Mediation analyses of the role of white matter integrity in the association between ADRB2 SNPs and cognition, controlling for age, 






























Note. Associations shown represent linear regressions between each variable. Note this mediation is in the context of attenuation to non-significance when 
corrected for multiple comparisons (FDR). All beta values are standardised. FA = fractional anisotropy. Values in brackets are betas before controlling for 












































In an earlier report employing the full LBC1936 sample and using Wave 1 data, 
(Bochdanovits et al., 2009), ADRB2 SNPs were associated with cognitive tests performed at 
mean age 70 years. Specifically, rs1047213 and rs1042714 were associated with performance 
on two cognitive tests, namely Matrix Reasoning and the MHT. In a subsample study of the 
LBC1936 tested at mean age 73 years (Penke et al., 2010b), associations were found for 
rs1042714 with cognitive ability and particularly cognitive change from childhood to older 
age that were mediated by white matter integrity in the splenium of the corpus callosum. In 
the present study of only right-handed participants who completed cognitive testing, the 
majority of whom also underwent diffusion MRI, and with identical covariates, these 
associations with cognitive function and white matter integrity did not replicate. 
 
3.6.2. Interpretation: failure to replicate previous reports 
The effect sizes reported by Penke et al. were not found here and Bochdanovits et al. reported 
small coefficients, suggesting that associations may be sensitive to changes in sample size; 
specifically selection effects, restriction of range and random fluctuation. Compared with the 
associations reported by Bochdanovits et al., the effect sizes reported here are similar but 
slightly smaller, and with a smaller sample size did not attain statistical significance. The 
current study differed from Bochdanovits et al. in two ways: The earlier report assessed 
participants that attended Wave 1 and included left, right and ambidextrous-handed 
participants, whereas the current study included only right-handed individuals that attended 
Wave 2. One previous association that was reported by Bochdanovits et al. attenuated when 





discrepancy between the two reports. There is also evidence that another source of 
discrepancy may be selective attrition of more cognitively impaired individuals between 
Waves 1 and 2. It is important to note that Bochdanovits et al. reported opposing associations 
for the rs1042713 G allele; in the deleterious direction for younger participants, but in the 
protective direction for older participants. Their findings were therefore not unambiguous. 
Failure to replicate Penke et al. may reflect the limited number of participants in the original 
study compared to the current report. It is therefore possible that previous findings were type 
1 errors.  
 
3.6.3. Interpretation: exploratory analyses 
In exploratory analysis of a range of age 73 white matter and cognitive phenotypes as well as 
MHT scores at ages 11 and 70, after controlling for gender, high blood pressure and age in 
days, rs1042713 was associated with faster Simple RT in the direction of the G allele. For 
rs1042714, associations were found with faster Simple RT and greater Matrix Reasoning 
performance in the direction of the G allele. After controlling for age 11 MHT scores, 
association between rs1042713 and faster Simple RT remained statistically significant in 
addition to an association with lower Symbol Search performance. When also adjusted for 
age 11 MHT scores, rs1042714 showed significant associations with lower Digit Symbol 
Coding, Symbol Search and gSpeed scores however previous associations with Simple RT and 
Matrix Reasoning attenuated to non-significance, indicating those effects were specific to 
cross-sectional ability at age 73 rather than cognitive ageing. In terms of white matter 
integrity, the G allele of rs1042713 was associated with lower FA of the left arcuate 
fasciculus and right anterior thalamic radiation tracts, while the G allele of rs1042714 was 
associated with lower FA/MD in the left arcuate fasciculus. When adjusted for multiple 





Bearing in mind that correction for multiple testing could have been overly conservative, 
analyses explored, using bootstrapping, mediation of associations between ADRB2 and 
cognitive task performances by specific white matter tracts where the uncorrected p-levels 
were indicative of such links.  It should be emphasised that these analyses were cautiously 
exploratory in the context of genotype-phenotype associations that were non-significant when 
corrected for FDR. However, they could provide indications for future studies.  
The relationship between rs1042714 and Digit Symbol Coding attenuated when left 
arcuate fasciculus FA was controlled for. This may suggest partial mediation (Salthouse 
2010). Integrity of the arcuate fasciculus has been associated with performance on different 
cognitive domains (Schmithorst et al., 2005) and has been suggested to underlie parieto-
frontal cortical integration, a proposed foundation of higher cognitive ability (Jung and Haier, 
2007; Deary et al., 2010). The mediation reported here may therefore reflect the general role 
that this tract plays in subserving cognitive functioning in addition to the high sensitivity of 
the Digit Symbol Coding task in detecting even subtle cognitive dysfunction (Lezak et al., 
2004). The association between rs1042713 and Simple RT showed evidence of being 
mediated by FA of the right anterior thalamic radiation tract. The strength of association 
between rs1042713 and Simple RT did not attenuate when relevant white matter integrity 
measures were controlled for however, and instead strengthened. This does not suggest true 
partial mediation; rather, these measures suppressed the relationship between rs1042713 and 
Simple RT (MacKinnon et al., 2000). It is counter-intuitive for the same allele to associate 
with faster Simple RT but lower integrity in associated white matter tracts. This suggests that 
this direct SNP-cognitive task association may instead be mediated by other related but 
distinct brain measures, for example integrity of the superior longitudinal fasciculus white 
matter tract which was not assessed here. It is also possible that this counter-intuitive finding 





3.6.4. Limitations and future studies 
A large number of association tests were conducted, and all significant associations 
attenuated once corrected for multiple testing using FDR. Whereas there are likely to be type 
1 errors in the current study, given the number of associations conducted, it is also possible 
that correction for multiple testing is rejecting modest but true signals (Williams and Haines, 
2011). Cognitive and water diffusion tensor phenotypes are individually highly correlated as 
indicated by the g, gSpeed, gMemory, gMD, and gFA factors, which means that each association test 
does not represent an independent observation. This can make correction for multiple testing 




The current study examined healthy older adults that were cognitively assessed at age 11 
years and again in older age. ADRB2 previously showed significant associations with 
cognitive ageing mediated by white matter tract integrity in a pilot study of the LBC1936 
cohort. These associations were not replicated in this larger sample from the same cohort. 
Novel three-way associations were evident between ADRB2 G alleles and specific cognitive 
and white matter tract integrity measures; however, all associations attenuated to non-
significance upon correction for multiple testing. This correction could be considered 
conservative, so further research on functional ADRB2 SNPs in large, independent samples is 
needed. This chapter provides proof of concept for subsequent Chapters 4-7 because analyses 
show significant mediating relationships between genetic, cognitive and brain imaging 
variables (based on unadjusted, nominal three-way associations). 












Chapter 4: Alzheimer’s disease susceptibility genes APOE and 
TOMM40, and brain white matter integrity 
 
A version of this chapter is in preparation for submission for publication: Lyall, D.M., Harris, 
S.E., Bastin, M.E., Muñoz Maniga, S., Murray, C., Lutz, M.W., Saunders, A.M., Roses, 
A.D., Valdés Hernández, M. del C., Royle, N.A., Starr, J.M., Porteous, D.J., Wardlaw, J.M. 






An 2/3/4 haplotype in the APOE gene has previously been significantly associated with 
cognitive, brain imaging, and Alzheimer’s disease-related (e.g. age of onset) phenotypes. In 
the TOMM40 gene, the rs10524523 (‘523’) variable length poly-T repeat polymorphism has 
more recently been associated with similar cognitive and AD-related phenotypes, although 
the allelic directions of these associations have varied between initial reports. Using diffusion 
MRI tractography, the current study aimed to investigate whether there are independent 
effects of APOE and TOMM40 on human brain white matter integrity in a community-
dwelling sample of older adults, the Lothian Birth Cohort 1936 (mean age = 72.70 years, 
standard deviation [SD] = 0.74, N approx. 640-650 for most analyses).  
Some nominally significant effects were observed (i.e. covariate-adjusted differences 
between genotype groups at P < 0.05). For APOE, deleterious effects of 4 ‘risk’ allele 
presence (versus absence) were found in the right ventral cingulum and left inferior 
longitudinal fasciculus. To test for biologically independent effects of the TOMM40 523 
repeat, participants were stratified into APOE genotype subgroups. In participants with the 
APOE 3/4 genotype, effects of TOMM40 523 status were found in the left uncinate 
fasciculus, left rostral cingulum, left ventral cingulum, and a general factor of white matter 
integrity. In all four of these tractography measures, carriers of the TOMM40 523 ‘short’ 
allele showed lower white matter integrity when compared with carriers of the ‘long’ and 
‘very-long’ alleles. The majority of these effects survived correction for childhood 
intelligence test scores and cardiovascular disease history, though only the effect of TOMM40 
523 on left ventral cingulum integrity survived correction for false discovery rate.  
The effects of APOE in this older population are more specific and restricted 
compared with those reported in previous studies, and the effects of TOMM40 on white 




4.2. Introduction  
APOE and TOMM40 genetic loci 
This APOE ε and TOMM40 523 gene loci are detailed in Chapter 1 (‘Introduction’) and 
Chapter 2 (‘Methodology’).  
 
4.2.1. Brain white matter integrity 
Diffusion tensor MRI (DTI) and quantitative tractography were introduced in Chapter 3 
(‘ADRB2…’) and are recapped here. Briefly, DTI allows examination of brain white matter 
microstructure in vivo in specific white matter tracts thought to relate to cognitive functions 
(Behrens et al., 2007; Pierpaoli et al., 1996). Fractional anisotropy (FA) is an example of a 
common DTI-derived metric, and reflects the level of directional coherence of water 
molecule diffusion (Pierpaoli et al., 1996). Specifically, FA measures are high in healthy, 
structurally intact, coherently organised white matter, but fall in diseased tissue.  
There are significant deleterious changes in brain white matter integrity in people 
diagnosed with Alzheimer’s disease (AD). Sexton et al. (2011) conducted a meta-analysis of 
41 independent studies that had compared samples of people with clinical AD (typically 
based on DSM-4 or NINCDS-ADRDA diagnostic criteria; N = 617), with healthy controls 
(HC; N = 915), corrected for age and education (in years). They calculated an effect size, 
Hedge’s g, reflecting the difference between groups divided by the pooled SD, and therefore 
corrected for any bias associated with small sample sizes. Sexton et al. reported significant, 
deleterious effects of AD group membership on 11 of 13 regions where brain white matter 
FA was assessed in different studies (Hedge’s g range = -0.23 to -1.14; P < 0.05; ‘Small’ to 
‘Large’ effect sizes).  
White matter tract integrity shows significant non-pathological age-related change 




coefficient for age on frontal lobe white matter integrity = 0.34, P <0.001), and may be 
associated with cognitive abilities by forming the basis for connecting brain networks, where 
lower integrity may hinder the efficient processing of information (Westlye et al., 2012a). 
Penke et al. (2010a), for example, reported that a general factor of white matter tract integrity 
FA (gFA), constructed with principal components analysis (PCA), was significantly associated 
with a general factor of information processing speed (r = -0.24, P = 0.007) in a subsample 
of the LBC1936 dataset that had by that time undergone DTI (n = 132; aged around 73 
years), adjusted for age and gender. 
 
4.2.2. APOE, TOMM40 and brain white matter integrity 
Associations between the APOE gene and white matter integrity have been investigated 
previously (see Gold et al., 2012 for a review of significant findings, and Table 4.1 which 
provides an outline). Observing Table 4.1, certain points are salient: 
1. The majority of previous reports investigate samples with relatively wide age ranges. 
Heterogeneous age ranges in samples of older adults can be problematic; the correlation 
between age and white matter integrity is unlikely to be completely unique and rather 
may be via several processes associated with chronological age, such as amyloid-beta 
accumulation (Hofer and Sliwinski, 2001). Several studies statistically adjust for the 
effects of age. This only partially removes ageing effects; it is unlikely to control for the 
cumulative effects of all subtle age-related changes (Hofer and Sliwinski, 2001). This 
could result in spurious results because several brain imaging/cognitive phenotypes show 
change with age. Homogeneous age samples are therefore preferable. 
2. Cardiovascular disease history is not consistently controlled for; significant associations 
between APOE/TOMM40 genotypes and cardiovascular pathology could result in 




The largest previous study of APOE and brain white matter tract integrity had 203 
participants (Westlye et al., 2012b; mean age = 47.6 years, SD = 14.9). That report found 
widespread differences in microstructural integrity depending on APOE status. Controlling 
for age and gender, 3/4 carriers had lower white matter integrity (vs. 3/3) in the 
brainstem, basal temporal lobe, internal capsule, anterior parts of the corpus callosum, 
forceps minor, superior longitudinal fasciculus, occipital and corticospinal motor pathways 
(Cohen’s d range = 0.77 to 0.79; ‘medium-large effects’). To date there appear no studies that 



























Notes & limitations 
Heise et  
al. 2011 
Whole brain TBSS; FA & 
MD.  
(1. APOE ɛ4+ vs. -). 
(2. age*ɛ4 interaction). 
Healthy young  adults 
(28.6 years; ±4.20*)  






Age, sex, education, 
family history of AD &  
ACE-r scores (all n.s; p > 
0.05 between genotypes). 
FA ↓ & MD ↑; Cingulum, Corona Radiate, 
Corpus Callosum, External/Internal 





P < 0.05). 
No effect sizes reported.  
No age group*ɛ4 interaction  
(P > 0.05). 
Honea et 
al. 2009 
TBSS; FA  
(ɛ4+ vs. -). 
Healthy older adults 
(73.4; ±6.3). 
39 Age & gender 
(statistically controlled 
for); education & type-2 
diabetes, frailty inventory 
(PPT) (n.s.). 
 
FA ↓; (L) Parahippocampal gyrus (coordinates -
27X, -24Y, -23Z, voxel cluster size =N/A, P <0.001, n.s. 
after FWE correction). 
FWE rate 
(P <0.05). 
Standard TBSS template may 
introduce error through 
discrepancy between template & 
subject ages (Chiang et al., 2012). 
Persson et 
al. 2006 
1. ROI; FA.  
Genu/splenium/body of 
corpus callosum 
2. whole brain 
comparisons  
(ɛ4+ vs. ɛ3/ɛ3). 
Healthy older adults 
(66.3; ±7.8*). 
60 Age, sex, education, 
cardiovascular disorder 
history, blood pressure & 
associated medication & 
MMSE scores  (n.s.) 
i. FA ↓; splenium (F [1, 56] = 7.39, M = .0.70 vs. 
0.74], P = <0.01) 
ii. FA ↓; anterior cingulum/occipito-frontal 
fasciculus (cluster; 14X, 12Y, 28Z), splenium (-4X, 
-44Y, 16Z), & body of corpus callosum (14X, 
12Y, 28Z), & left hippocampus (-26X, -38Y, -4Z) 
(further data N/A).  
 
None. No whole-brain data reported & 




level of inter-connectivity 
between specific brain 
structures and the rest of 
the brain, based on FA 
(age*ɛ4 interaction). 
Healthy older adults  
(62.4; ±8.9). 
55 Sex (controlled), 
education, family history 
of AD (n.s). 
Age*ɛ4 deleterious interaction for FA; R 
precuneus (ɛ4+ r = -0.64 vs. ɛ4- r = -0.13, P 
<0.001), L orbitofrontal cortex (r = -0.64, vs.  r = 
-0.13, P = 0.004), L supramarginal gyrus (r = 
0.54 vs. r =  -0.35, P = 0.002), R inferior temporal 




APOE ɛ4 carriers had trajectories 
indicative of antagonistic 
pleiotropy; greater connectivity at 
younger ages, but sharper decline 
(vs. ɛ4-). 
Bartzokis 
et al. 2006 
ROI; T2 relaxation rates. 
Orbitofrontal cortex, genu 
& splenium of corpus 
callosum 
(1. ɛ4+/ɛ2+ vs. ɛ3ɛ3) 
(2. age*ɛ4/ɛ2 interaction). 
Healthy older adults 
(66.0; ±5.7*). 
102 Age, education, sex, 
cardiovascular pathology, 
MMSE, white matter 
hyperintensities (n.s.). 
1. ɛ2+ T2 ↑: orbitofrontal cortex (F [1, 101] = 
5.39, ɛ2+ M = 15.97 vs. ɛ2- M = 15.65), genu (F [1, 
101] = 7.59, M = 15.87 vs. 16.24) 
2. ɛ2+*age interaction; less decline with age 
in orbitofrontal cortex (ɛ2+ r = -0.011 vs. ɛ2-= -
0.059). 
 
None. No effects of ɛ4 allele presence. 
Continued 












2. voxelwise whole-brain 
analysis  
(ɛ2+ vs. ɛ3/ɛ3). 
 
Healthy older adults  
(68.5; ±10.9*). 
39 Age (statistically 
controlled), gender, 
MMSE, T2 FLAIR white 
matter lesion load (all 
n.s.). 
 
1. ɛ2+ FA ↑; posterior cingulate (P <0.01, 
Cohen’s D = 0.87; large effect size), anterior corpus 
callosum (p 0.005, D = 0.95; large). 
2. ɛ2+ FA ↑; bilateral anterior thalamic 
radiations, corticopontine tracts, superior 
longitudinal fasciculus, right thalamus, 
cingulate and corpus callosum (P <0.005, 
further data N/A). 
None  
(P set to 
<0.005) 
Large age range; 49 to 90 years. 
Note that TBSS is a more 
sensitive measure compared with 
defined ROI because it has less 
averaging of images, however is 
more sensitive to image/template 
misregistration (Chiang et al., 
2012). 
Ryan et al. 
2010 
ROI; FA & MD. Frontal 
lobe, parietal lobe, 
centrum semiovale, genu 
& splenium of corpus 
callosum, temporal stem.  
(1. ɛ4+ vs. ɛ4-) 
(2. age*ɛ4 interaction). 
Healthy  older adults  
(70.8; ±9.2*). 




1. ɛ4+ FA ↓; frontal lobe (F [1, 122] = 4.76, P 
<0.05, data N/A), splenium (F [1, 122] = 4.76, P 
<0.05, data N/A). 
2. age*ɛ4, FA ↓; frontal lobe (ɛ4+ r = -0.71 vs. 
ɛ4- r = -0.31), temporal stem (r = -0.59 vs -0.30), 
genu (r = -0.22 vs -0.22), MD ↑; frontal lobe  (r = 
0.73 vs 0.38), temporal stem (r = 0.78 vs 0.42), 
parietal lobe (r = 0.45 vs 0.55), centrum 
semiovale (r = 0.52 vs. 0.58) splenium (r = 0.67 vs 





Stronger results for age*genotype 
interaction models compared with 
main effect models.  
Bendlin et 
al. 2010 
1. Voxel-wise comparison; 
FA & MD (APOE ɛ4+ vs.  
ɛ4 - & FH+ vs. FH-). 
2. ‘AD risk’ model
a
 (FH-
/ɛ4-; FH-/ɛ4+; FH+/ɛ4-; 
FH+/ɛ4+). 
Healthy  older  adults  
(56.77; ±5.35). 
136 Age, sex, education 
(controlled). 
1. No main effect of ɛ4+ vs ɛ4-. 
2. Linearly lower FA with AD risk:  L 
anterior & posterior corona radiate, uncinate, 
superior corona radiata, L tapetum, R 
external capsule, R posterior cingulum 
bundle, hippocampus and adjacent white 
matter (all cluster sizes >20 voxels, P < 0.05). 
 
None. No main effect of APOE 
independent of FH. Main effects 
of FH+ vs. FH- in most of the 
listed white matter regions (left). 
No effect sizes are reported. 
Smith et 
al. 2010 
Whole brain TBSS; FA   
(ɛ4+/FH+ vs. ɛ4-/FH-). 
Healthy  older  
females  
(61.0±1.2*). 
65 Age, education 
(controlled). 
FA significantly lower in inferior fronto-
occipital/uncinate fasciculus, inferior 
longitudinal fasciculus, cingulum bundle 
(posterior & mid), cortico-pointinte tracts, 
splenium of the corpus callosum, subcallosal 











Note. TBSS = Tract Based Spatial Statistics, FA = fractional anisotropy, MD = mean diffusivity, Dra  = radial diffusivity, DA = axial diffusivity T2 = transverse 
relaxation rate, AD = Alzheimer’s disease, FWE = Family wise error, FDR = false discovery rate, n.s. = not statistically significant between groups at P > 0.05, 
L/R = left/right, N/A = not available/applicable, SD = standard deviation, ACE-r = Addenbrookes Cognitive Exam, PPT = physical performance test, M = 
mean, r = correlation coefficient, MMSE = mini mental state exam. FH = family history of AD, NART = National Adult Reading Test. All significant findings 
(P < 0.05) survived correction for multiple testing unless otherwise stated. All ages are in years. Higher FA indicates greater white matter integrity; higher MD, 
Dra and T2 indicate lower integrity. 
a
Weighted contrasts tested for an additive effect of AD. * = weighted estimates. 
Gold et al. 
2010 
Whole brain TBSS; FA,  
MD, DA and DR  
(ɛ4+/FH+ vs. ɛ4-/FH-). 
Healthy  older  adults  
(58.8; ±5.8*). 
57 Age, education 
(controlled). 
FA ↓: fornix, inferior longitudinal fasciculus, 
inferior fronto-occipital fasiculus/uncinate 
fasciculus (main deleterious effect of  ɛ4). 
MD ↑: genu of the corpus callosum, R 
inferior frontal /inferior longitudinal 
fasciculi. 
Dra ↑: inferior longitudinal fasciculus, 
inferior frontal-occipital/uncinate fasciculi. 
DA ↓: rostral cingulum. No effect sizes 
reported. 
None 
(P set at 
< 0.01) 
Smith et al. & Gold et al. took 
subjects from the same sample 
(University of Kentucky 
imaging genetics project). It is 
unclear if subjects were 
included in both studies. The 
reports have different sample 
sizes. All association directions 
reflect lower integrity in the 





Cingulum bundle FA.  
(ɛ4+ vs. ɛ4-). 
Healthy older adults 
(mean age not 
detailed; range 18-86 
years). 
 
97 Age, gender, IQ (n.s.) Significant deleterious age by ɛ4+ interaction 




Whole brain and then  ROI 
(medial temporal lobes); 
FA & MD 







90 Age and gender 
(controlled). Education, 
gender, disease duration, 
NART, expanded 
disability severity scores, 
white matter lesion 
volume (n.s.).  
 
No significant main effects or interactions 
(all P values > 0.100). 
 
None Possible that the effects of 






4.2.3. The current study 
The current study aims to investigate the effects of APOE and TOMM40 on brain white 
matter integrity as assessed using quantitative tractography in a large, age-homogeneous 
sample of relatively healthy older people. Fourteen major projection, commissural and 
association fibre tracts were examined that have previously been significantly associated with 
cognitive abilities in this sample (Penke et al., 2012).  
 
4.3. Methods 
4.3.1. Sample and procedure 
The LBC1936 recruitment, sample and procedure are detailed in Chapter 2 (‘Methodology’; 
Deary et al., 2007; 2012).  
 
4.3.2. Childhood intelligence 
The Moray House Test no.12 (MHT) completed at around age 11 years is described in Chapter 
2 (‘Methodology’). MHT scores were adjusted for age in days at time of assessment, and 
standardised to an IQ score with a mean of 100 and a standard deviation of 15 for the whole 
LBC1936 sample.  
 
4.3.3. Genotyping  







4.3.4. Diffusion MRI and tractography analysis 
The core brain MRI procedure is described in Chapter 2 (‘Methodology’) and the DTI 
processing is broadly described in Chapter 3 (‘ADRB2…’). Both are detailed in the imaging 
protocol paper by Wardlaw et al. (2011). Principal components analysis (PCA) was 
performed on the tractography data to give a clear single factor model for FA (gfa) that 
accounted for 38.8% of the overall variance, as described in Chapter 3 (‘ADRB2…’).  
General white matter integrity factors have previously been found to be associated with 
cognitive abilities in this sample (Penke et al., 2012; Penke et al., 2010a).  
 
4.4. Statistical analysis 
4.4.1. Statistical models 
Three statistical models were used to investigate the effect of APOE and TOMM40 genetic 
variants (the independent variables) on tract-averaged FA values (the dependent variables) 
for the fourteen tracts and gfa. These models are detailed in Chapter 2 (‘Methodology’), 
however for ease are recapped in Table 4.2. Briefly, Model 1 adjusted for the covariates of 
gender and age in days at neuroimaging; significant effects were re-tested controlling for the 
additional covariate of age 11 IQ (‘Model 2’), and then effects that remained significant were 
re-tested controlling for self-reported cardiovascular disease histories (Table 4.2).  
To protect against Type 1 errors, false discovery rate (FDR) was used to estimate the 
number of significant findings in the context of multiple testing (Benjamini et al., 1995). A 
Microsoft Excel program (Pike 2011) was used to conduct classical one-stage FDR based on 
associations with white matter integrity. All P values are raw unless stated as being FDR-




differ whether FDR was applied separately to individual sets of analyses (i.e. APOE and then 
TOMM40 sub-analyses), or to a collated list of all analyses. 
 
Table 4.2. Final analytic strategies for APOE ε and TOMM40 ‘523’ poly-T repeat 
gene loci for Chapters 4-7.  
 
 
 APOE ε TOMM40 ‘523’ 
Gene locus: rs7412 + rs429358 









ε4 present (vs. ε4 absent) 
Overall effect of genotype? 
(S/S; S/L; VL/L; L/L; VL/VL) 






ε3/ε4 (vs. ε3/ε3) 
S/S; S/L*; L*/L* 






ε2 present (vs. ε3/ε3) 
S/S; S/L*; L*/L* 






Model 1: Age + Gender 
Model 2: Age + Gender + Age 11 IQ 
Model 3: Age + Gender + Age 11 IQ + Cardiovascular disease history 
 
Note. The term ‘ε4 present’ includes participants with ε3/ε4; ε2/ε4; ε4/ε4 genotypes pooled 
together, while ‘ε4 absent’ includes all other genotypes. ‘ε2’ present includes participants 





4.4.2. APOE/TOMM40 analysis 
The analytic strategies for the APOE  and TOMM40 523 genetic loci are detailed in Table 
4.2. Briefly, the first analytic step tested the effects of APOE 4 allele presence vs. absence, 
i.e. pooled 2/4, 3/4 and 4/4 genotypes versus pooled 2/2, 2/3 and 3/3 (‘Step 1’). 
To test the effects of a single ɛ4 allele against a neutral genotype, ɛ3/ɛ4 was then compared 
with ɛ3/ɛ3 (‘Step 2’). The third analytic step tested genotypes which may be protective for 
neurodegenerative pathology, compared with the neutral genotype; i.e.; pooled 2/3 and 
2/2 versus 3/3 (‘Step 3’; Deary et al., 2004; Luciano et al., 2009a). 
The variable-length poly-T repeat rs10524523 (‘523’) was split into three categories: 
‘S’ (<20 T residues), ‘L (≥ 20) and ‘VL (≥ 30) (Lutz et al., 2010), of which the S allele may 
or may not be protective in terms of neurodegenerative pathology (Bruno et al., 2011a; Chu 
et al., 2011). In the first analytic step, in the whole sample, a GLM tested for a significant 
effect of TOMM40 523 genotype (i.e. S/S; S/L; L/L; L/VL; VL/VL; ‘Step 1’). To investigate 
the effects of TOMM40 523 repeat length independent of biological variation in APOE 
genotype, analysis then focussed separately on two different APOE ε genotype subgroups; 
firstly participants with the 3/4 genotype (‘Step 2’). Finally, analysis focussed on 
participants with the neutral APOE genotype (3/3) (‘Step 3’), because this eliminates 
variance associated with protective and risk APOE alleles (Roses et al., 2010).  
In large samples of Caucasians, linkage between the APOE  genotype and TOMM40 
523 length (i.e. 4 links primarily to ‘L’, 3 primarily to ‘S’ or ‘VL’) is such that in the APOE 
3/3 genotype, relatively few L carriers would be predicted while in the 3/4 genotype 
typically one L allele would be predicted in addition to either an S or VL allele (Linnertz et 
al., 2012). Slight errors in poly-T repeat length measurement may occur through PCR 




incorrectly classified (Linnertz et al., 2012). To attempt to control for this, in Steps 2 and 3 
the L and VL alleles were pooled into an ‘L*’ group; participants with the S/S genotype were 
compared with those carrying only one S allele (pooled S/L and S/VL; hereinafter S/L*), and 
also against participants carrying no S alleles (pooled L/L, L/VL and VL/VL; hereinafter 
L*/L*; Caselli et al., 2012). A GLM therefore tested for effects of S-allele group (S/S; S/L*; 




4.5.1. Descriptive statistics 
Of the 1091 total LBC1936 participants, 866 attended Waves 1 and 2. Of those 866, 731 
underwent neuroimaging of which n = 700 completed the scans (reasons for non-completion 
generally included discomfort or claustrophobia). As described in Chapter 2 (‘Methodology’), 
Individuals who reported being ambidextrous or left handed at either ‘Wave 1’ or ‘Wave 2’, 
reported history of dementia, had MMSE scores below 24 or did not complete the MMSE at 
Wave 2 were excluded. Overall, this left 675 participants, of which 642 and 652 participants 
had successful genotyping for APOE and TOMM40, respectively.   
APOE had allele frequencies of 2 = 7.4%, 3 = 77.0% and 4 = 15.6%, with 
genotype frequencies of: 2/2 = 2 (0.3%), 2 /3 = 77 (12.0%), 2 /4 = 14 (2.2%), 3/3 = 
376 (58.6%), 3/4 = 160 (24.9%), and 4/4 = 13 (2.0%). TOMM40 523 had allele 
frequencies of S = 41.3%, L = 15.3% and VL = 43.4%, with genotype frequencies of S/S = 
102 (15.6%), S/L = 94 (14.4%), S/VL = 240 (36.8%), L/L = 15 (2.3%), L/VL = 76 (11.7%) 
and VL/VL = 125 (19.2%). Exact tests confirmed that APOE and TOMM40 were in Hardy-




4.5.2. APOE and quantitative tractography  
For the APOE 4 present vs. absent comparison, significant effects were found for two tracts, 
where presence of the 4 allele was associated with poorer white matter integrity in the 
predicted direction (see Tables 4.3 and 4.5).  
Step 1: The first significant effect was found in the right ventral cingulum (F [1, 570] 
= 5.48, P = 0.020, partial η
2
 = 0.010). This survived correction for age-11 IQ (F [1, 535] = 
4.17, P = 0.042, partial η
2
 = 0.008), and cardiovascular disease history (F [1, 530] = 3.90, P = 
0.049, partial η
2
 = 0.007). 
The second significant effect was found in the left inferior longitudinal fasciculus (F 
[1, 575] = 5.04, P = 0.025, partial η
2
 = 0.009). This survived correction for age-11 IQ (F [1, 
539] = 7.30, P = 0.007, partial η
2
 = 0.013) and cardiovascular disease history (F [1, 534] = 
7.00, P = 0.008, partial η
2
 = 0.013). 
Step 2: For the ɛ3/ɛ4 vs. ɛ3/ɛ3 comparison, two significant deleterious effects of ɛ3/ɛ4 
were found (see Tables 4.3 & 4.5). This indicates that the presence of a single ɛ4 allele 
(compared with a neutral genotype) was associated with poorer white matter integrity, in the 
predicted direction.  
Firstly, a deleterious significant effect of one ɛ4 allele was found in the left ventral 
cingulum (F [1, 471] = 4.33, P = 0.038, η
2 
= 0.009), which survived correction for age 11 IQ 
(F [1, 441] = 4.06, P = 0.044, η = 0.009) but not cardiovascular disease history (F [1, 436] = 
3.23, P = 0.073, η
2
 = 0.007). 
Secondly, the deleterious significant effect found in the left inferior longitudinal 
fasciculus (F [1, 481] = 4.15, P = 0.042, η
2
 = 0.009) survived correction for age 11 IQ (F [1, 
451] = 6.47, P = 0.011, η
2
 = 0.014) and cardiovascular disease history (F [1, 446] = 6.75, P = 
0.010, η
2




Step 3:  There was no main effect of the pooled 2/3 and 2/2 genotypes (vs. 3/3) 
on the white matter integrity of any of the tracts analysed (see Table 4.3). 
 
 
Table 4.3. Apolipoprotein-ε (APOE) and white matter integrity 
Note. Age in days at time of testing and gender statistically controlled. Associations 
significant at P < 0.05 are printed in bold-face and italics. FA = fractional anisotropy. 
 
 
4.5.3. TOMM40 523 length and quantitative tractography 
Step 1: In the whole sample, two significant effects of TOMM40 523 genotype were found 
(see Table 4.4). The first significant effect was found in the left ventral cingulum (F [5, 564] 
= 2.60, P = 0.025, partial η
2 
= 0.022). This effect survived correction for additional covariates 
of age-11 IQ (F [5, 531] = 2.57, P = 0.026, partial η
2
 = 0.024) and cardiovascular disease 
history (F [5, 526] = 2.79, P = 0.017, partial η
2




White matter tract (FA) 
 
Step 1 
4 allele presence (vs. absence) 
 
Step 2 
APOE  ɛ3/ɛ4 (vs. ɛ3/ɛ3) 
 
Step 2 
APOE 2/3 & 2/2  (vs. 3/3) 














General factor (gfa) (1, 524) = 0.83 0.362 0.002 (1, 436) = 1.10 0.294 0.003 (1, 376) = 0.12 0.730 0.000 
Genu of the corpus callosum  (1, 559) = 0.20 0.659 0.000 (1, 465) = 0.12 0.730 0.000 (1, 399) = 0.26 0.612 0.001 
Splenium of the corpus callosum  (1, 575) = 0.07 0.788 0.000 (1, 480) = 0.34  0.336 0.001 (1, 409) = 0.00 0.985 0.000 
Left arcuate fasciculus  (1, 552) = 0.00 0.987 0.000 (1, 461) = 0.16 0.689 0.000 (1, 393) = 0.62 0.432 0.002 
Right arcuate fasciculus.  (1, 500) = 0.17 0.683 0.000 (1, 417) = 0.51 0.475 0.001 (1, 356) = 0.03 0.873 0.000 
Left anterior thalamic radiation  (1, 479) = 0.00 0.962 0.000 (1, 400) = 0.10 0.754 0.000 (1, 341) = 0.00 0.957 0.000 
Right anterior thalamic radiation  (1, 556) = 0.11 0.745 0.000 (1, 465) = 0.13 0.716 0.000 (1, 395) = 0.00 0.979 0.000 
Left uncinate fasciculus.  (1, 492) = 1.57 0.212 0.003 (1, 408) = 1.56 0.212 0.004 (1, 348) = 0.00 0.956 0.000 
Right uncinate fasciculus.  (1, 545) = 0.00 0.990 0.000 (1, 455) = 0.01 0.935 0.000 (1, 390) = 0.03 0.873 0.000 
Left rostral cingulum  (1, 556) = 0.06 0.803 0.000 (1, 463) = 0.09 0.769 0.000 (1, 394) = 0.27 0.604 0.001 
Right rostral cingulum  (1, 564) = 0.09 0.760 0.000 (1, 472) = 0.03 0.862 0.000 (1, 402) = 0.28 0.603 0.001 
Left ventral cingulum (1, 561) = 2.36 0.125 0.004 (1, 471) = 4.33 0.038 0.009 (1, 396) = 1.05 0.305 0.003 
Right ventral cingulum (1, 570) = 5.48 0.020 0.010 (1, 476) = 3.47 0.063 0.007 (1, 404) = 1.19 0.277 0.003 
Left inferior longitudinal fasciculus  (1, 575) = 5.04 0.025 0.009 (1, 481) = 4.15  0.042 0.009 (1, 407) = 0.17 0.689 0.000 




genotype had significantly lower FA compared with S/S (P = 0.029), S/VL (P = 0.008), L/L 
(P = 0.033) and L/VL (P = 0.003) genotypes (all other comparisons were P > 0.05).  
The second significant effect was found in the right rostral cingulum (F [5, 568] = 
2.99, P = 0.011, partial η
2
 = 0.026). This effect survived correction for age-11 IQ (F [5, 533] 
= 3.73, P = 0.003, partial η
2
 = 0.034) and cardiovascular disease history (F [5, 528] = 3.62, P 
= 0.003, partial η
2
 = 0.033). Post-hoc tests showed that the S/L genotype had significantly 
lower FA compared with the S/VL (P = 0.011) and L/VL (P = 0.026) genotypes, with VL/VL 
having significantly lower FA compared with L/VL (P = 0.017; all other comparisons were P 
> 0.05). 
To determine whether association between TOMM40 523 length and white matter 
tract integrity was driven by linkage with APOE, the above associations were re-tested 
controlling for presence of the ε4 allele. Controlling for age, gender and APOE ε4 presence, 
the main effect of TOMM40 523 length remained for both right cingulum FA (F [5, 547] = 
3.00, P = 0.011, partial η
2
 = 0.024) and left ventral cingulum FA (5, 544] = 3.45, P = 0.004, 
partial η
2





Table 4.4. Translocase of outer mitochondrial membrane 40 (TOMM40) ‘523’ length 
and white matter integrity.  
 
Note. Age in days at time of testing and gender statistically controlled. Associations 
significant at P <0.05 are printed in bold-face and italics. FA = fractional anisotropy.  
  
 
Step 2: In 3/4 carriers, four significant effects of TOMM40 523 length were found; these 
suggested a deleterious effect of the S/L* genotype versus L*/L* (see Tables 4.4 and 4.5). 
This indicates that possessing an S allele is associated with lower white matter integrity 
compared with possessing only L or VL alleles (as pooled into the ‘L*’ group). Note that the 
3/4 group had no S/S homozygotes. 
The first significant effect was found for gfa (F [1, 122] = 4.95, P = 0.028, partial η
2 
= 
0.039). This survived correction for additional covariates of age-11 IQ (F [1, 114] = 5.35, P = 
0.023, partial η
2
 = 0.045) and cardiovascular disease history (F [1, 109] = 5.84, P = 0.017, 
partial η
2









APOE 3/4 genotype 
 
APOE 3/3 genotype 
 





























General factor (gfa) (5, 529) = 2.11 0.063 0.020 (1, 122) = 4.95 0.028 0.039 (2, 303) = 1.04 0.356 0.007 
Genu of the corpus callosum  (5, 564) = 1.83 0.105 0.016 (1, 131) = 2.42 0.122 0.018 (2, 321) = 0.92 0.401 0.006 
Splenium of the corpus callosum  (5, 580) = 0.20 0.963 0.002 (1, 136) = 1.56 0.214 0.011 (2, 331) = 0.21 0.810 0.001 
Left arcuate fasciculus  (5, 557) = 0.64 0.669 0.006 (1, 131) = 0.92 0.339 0.007 (2, 317) = 0.62 0.539 0.004 
Right arcuate fasciculus.  (5, 507) = 0.50 0.774 0.005 (1, 117) = 0.30 0.584 0.003 (2, 289) = 0.84 0.435 0.006 
Left anterior thalamic radiation  (5, 481) = 1.68 0.139 0.017 (1, 110) = 2.68 0.104 0.024 (2, 277) = 0.19  0.826 0.001 
Right anterior thalamic radiation  (5, 560) = 1.47 0.197 0.013 (1, 132) = 3.22 0.075 0.024 (2, 320) = 2.06 0.129 0.013 
Left uncinate fasciculus.  (5, 594) = 1.61 0.157 0.016 (1, 117) = 4.16 0.044 0.034 (2, 279) = 0.49 0.616 0.003 
Right uncinate fasciculus.  (5, 549) = 1.13 0.343 0.010 (1, 128) = 1.39 0.240 0.011 (2, 314) = 0.88 0.416 0.006 
Left rostral cingulum  (5, 561) = 2.09 0.065 0.018 (1, 133) = 5.51 0.020 0.040 (2, 317) = 1.87 0.156 0.012 
Right rostral cingulum  (5, 568) = 2.99 0.011 0.026 (1, 133)  = 1.96 0.164 0.015 (2, 326) = 2.87 0.058 0.017 
Left ventral cingulum (5, 564) = 2.56 0.025 0.022 (1, 136) = 13.35 <0.001 0.089 (3, 322) = 0.72 0.487 0.004 
Right ventral cingulum (5, 576) = 0.75 0.584 0.006 (1, 137) = 0.00 0.980 0.000 (2, 326) = 0.83 0.439 0.005 
Left inferior longitudinal fasciculus  (5, 580) = 0.88 0.492 0.008 (1, 138) = 0.12 0.725 0.001 (2, 330) = 0.83 0.436 0.995 




The second significant effect was found in the left uncinate fasciculus (F [1, 117] = 
4.16, P = 0.044, partial η
2
 = 0.034), which did not survive the addition of the covariate of 
age-11 IQ (F [1, 108] = 3.68, P = 0.058, partial η
2
 = 0.033). However, the initial significant 
effect remained when including cardiovascular disease history but not age-11 IQ as a 
covariate, (F [1,112] = 4.12, P = 0.045, partial η
2
 = 0.035). 
The third significant effect was found in the left rostral cingulum (F [1, 133] = 5.51, P 
= 0.020, partial η
2
 = 0.040). This survived correction for additional covariates of age-11 IQ 
(F [1, 124] = 5.50, P = 0.021, partial η
2
 = 0.042) and cardiovascular disease history (F [1, 
119] = 5.83, P = 0.017, partial η
2
 = 0.047).  
The fourth and final significant effect was found in the left ventral cingulum (F [1, 
136] = 13.35, P <0.001, partial η
2
 = 0.089) and remained after correction for additional 
covariates of age-11 IQ (F [1, 125] = 14.40, P = <0.001, partial η
2
 = 0.103) and 
cardiovascular disease history (F [1, 120] = 15.75, P = <0.001, partial η
2
 = 0.116). 
Step 3: No significant effects of the TOMM40 523 poly-T repeat length 
polymorphism were found at Step 3 (i.e. in the 3/3 genotype; see Table 4.4). 
 
4.5.4. Correction for multiple testing 
With FDR correction, all nominally significant (uncorrected) effects attenuated to non-
significance except for the main effect of TOMM40 523 S/L* vs. L*/L* on left ventral 




Table 4.5. Apolipoprotein-e (APOE), translocase of outer membrane 40 (TOMM40) ‘523’ loci and white matter integrity; nominally significant 
findings (P < 0.05 in Table 4.3, and Table 4.4 subgroup analyses) adjusted for additional covariates. 
 
Note. Age in days at time of testing and gender statistically controlled. Est. mean = estimated marginal mean difference adjusted for applicable covariates. FA = 
fractional anisotropy *Age-11 IQ not included as a covariate. TOMM40 523 ‘S’ = ‘Short’ allele, ‘L*’ = pooled ‘Long’ and ‘Very-long’ alleles.   
  
 
 Adjusted for age 11 IQ Additionally adjusted for cardiovascular disease history 
 Contrasts  Contrasts 
  
White matter tract (FA) 
 














 (95% C.I’s) 
 














 (95% C.I’s) 
 
APOE 









ε4 + vs. ε4 – 
comparison 
Right ventral cingulum 
 









 Left inferior longitudinal 
fasciculus 
 





(1, 534) = 7.00 0.008 0.013 157 0.392  
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The current study investigated the effects of variants in two genes upon brain white matter 
tract integrity in a large sample of non-demented, community-dwelling people in their early 
70s. These gene loci were the APOE ε haplotype (commonly and herein referred to as ‘ε 
genotype’) and the TOMM40 523 poly-T repeat. The current report is the largest examination 
of the APOE locus and white matter integrity in a single study (Gold et al., 2012; Westlye  et 
al., 2012b) and therefore adds a significant amount of new data to the literature. No previous 
studies have examined TOMM40 523 in relation to this phenotype.  
The current study found significant effects of the APOE 4 risk allele in the predicted 
deleterious direction on: i) the right ventral cingulum; and ii) the left inferior longitudinal 
fasciculus. The ventral cingulum is a parieto-occipital tract connecting the cingulate cortex 
with parahippocampal gyri and terminating in the anterior part of the medial temporal lobes. 
The left inferior longitudinal fasciculus connects occipital and temporal areas including the 
hippocampus (Catani and Thiebat de Schotten, 2008). 
TOMM40 523 poly-T repeat length genotype had significant effects in the whole 
sample and in the subgroup of participants that possessed the APOE 3/4 genotype. In the 
whole sample, significant effects were found in the left ventral cingulum and the right rostral 
cingulum, both primarily driven by the S/L genotype being associated with significantly 
lower FA compared with other TOMM40 523 length genotypes. These significant 
associations survived statistical correction for presence of the APOE ε4 allele, however were 
not significant in the subgroup of participants with the ‘neutral’ 3/3 genotype, suggesting 




or ii) sensitive to reductions in sample size. Larger samples of individuals with the 3/3 
genotype would be required to address this further. 
In APOE 3/4 carriers, a significant deleterious effect of possessing an S allele 
(versus not) was found in: the i) left uncinate fasciculus; ii) left rostral cingulum; iii) left 
ventral cingulum; and iv) general factor of white matter integrity (gfa). The uncinate 
fasciculus connects the anterior temporal lobe to medial and lateral orbitofrontal cortex, 
whereas the rostral cingulum projects from the cingulate to orbitofrontal cortices (Catani and 
Thiebat de Schotten, 2008). The gfa parameter, which is determined from PCA of the tract-
averaged FA values for twelve major fibre pathways in each subject, shows that the integrity 
of white matter is to a substantial degree shared across tracts throughout the brain, possibly 
indicating shared influences (Lopez et al., 2012;  Penke et al., 2012).  
The majority of reported associations remained when corrected for history of 
cardiovascular disease (e.g. history of stroke, etc.) and childhood intelligence. Corrected for 
multiple testing, only the deleterious effect of the TOMM40 523 S allele (vs. pooled non-
carriers, in the APOE 3/4 subgroup analysis) upon left ventral cingulum integrity remained 
significant. White matter diffusion tensor phenotypes are highly correlated as indicated by the 
gfa factor. This can make correction for multiple testing overly conservative; therefore, for 
different reasons, nominal and adjusted effects require caution in their interpretation (Nyholt 
et al., 2011). All findings reported therefore require replication in large independent samples. 
 
4.6.2. Interpretation: APOE  genotype 
It is unclear why the left inferior longitudinal fasciculus and right ventral cingulum would be 
particularly vulnerable to the effects of the APOE 4 allele, and not the integrity of other 
white matter tracts. Having noted this, it is important to consider how these discreet and 




healthy ageing brain but usually with an anterior-posterior gradient, in contrast to AD 
pathology which affects more posterior, temporal regions first (Bendlin et al., 2010; Bennett 
et al., 2010). The hippocampus for example shows the earliest evidence of amyloid-β and 
neurofibrillary tangle accumulations (Braak and Braak, 1991). The current study partially 
replicates previous associations between ε4 and tracts associated with temporal lobe 
structures before correction for multiple testing; specifically the inferior longitudinal 
fasciculus (Gold et al., 2010;  Smith et al., 2010), and ventral cingulum (Smith et al., 2010; 
‘posterior cingulum’). It is possible that the effects of APOE seen here are indicative of 
prodromal AD in the current sample. However, this does not account for why no effects were 
found in other tracts associated with temporal lobe structures.  
The current study is the largest assessment of APOE and white matter integrity to date 
and reports more circumscribed effects of ε4 allele possession compared with previous 
reports (Gold et al., 2012). This could relate to the large sample size and relatively 
homogenous age ranges assessed here compared with previous studies. Larger samples are 
likely to be more reliable, and wide age ranges across genotypes could include the cumulative 
influence of subtle age-related processes that affect the phenotype of interest; statistically 
controlling for age may not completely eradicate these effects (Hofer and Sliwinski, 2001).  
Discrepancies may also relate to differences between image analysis methods (e.g. TBSS; 
Westlye et al., 2012b) vs. probabilistic neighbourhood tractography used here). The current 
study does not interrogate white matter integrity across the whole brain and therefore cannot 
exclude the possibility of significant ε4 effects in regions that were not assessed, such as the 
fornix. Regardless, the nominally significant effects observed here were weaker and more 
specific than would have been expected when compared with the ‘medium-large’ effects 





4.6.3. Interpretation:  TOMM40 523 poly-T repeat 
Associations between the TOMM40 523 poly-T repeat and white matter integrity have not 
been investigated by previous studies. The above results indicate an independent deleterious 
effect of the TOMM40 523 S allele in APOE 3/4 but not 3/3 genotypes. This association 
is independent in the sense that any deleterious effects of TOMM40 523 S allele possession 
(vs. non-possession) cannot be causally attributed to linkage with APOE  alleles, because a 
specific stable subgroup was analysed. Similar to APOE, the tracts that showed negative 
association with the S allele have been implicated in early AD pathology; the (left) uncinate 
fasciculus, (left ventral) cingulum and (left rostral) cingulum (Gold et al., 2010; Heise et al., 
2011; Smith et al., 2010). As with APOE, it is unclear why these specific tracts (and not 
others) would be exclusively affected by TOMM40 523 length. 
A significant effect was found for gfa. This suggests that the TOMM40 523 repeat may 
influence processes that are sufficiently pleiotropic to affect general white matter integrity. 
Lopez et al. (2012) conducted a pathway analysis on gfa based on the current sample dataset 
(n = 535). The authors used the web-based Gene Set Enrichment Analysis Toolkit 
(WebGestalt; Duncan et al., 2010; Zhang et al., 2005) to conduct enrichment analysis for 
gene ontology on genes that were significantly associated with gfa (n = 173 genes, P < 0.01). 
Twenty-three ontology categories had enriched gene numbers, the most significant of which 
were “calcium-dependent cell-cell adhesion” (P = 1.15  10
-11
) and “synapse assembly” (P = 
5.20  10
-8
). Speculatively, the nominally significant association between TOMM40 523 
repeat length and gfa may relate to these ontologies. Lopez et al. found that TOMM40 did not 
reach gene significance based on 19 SNPs; note, however, that report did not directly assess 
variation in the poly-T repeat locus. 
Significant effects of TOMM40 523 length were found only in the APOE 3/4 




al., 2011a). In the current study this appears to be the case, with a negative effect of the S 
allele. This is consistent with the deleterious effect of the S allele on AD diagnosis risk in 
3/3 carriers as reported by Cruchaga et al. (2011), but inconsistent with studies that report 
protective effects on age of AD onset in 3/4 carriers (Roses et al., 2010), specific 
normalized grey matter volumes in 3/3 carriers (Johnson et al., 2011), or null effects on 
cognitive ageing in 3/4 and 4+/- groups (Schiepers et al., 2012). Crenshaw et al. (2013) 
report a protective effect of the S allele on the age of onset of mild cognitive impairment in 
3/4 participants, but in contrast a deleterious effect of the S/S genotype > S/VL genotype > 
VL/VL genotype in the 3/3 and 2/3 genotype. It is unclear what drives these differing 
directions, but the effect was significant on age of onset distributions in 106 conversion 
events using standard neuropsychological tests in a series of 508 Caucasians ascertained 
prospectively.  
 
4.6.4. Limitations and future studies 
This study conducted a large number of association tests which assessed significantly inter-
correlated brain imaging phenotypes (as reflected by the gFA, for example); this may make 
correction for multiple testing overly conservative, as discussed in Chapter 3 (‘ADRB2…’).  
Better understanding of the functional significance of TOMM40 523 repeat length and 
its relationship with APOE may inform age-related phenotypic data. Bekris et al. (2012) 
conducted functional analysis of different poly-T repeat haplotypes on reporter assay 
expression levels in SHSY5Y, HepG2 and U118 neuronal cell lines. Results indicated that 
the TOMM40 523 poly-T repeat had measurable effects on enhancer/silencer activity, and 
that the direction of its effect on expression depends on the cell type and specific haplotype 




including those with AD, APOE data, and age of onset data (Bekris et al., 2011; Hedskog et 
al., 2012; Cruchaga et al., 2011).  
 
4.6.5. Summary 
The current study found relatively circumscribed nominal significant effects of the APOE ε 
and TOMM40 523 gene loci on brain white matter integrity in the LBC1936. The majority of 
these associations attenuated when corrected for multiple testing. Replication in large 













Chapter 5: Alzheimer’s disease susceptibility genes APOE and 
TOMM40, and hippocampal volume 
 
A version of this chapter has been submitted for publication in PLOSONE: Lyall, D.M., 
Royle, N.A., Harris, S.E., Bastin, M.E., Muñoz Maniega, S., Murray, C., Lutz, M.W., 
Saunders, A.M., Roses, A.D., Valdés Hernández, M. del C., Starr, J.M., Porteous, D.J., 





The APOE ε and TOMM40 rs10524523 (‘523’) variable length poly-T repeat gene loci have 
been significantly and independently associated with Alzheimer’s disease (AD) related 
phenotypes such as age of clinical onset. Hippocampal atrophy has been significantly 
associated with memory impairment, a previously reported characteristic of AD. The current 
study aimed to test for independent effects of APOE ε and TOMM40 ‘523’ genotypes on 
hippocampal volumes as assessed by brain structural MRI in a relatively large sample of 
community-dwelling older adults. As part of a longitudinal study of cognitive ageing, 
participants in the Lothian Birth Cohort 1936 underwent genotyping for APOE ε2/ε3/ε4 
status and TOMM40 ‘523’ poly-T repeat length, and detailed structural brain MRI at a mean 
age of 72.70 years (Standard deviation [SD] = 0.74, N range = 624 to 636). No significant 
effects of APOE ε or TOMM40 523 genotype were found on hippocampal volumes when 
analysed raw, or when adjusted for either intracranial or total brain tissue volumes. In 
summary, in a large community-dwelling sample of older adults, analyses found no effects of 
APOE ε or TOMM40 523 genotypes on hippocampal volumes. This is discrepant with some 
previous reports of significant association between APOE and left/right hippocampal 
volumes, and instead echoes other reports that found no association. Previous significant 
findings may partly reflect type 1 error. Future studies should carefully consider: 1) their 
specific techniques in adjusting for brain size; 2) assessing more detailed sub-divisions of the 
hippocampal formation; and 3) testing whether significant APOE-hippocampal associations 







Dementia is a growing world-wide problem, and it is important to understand the risk factors 
and mechanisms underlying the disease. The major and most common sub-type of dementia 
is Alzheimer’s disease (AD; Rocca et al., 2011). A key brain region involved in the illness is 
the hippocampus, and hippocampal volumetric atrophy has been used as an indicator of AD 
risk (Potkin et al., 2009; Lind et al., 2006). Two genetic risk factors are in the APOE and 
TOMM40 genes (Roses et al., 2010). The present study concerns the association between 
specific variants in these genes and hippocampal volume in non-demented older people, in an 
attempt to investigate further possible links between these candidate genes and a prominent 
brain imaging phenotype thought to be indicative of AD risk.  Having detailed the APOE ε 
and TOMM40 ‘523’ poly-T repeat gene loci in Chapter 1 (‘Introduction’) and Chapter 2 
(‘Methodology’), the following sections detail the hippocampus and its role in cognitive 
ability/AD. 
 
5.2.1. The hippocampus, Alzheimer’s disease and cognitive ability 
The hippocampal formation of the brain includes the dentate gyrus, subiculum, entorhinal 
cortex, cornu ammonis (CA) areas 1-4 and the hippocampus proper (Braak and Braak, 1991; 
Amaral and Lavenex, 2006). The hippocampus itself occupies the floor of the temporal horn 
of the lateral ventricle. It is typically 4.0 to 4.5 cm long and around 1.5 cm wide (Duvernoy, 
2006). 
Braak and Braak (1995) outline stages of neurofibrillary change in AD 
pathophysiology, based on the observed accumulations of neurofibrillary tangles, neuropil 
threads and amyloid beta plaques. Neurofibrillary changes are associated with neuronal loss 
in the hippocampal formation because accumulations aggregate and impede inter/intra-




AD (Hyman, 1997). AD-like neurofibrillary changes have been reported in the human brain 
in the absence of significant cognitive decline (Ohm et al., 1995; Simic et al., 1997), and are 
apparent first in the hippocampal formation (Braak and Braak, 1991; Price and Morris, 1999).  
Hippocampal atrophy is associated with a common symptom of AD, namely memory 
impairment (Potkin et al., 2009; Lind et al., 2006). For example, Laakso et al. (1995) reported 
that in 32 participants with probable AD (mean age = 69.0, SD = 8.0), left hippocampal 
volume correlated significantly with immediate (r = 0.39, P = 0.029) and 30-minute delayed 
verbal memory scores (r = 0.50, P = 0.003). Similar findings have been reported in 
independent samples of individuals with very mild, or clinically diagnosed AD (e.g. Stoub et 
al., 2010), and in neuropsychological samples of individuals with relatively localised 
hippocampal lesions (e.g. Bechara et al., 2002).  
 
5.2.2. APOE ε and hippocampal volume  
Cross-sectional hippocampal volumes and APOE ε genotype in healthy older adults has been 
examined by a number of small (N range = 20 to 134) brain MRI studies, which vary 
between showing significant and null effects (e.g. Plassman et al., 1997; Richter-Schmidinger 
et al., 2011; Jak et al., 2007; Tupler et al., 2007; Chiang et al., 2011) and a few much larger 
reports including several hundred participants, which also show varying results (i.e. N > 150; 
Lemaitre et al., 2005; Den Heijer et al., 2002; Cherbuin et al., 2008; Panizzon et al., 2010; 
Ferencz et al., 2013; Hostage et al., 2013). These larger reports are likely to be more reliable, 
and are summarised in Table 5.1. Specifically, possession of the APOE ε4 allele has 
occasionally been significantly associated with lower hippocampal volumes in cross-sectional 




Table 5.1. Summary of previous large cross-sectional studies (i.e. N > 135) examining 








Technique used in 
correcting 
hippocampal volumes 
























expressed as a 
percentage fraction of 
intracranial volume.  
750 69.4 (2.9) Gender (statistically 
controlled), age, 
education, diagnosis 
of hypertension, Mini 
Mental State Exam 
score (no group 
differences; P > 0.05)  
 
Significant deleterious 
effect of ε4/ε4 genotype 
(vs. non-ε4 carriers). 
Left: ε4/ε4 = 0.23%, 
vs. non-ε4/ = 0.26% (P 
<0.001).  
Right ε4/ε4 = 0.22% 
vs. non-ε4 = 0.24% (P 
= 0.006). 
Den Heijer 
et al., 2002 
Midsagittal area 
included as model 
covariate.  
949 72.3 (7.0) Age, gender 
(controlled). 
Significant deleterious 
effect of ε4 allele 
presence (vs. non-ε4 
carriers). 
Left:  ε4+ difference to 
ɛ3/ɛ3 genotype = -0.11 
millilitres.  
Right: ε4+ difference 
to ɛ3/ɛ3 genotype = -





included as model 
covariate.  
331 62.6 (1.4) Age, gender, 
education (controlled).  
No significant main 







included as a model 
covariate. 
375 55.9 (2.6) Relatedness between 
twins, handedness, age 
(controlled). 
No significant main 





 al., 2012  
Intracranial volume 
included as a model 
covariate. 
424 69.9 (8.6) Age (controlled).  No significant main 





et al., 2012 
Intracranial volume 
included as a model 
covariate. 
198 76.0 (0.5) Age (controlled). No significant main 
effects of ε4 allele (P > 
0.05).  
-  
Note. The age mean and standard deviation data provided above for Lemaitre et al., Den Heijer et al. 





5.2.3. TOMM40 ‘523’ and hippocampal volume 
TOMM40 523 poly-T repeat length is linked to APOE genotype, and it would appear that 
only one study has so far examined the independent effects of the TOMM40 523 gene locus 
on hippocampal volumes in healthy older adults. Johnson et al. (2011) tested for an effect of 
poly-T repeat length genotype on a whole-brain voxel-wise comparison of grey matter 
volumes in participants with the APOE ε3/ε3 genotype (N = 117, mean age = 55.42 years, SD 
= 6.00), and found no significant effect of poly-T repeat genotype on hippocampal volume. A 
recent large-scale genome wide association study in healthy adults (N = 5776) reported no 
significant associations with SNPs in the TOMM40 gene however did not directly analyse the 
TOMM40 523 poly-T repeat locus (Stein et al., 2012).  
 
5.2.4. The current study 
The Lothian Birth Cohort 1936 (LBC1936; Deary et al., 2007) is large group of relatively 
healthy older adults of a narrow age range, that have undergone detailed brain MRI and 
APOE/TOMM40 genotyping. The current study aims to add to the literature by investigating: 
1) the effects of APOE ε in a large age-homogeneous sample of generally healthy older 
adults, and 2) the independent effects of the TOMM40 523 poly-T repeat length, on 
hippocampal volumes in the LBC1936. 
 
5.3. Methods 
5.3.1. Sample and procedure 
The LBC1936 recruitment, sample and procedure are detailed in Chapter 2 (‘Methodology’; 





5.3.2. Childhood intelligence 
The Moray House Test no.12 (MHT) completed at around age 11 years is described in 
Chapter 2 (‘Methodology’). MHT scores were adjusted for age in days at time of assessment, 
and standardised to an IQ score with a mean of 100 and a standard deviation of 15 for the 
whole LBC1936 sample.  
 
5.3.3. Genotyping  
The genotyping of the APOE 2/3/4 and TOMM40 523 loci is detailed in Chapter 2 
(‘Methodology’).  
 
5.3.4. Brain MRI analysis 
The core brain MRI procedure is described in Chapter 2 (‘Methodology’; Wardlaw et al., 
2011).  This protocol paper states that left and right hippocampal volumes were semi-
automatically segmented using FSL’s FIRST automated segmentation program 
(http://fsl.fmrib.ox.ac.uk) with manual correction, registered using FSL FLIRT to a locally 
developed template of similarly older brains (i.e. aged around 70 years). Final results were 
visually assessed for accuracy and manually edited using Analyse 9.0 where appropriate 
(www.analyzedirect.com). Further details are provided in the protocol paper by Wardlaw et 
al. (2011).  
This method of semi-automated hippocampal segmentation has been validated against 
the ‘gold-standard’ approach of manual tracing – which, while very accurate (assuming a 
degree of technical expertise), is extremely time consuming (Wardlaw et al., 2011). 
Specifically, the automatic FSL segmentation results were compared with 120 manually 




enough to be used without closer examination. Automated results were therefore visually 
inspected for each participant, and corrected manually where necessary.  
Intracranial volume measurements were obtained semi-automatically using the T2*-
weighted sequence.  Total brain tissue volumes were obtained using T2*-weighted with 
FLAIR. The volume of cerebrospinal fluid, venous sinuses and meninges was used to 
estimate total brain tissue volume by subtracting it from intracranial volume (Wardlaw et al., 
2011). Further details for these measurements are available from Wardlaw et al. (2011).  
 
5.4. Statistical analysis 
5.4.1. Covariate models & APOE/TOMM40 statistical analysis 
The covariate models and analytic strategies for the APOE and TOMM40 gene loci were 
described in Chapter 2 (‘Methodology’), and briefly recapped in Chapter 4 (‘…White Matter 
Integrity’). All initially-reported P-values are raw (and then FDR-adjustment is applied), and 
P-values < 0.05 are considered nominally significant. 
 
5.4.2. Hippocampal volume; statistical analysis 
It is important to correct (commonly and herein ‘normalize’) left and right hippocampal 
volumes relative to an individual’s head or brain size. To this end, left/right hippocampal 
volumes were analysed in three separate ways, controlling for age and gender throughout. 
First, left/right hippocampal volumes were examined raw. Second, hippocampal volumes 
were analysed with intracranial volume as an additional model covariate, reflecting maximum 
lifetime brain volume as a general proxy for head size. Finally, hippocampal volumes were 




that any significant genetic associations with hippocampal volume were not reflective of 
more general brain atrophy (Free et al., 1995).  
Regression-based normalization more comprehensively eliminates variance in 
hippocampal volume that is associated with intracranial or current brain tissue volumes, 
compared with proportional percentile- or ratio-based corrections (Free et al., 1995; Van 
Petten, 2004; Arndt et al., 1991). Rather than creating new variables reflecting ‘left/right 
hippocampal volumes residualized for intracranial/total brain tissue volumes’, where 
appropriate analyses included intracranial/total brain tissue volumes as model covariates in 
addition to gender and age. This is preferable because it also adjusts for any effects that 
gender and age may have on associations between hippocampal and intracranial/total brain 
tissue volumes (Garcia-Berthou, 2001).  
 
5.6. Results 
5.6.1. Descriptive statistics 
Of the 1091 total LBC1936 participants, 866 attended Waves 1 and 2. Of those, 700 
completed the brain MRI scans. As described in Chapter 2 (‘Methodology’), Individuals who 
reported history of dementia, had MMSE scores below 24 or did not complete the MMSE at 
Wave 2 were excluded.  Overall, this left 655 participants which had successfully segmented 
left and right hippocampal volumes. Of these, 624 and 636 participants had successful 
genotyping for APOE ε and TOMM40 523, respectively.  
In this specific sample of the LBC1936 ‘Wave 2’ dataset (i.e. with segmented 
hippocampal volumes, APOE or TOMM40 data etc.),  APOE had allele frequencies of ε2 = 
7.4%, ε3 = 76.9% and ε4 = 15.7%, with genotype frequencies of: ε2/ε2 = 2 (0.3%), ε2/ε3 = 




(1.9%). TOMM40 523 had allele frequencies of S = 41.0%, L = 15.4% and VL = 43.6%, with 
genotype frequencies of S/S = 106 (15.2%), S/L = 103 (14.7%), S/VL = 259 (37.1%), L/L = 
16 (2.3%), L/VL = 80 (11.4%) and VL/VL = 135 (19.3%). Exact tests with an online 
calculator (2012) confirmed that APOE ε and TOMM40 523 genotypes were in Hardy-
Weinberg equilibrium (P values = 0.449 and 0.111 respectively). Descriptive statistics are 
shown in Table 5.2, and intercorrelations between intracranial, total brain tissue and 
hippocampal volumes in mm
3
 are presented in Table 5.3, showing medium to strong 
statistically significant intercorrelations. Reported volumes are similar to those in 





Table 5.2. Descriptive statistics for raw hippocampal, intracranial and total brain tissue 
volumes, grouped by genotype. 
Note. All volumes are in mm
3
, estimated marginal means adjusted for age and gender. ICV-corrected 
= additionally adjusted for intracranial volume, TBV-corrected = additionally adjusted for total brain 
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Table 5.3. Inter-correlations between hippocampal, intracranial and total brain tissue 
volumes. 




Intracranial volume Total brain tissue 
volume 
Left hippocampal volume - 0.78 0.40 0.47 
Right hippocampal volume 0.78  - 0.45 0.50 
Intracranial volume 0.40 0.45 - 0.87 
Current brain tissue volume 0.47 0.50 0.87 - 
Note. Unadjusted Pearson bivariate correlations. All volumes are raw in mm
3
, and figures 
reflect ‘r’ correlations. All associations were significant at P <0.001.  
 
5.6.2. APOE ε, TOMM40 523 poly-T repeat and hippocampal volumes 
There was no effect of the APOE ε4 present vs. absent comparison (‘Step 1’), ε3/ε4 vs. ε3/ε3 
comparison (‘Step 2’), nor pooled ε2/ε3; ε2/ε2 genotype (vs. ε3/ε3; ‘Step 3’) on hippocampal 
volumes analysed raw, or normalized for either intracranial or total brain tissue volumes (all 
P > 0.05; see Table 5.4).  
No effects of TOMM40 523 poly-T repeat genotype were found in the whole sample 
(‘Step 1’), nor in subgroup analyses of APOE ε3/ε4 (‘Step 2’) or ε3/ε3 genotypes specifically 




Table 5.4. Apolipoprotein-e (APOE) ε genotype and hippocampal volumes. 
Note. Age at time of testing and gender statistically controlled. ICV-corrected = intracranial volume 




Volume in mm3 
 
ɛ4 allele presence vs. absence 
 
ɛ3/ɛ4 vs. ɛ3/ɛ3 
 
ɛ2/ɛ3 & ɛ2/ɛ2  vs. ɛ3/ɛ3 


















Left raw hippocampal 
volume 
1, 620 = 0.08 0.784 0.000 1, 519 = 0.33 0.566 0.001 1, 434 = 1.61 0.205 0.004 
Right raw hippocampal 
volume 
1, 620 = 0.24 0.626 0.000 1, 519 = 0.48 0.488 0.001 1, 434 = 0.20 0.654 0.000 
Left hippocampal volume  
(ICV-corrected) 
1, 619 = 1.45 0.228 0.002 1, 518 = 2.43 0.120 0.005 1, 433 = 2.43 0.120 0.006 
Right hippocampal volume  
(ICV-corrected) 
1, 619 = 2.04 0.154 0.003 1, 518 = 2.92 0.088 0.006 1, 433 = 0.41 0.521 0.001 
Left hippocampal volume  
(TBV-corrected) 
1, 618 = 0.75 0.388 0.001 1, 517 = 1.94 0.164 0.004 1, 433 = 3.12 0.077 0.007 
Right hippocampal volume  
(TBV-corrected) 




Table 5.5. Translocase of outer membrane 40 (TOMM40) ‘523’ poly-T repeat genotype and 
hippocampal volumes. 
Note. Age at time of testing and gender statistically controlled. ICV-corrected = intracranial volume 








ɛ3/ɛ4 genotype subgroup 
 
ɛ3/ɛ3 genotype subgroup 












Left  raw hippocampal  
volume 
5, 628 = 1.47 0.198 0.012 1, 156 = 1.42 0.235 0.009 2, 349 = 1.32 0.268 0.008 
Right raw hippocampal  
volume 
5, 628 = 1.23 0.292 0.010 1, 156 = 0.61 0.435 0.004 2, 349 = 1.57 0.210 0.009 
Left hippocampal volume 
(ICV-corrected) 
5, 627 = 1.47 0.198 0.012 1, 155 = 1.22 0.271 0.008 2, 348 = 1.15 0.316 0.007 
Right hippocampal volume 
(ICV-corrected) 
5, 627 = 1.33 0.250 0.010 1, 155 = 0.429 0.513 0.003 2, 348 = 1.70 0.184 0.010 
Left hippocampal volume 
(TBV-corrected) 
5, 626 = 1.34 0.244 0.011 1, 154 = 1.55 0.216 0.010 2, 348 = 0.79 0.455 0.005 
Right hippocampal volume 
(TBV-corrected) 




5.6.3. Additional comparative analysis 
To permit comparison with other reports that use alternative methods of normalization for 
head size – namely, reporting hippocampal volumes as an absolute proportion of total 
intracranial volume – the above main results were re-run using the formula “Left-or-right 
hippocampal volume in mm
3
 / intracranial volume  in mm
3
 x 1000” (DeToledo-Morell et al., 
2004). Re-analysis showed that the main results were for the most part unchanged, i.e. not 
significant at P < 0.05. One exception was that for the APOE ε4 present vs. absent 
comparison, there was a significant deleterious effect of the ε4 allele for the right 
hippocampus (F [1, 620] = 4.54, P = 0.034, η2 = 0.007).  
To check the extent to which left and right hippocampal ‘ratios’ were independent of 
intracranial volume, unadjusted bivariate correlations were run. Intracranial volume 
correlated significantly with left (r = -0.26) and right (r = -0.28) hippocampal volumes 





The current study investigated the effects of the APOE ε and TOMM40 rs10524523 (‘523)’ 
poly-T repeat gene loci on hippocampal volumes - raw and also corrected (commonly and 
herein referred to as ‘normalized’) separately for intracranial and total brain tissue volumes - 
in the LBC1936. This normalization was implemented because analyses aimed to test for 
genetic influence on the hippocampus independent of any possible effects on intracranial or 




either the APOE ε or TOMM40 523 loci, on left or right hippocampal volumes, when 
analysed either raw or normalized by intracranial or total brain tissue volumes. 
Hippocampal volumes and APOE have been investigated in a number of previous 
reports, the majority of which were relatively small (N < 135). TOMM40 523 and 
hippocampal volumes have been investigated by one previous study (Johnson et al., 2011), 
however that report examined specifically participants with the APOE ε3/ε3 genotype (N = 
117), and found no significant associations. The current study tested the TOMM40 523 locus 
in a larger sample of older adults and included all APOE ε genotypes (n = 623), ε3/ε4 carriers 
only (n = 160), and ε3/ε3 carriers only (n = 376), and found no effect of poly-T repeat length 
genotype. 
 
5.7.2. Interpretation: APOE ε 
Previous large studies have reported significant effects of APOE ε genotype on hippocampal 
volumes in healthy older adults (LeMaitre et al., 2005; Den Heijer et al., 2002). In a similarly 
large sample of older adults, this study did not replicate these, and instead echo other large 
reports which show no association with genetic variation at the APOE locus (Cherbuin et al., 
2008; Panizzon et al., 2010; Ferencz et al., 2013). There is no evidence that large positive 
studies by LeMaitre et al. (2005; mean age = 69.2; mean MMSE = 27.3) or Den Heijer et al. 
(2002; mean age = 72.0 years; mean MMSE score = 27.4) were composed of markedly more 
cognitively impaired or younger/older subjects than those reported here (mean age = 72.7, 
mean MMSE = 28.8). The discrepancy may reflect type 1 error in previous reports. Part of 
the discrepancy may also relate to normalization technique. Previous studies vary in how they 
normalize left and right hippocampal volumes - namely they use either ‘ratio’ (e.g. Lemaitre 




results report on hippocampal volumes covaried separately for intracranial and brain tissue 
volumes as this would seem to be the most appropriate correction (see below; Free et al., 
1995; Van Petten, 2004; Arndt et al., 1991). 
To permit comparison with other reports, the main results were additionally re-
analysed with hippocampal volumes normalized as a ratio of intracranial volume. The results 
were unchanged except for a significant deleterious effect of APOE ε4 allele presence vs. 
absence. However, statistically controlling for intracranial volume is judged to be the more 
appropriate normalization technique for the following reasons: 
1. Ratio measures do not completely eliminate association between head size and 
hippocampal volume (Free et al., 1995; Van Petten, 2004; Arndt et al., 1991). Further 
analysis showed that hippocampal volumes expressed as a ratio of intracranial volume 
correlated significantly with intracranial volume itself. Ratios therefore do not allow for 
an assessment of APOE, TOMM40 and hippocampal volume completely independent of 
head size, which was the main aim of the current study.  
2. Any disparity between genotype groups as assessed by ratios may reflect differences in 
any of the numerator (hippocampus), the denominator (intracranial volume) or their 
interaction, reduced to one variable, which could lead to spurious type 1 error. This 
variable is generally less informative than regression techniques which take into account 
the strength of association between the specific brain structure and the larger denominator 
(Free et al., 1995; Arndt et al., 1991) 
Critically reviewing previous reports further, there appears to be no study that corrects 
significant APOE-hippocampal volume associations for current total brain tissue volume. 
MacLullich et al. (2002) reported in a sample of older adults (N = 97, age range = 65-70 
years), that left/right hippocampal, frontal lobe, temporal lobe and intracranial volumes 




0.005). Data reduction with principal component analysis showed that these loaded strongly 
and significantly onto a ‘general brain size’ factor (range of loadings = 0.64 to 0.73, P < 
0.05). Intracranial volume is relatively constant throughout the lifespan, while actual brain 
tissue volume is susceptible to age-related change (Rushton et al., 1996). Given that the 
author is not aware of any previous study that reports significant APOE-hippocampal volume 
associations in older adults that also controls for current total brain tissue volume, we cannot 
exclude the possibility that those associations may be secondary to more generalized brain 
atrophy (Den Heijer et al., 2002; MacLullich et al., 2002; Shenkin et al., 2009; Raji et al., 
2012). (Note however that Den Heijer et al.
 
reported no significant ε4 effect on semi-
qualitative observer-rated cortical atrophy; ranged 0-3 at various locations). It is also unclear 
whether previous large significant positive studies have assumed normal distributions for 
normalized hippocampal volumes in older-age samples, as this may introduce errors in 
analysis and increase the risk of spurious results.  
 
5.7.3. Interpretation: TOMM40 ‘523’ poly-T repeat 
No effects of TOMM40 523 were found, and this could be cautiously interpreted in terms of 
different explanations, given the absence of further relevant data. Specifically: 
1. The TOMM40 523 repeat does not significantly affect mitochondrial function (Cruchaga 
et al., 2011; Bekris et al., 2012; Hedskog et al., 2012). 
2. TOMM40 523 locus does affect mitochondrial function, but not to an extent that affects 
hippocampal volume (the outcome variable) in this sample: the mitochondrial cascade 
hypothesis describes a ‘threshold’ beyond which mitochondrial mutations are not 
adequately compensated for and significant histology resembling AD emerges (Braak and 
Braak, 1995; Ohm et al., 1999). Perhaps hippocampal volume assessed by MRI is 




3. The effect of TOMM40 523 length is moderated by or interacts with additional genetic 
variants for example loci in LD with APOE or TOMM40 such as APOC1 (Bekris et al., 
2012). It may also be possible to investigate the possibility of moderation of 
TOMM40/APOE effects by other genetic factors; however, despite the relatively large 
sample size (by brain imaging standards), this would be statistically challenging. 
 
5.7.4. Limitations and future research 
This study examined left and right hippocampal volumes; specific subregions of the 
hippocampal formation may be more vulnerable to brain ageing or incipient AD pathology, 
and therefore more sensitive to variations at specific relevant genetic loci. Devanand et 
al.(2012) reported that subregions of the hippocampus differentially predicted longitudinal 
diagnosis of clinical AD over three years, in a sample of individuals with amnestic mild 
cognitive impairment (N = 130, of which 31 converted to AD; baseline MMSE scores all 
>22). Controlling for age, gender, years of education, and intracranial volume, cox regression 
analyses showed that volumes in the cornu ammonis 1 (left hazard ratio = 0.22, P = 0.054, 
right hazard ratio = 0.23, P = 0.06) and subiculum subregions (left hazard ratio = 0.22, P = 
0.054, right hazard ratio = 0.22, P = 0.03) were more predictive of longitudinal AD diagnosis 
compared with entorhinal cortical volume (right hazard ratio = 0.05, P = 0.06, left hazard 
ratio = 0.02, P = 0.26). Future studies of hippocampal volume in the LBC1936 may therefore 
consider more fine-grained analysis of the hippocampal formation as genetic variation at the 
APOE or TOMM40 loci may affect specific subregions first. Functional brain MRI may also 
be a more sensitive marker of hippocampal dysfunction, compared with left/right volumes as 
assessed here by structural MRI. 
 It is possible that the current sample of non-demented, generally healthy older adults 




atrophy to show significant differentiation according to genotype. The sample examined here 
is undergoing repeat structural brain MRI, around the age of 76. Significant associations with 
APOE or TOMM40 genotypes may become apparent at this older age, after more age-related 
atrophy.  
 
5.7.5. Summary   
This study examined the independent effects of variation at the APOE ɛ and the TOMM40 
523 poly-T repeat gene loci upon hippocampal volume assessed raw and also normalized 
separately for intracranial and total brain tissue volumes. Previous large studies have 
occasionally reported significant associations between the APOE ε4 allele and lower 
hippocampal volumes. The current study does not replicate those significant reports in a 
community dwelling sample of older adults of homogenous ages. Previous significant 
findings may reflect type 1 error, or partly reflect discrepancies in how the hippocampus has 
been normalized relative to head size in different studies. There appears to be  no obvious 
evidence that previously examined healthy older samples differed markedly from the current 
sample, either in terms of age or prevalence of cognitive decline (based on average MMSE 
scores). Studies that show significant genetic associations with the hippocampus should run 
further confirmatory analysis to investigate whether associations are independent of general 
volumetric brain atrophy. In this study there were also no significant effects of TOMM40 523 
poly-T repeat length. Future studies may investigate specific subregions of the hippocampal 
formation; there may be effects of the APOE or TOMM40 523 genetic loci that are not 













Chapter 6: The APOE ε and TOMM40 poly-T repeat genetic loci, 
white matter lesions and cerebral microbleeds 
 
A version of this chapter is in preparation for submission for publication: Lyall, D.M., Valdés 
Hernández, M. del C., Harris, S.E., Royle, N.A., Bastin, M.E., Muñoz Maniega, S., Murray, 







Two purported brain imaging markers of cerebral small vessel disease are white matter 
lesions and cerebral microbleeds, and these are significantly more common in people with 
Alzheimer’s disease (AD). Variations in the APOE ε haplotype and TOMM40 rs10524523 
(‘523’) variable length poly-T repeat have previously been significantly associated with AD, 
and this study sought to determine if these variations also associated with white matter lesion 
and microbleed burden in community-dwelling, generally healthy older adults.  
As part of a longitudinal study of cognitive ageing, participants in the Lothian Birth 
Cohort 1936 underwent genotyping for APOE ε2/ε3/ε4 status and TOMM40 523 poly-T 
repeat length, and detailed structural brain MRI at a mean age of 72.70 years (standard 
deviation [SD] = 0.74, n = ~700). 
No significant effects of APOE ε or TOMM40 523 genotype were found on white 
matter lesion burden (assessed volumetrically and also semi-qualitatively with the Fazekas 
scale), or cerebral microbleed burden (assessed with the Brain Observer MicroBleed Scale).  
In a large community-dwelling sample of non-demented older adults, analyses found 
no significant effects of APOE ε or TOMM40 523 genotypes on the intermediate phenotypes 
of brain white matter lesions or cerebral microbleeds. This is discrepant with some previous 
reports of significant association between APOE and both of these phenotypes, however 
generally supports other null studies and recent reviews which conclude that any association 
is modest at best. Previous significant findings may partly reflect type 1 error, or be due to 






6.2. Introduction  
There is evidence that the presence of cardiovascular disease pathology can increase the 
future risk of Alzheimer’s disease (AD) and cognitive decline. Two genetic risk factors are in 
the APOE and TOMM40 gene loci, and these have been occasionally associated with 
cognitive ability and AD-related phenotypes such as age of onset. Two specific brain MRI 
phenotypes – namely white matter lesions and brain microbleeds – are purported markers of 
cerebral small vessel disease. The present study tests for association between APOE and 
TOMM40, separately with white matter lesions and cerebral microbleeds. Having described 
the APOE ε and TOMM40 ‘523’ poly-T repeat gene loci in Chapter 1 (‘Introduction’) and 
Chapter 2 (‘Methodology’), the following sections of the introduction detail cardiovascular 
disease burden and its relevance to AD/cognitive decline, then white matter lesions, and then 
cerebral microbleeds and their relevance to AD/cognitive decline. Finally, previous studies of 
APOE ε/TOMM40 523 genetic contributions to white matter lesions/microbleeds are 
described.  
 
6.2.1. Cardiovascular disease burden, Alzheimer’s disease and cognitive decline 
Large-scale reports indicate significant positive association between possession of 
cardiovascular disease pathology, such as diagnosis of high blood pressure or diabetes, and 
increased risk of dementia and/or cognitive decline in the future (Launer, 2002; Brickmann et 
al., 2012; Debette and Markus, 2010; Lo et al., 2012; examples detailed below).  
The precise mechanisms underlying significant association between cardiovascular 
and neurodegenerative pathology are unclear, however there are three main hypotheses 
(Stampfer, 2006). Firstly, it is possible that cardiovascular diseases and AD/cognitive decline 
share common risk factors and are not mechanistically related (Stampfer, 2006). Secondly, it 




through promoting atherosclerosis and accumulations of amyloid-beta plaques, and/or 
(thirdly) by increasing vulnerability to such pathology and lowering the threshold at which 
cognitive decline becomes apparent behaviourally, even in the absence of a mechanistic link 
(Stampfer, 2006; Brickmann et al., 2011; Snowden et al., 1997). Two studies are described 
provided below (in turn) which report that baseline cardiovascular disease increased risk of 
AD and cognitive decline, in relatively large samples: 
Kivipelto et al. (2001) reported that midlife cerebrovascular risk factors associated 
significantly and positively with risk of AD in later life.  Participants from Finland received 
detailed physical examinations in midlife (n = 1409; mean age = 50.4 years, SD = 6.0), and 
again in later life (mean age 71.3, SD = 4.0) by which point 48 participants had developed 
AD, while 1352 had not. Midlife cerebrovascular risk factors significantly and positively 
increase the risk of AD in later life, including high systolic blood pressure (i.e. ≥159 mmHg; 
odds ratio [OR] = 3.1, 95% C.I’s 1.4 to 6.6), diastolic blood pressure (i.e. ≥95 mmHg; OR = 
1.7, 95% C.I’s 0.88 to 3.2) and overall cholesterol concentrations (≥65 mmol/l; OR = 2.9, 
95% C.I’s 1.4 to 4.4). Having combined high systolic blood pressure and high overall 
cholesterol was associated with a marked increase in risk (OR = 3.3, 95% C.I’s 1.7 to 6.4).  
Dregan et al. (2012) examined a large prospective sample; the English Longitudinal 
Sample of Ageing. Participants received cognitive and physical assessments (including blood 
pressure, cholesterol, body mass index, mood, smoking/drinking/exercise history etc.) at 
three time points (1998-2001, 2004-2005 and 2008-2009). Mean age at baseline was 62.5 (no 
age-range information was provided; N = 11,205). Participants completed cognitive tests 
from executive, memory, reasoning and memory domains, and scores were summed to create 
general ‘cognitive indexes’. At 2008/2009, 6,260 participants remained. Controlling for 
education, alcohol intake, physical exercise, depressive symptoms and mood, Dregan et al. 




C.I’s = -2.52 to -0.01) and history of smoking (unstandardized β = -1.51, 95% C.I’s = -2.29 to 
-0.074) were both associated with significantly lower cognitive index scores in 2008-2009.  
White matter lesions and cerebral brain microbleeds are generally considered to 
reflect cerebrovascular burden in ageing; they are manifestations and markers of cerebral 
small-vessel disease (Charidimou and Wearing, 2012). White matter lesions are relatively 
common in normal human ageing (Debette and Markus, 2010) and reflect increased water 
content relative to fatty lipid white matter; this may reflect demyelination, gliosis, axonal loss 
or possible infarction (Wahlund et al., 2001; Barkhof and Scheltens, 2002). Brain 
microbleeds are small haemosiderin deposits, possibly indicative of past cerebral amyloid 
angiography or hypertensive angiopathy linked to arteriosclerosis (Greenberg et al., 2009; 
Charidimou and Werring, 2012). (Haemosiderin is a remnant product from white blood cells 
engulfing the haemoglobin from decayed red blood cells after a haemorrhage).  
White matter lesions and brain microbleeds often co-occur; Wardlaw et al. (2006) for 
example reported that microbleeds were significantly more common in Stroke patients with 
greater white matter lesion pathology (N = 308, median age = 66.0 years, range = 19-89; ≥1 
microbleeds found in 54% of patients with Fazekas rating-scale scores ≥ 3 vs. 8% for those 
with scores of 0; P < 0.001). It is possible that these pathologies reflect diffuse abnormality 
of small cerebral microvessels and arterioles, including microatheroma, vasospasm, or 
arterial wall thickening, and subsequently impaired auto-regulation which leads to ischemia 
(Wardlaw, 2005). While matter lesions are more commonly considered to have ischemic 
origin, while microbleed pathology may relate more to microvascular permeability (i.e. 
leakage of the blood brain barrier; Wardlaw et al., 2003). The exact mechanisms are unclear, 
however (Fazekas and Wardlaw, 2013). These brain MRI phenotypes – brain white matter 





6.2.2. White matter lesions 
Human brain white matter is characterised by a fatty myelin layer that facilitates the high-
speed processing of information (Penke et al., 2012). White matter lesions can be assessed by 
brain MRI scans, namely T2-weighted or fluid attenuated inversion recovery (FLAIR) 
images. Lesions appear as high-intensity signals on scans (often ‘hyper intensities’). 
Typically these hyperintensities appear in white matter confluent to the lateral ventricles 
(commonly ‘periventricular’), or deep within cortical white matter (commonly ‘deep’). 
 De La Torre (2010) refers to the link between cardiovascular and brain function as 
‘neurovascular coupling’ in reference to the cardiovascular system dynamically providing 
blood to the brain. Cerebral white matter is largely supplied by long penetrating arteries and 
arterioles, the obstruction of which is associated with ischemia and white matter lesions 
(Assareh et al., 2010). White matter lesions are therefore purportedly a brain metric reflecting 
cerebral small vessel disease, in particular ischemia (Schuur et al., 2011; Brickman et al., 
2009).  
White matter lesions are important because they increase the risk of stroke, cognitive 
decline and diagnosis of dementia. Debette and Markus (2010) systematically reviewed 
primary studies published between 1966 and 2009 that had baseline white matter lesion 
burden as well as longitudinal data ranging from 1.3 to 9.5 years follow-up in terms of 
medical history. These studies variously tested the predictive power of lesion burden on 
longitudinal prospective a) incident stroke (6 healthy samples, 3 non-healthy/high risk 
samples e.g. diabetic), b) dementia (respectively 3 healthy, 3 non-healthy), and c) cognitive 
decline (5 healthy only). Cognitive decline was defined as a marked reduction in scores on 
cognitive screening tools, or general cognitive ability as assessed with specific tests of 
different domains such as memory. In terms of white matter lesions, all participants were 




ranged from 60.2 to 80.1 years at baseline. In terms of white matter burden and longitudinal 
risk of incident stroke, a meta-analysis including healthy and non-healthy samples showed a 
significant and positive association (total sample N  = 13,539; OR = 3.5, P <0.001). Greater 
white matter lesion burden was also significantly associated with greater longitudinal risk of 
dementia (sample N = 8803; OR = 1.9, P = 0.002), and cognitive decline (OR = 2.0, P not 
reported). The predictive power of baseline white matter lesion burden on longitudinal 
dementia/cognitive decline risk may therefore reflect cerebrovascular damage on the route to 
AD (i.e. it is a marker of progression but does not does not necessarily affect/interact), or it 
may affect/interact with other pathological changes to accelerate expression (Debette and 
Markus 2010; Brickman et al., 2012).  
 
6.2.3. Cerebral microbleeds  
Cerebral microbleeds appear as round or oval hypointense signals on T2*-weighted MRI 
(Greenberg et al., 2009). These reflect small deposits of blood product (haemosiderin) that 
typically appear at under 10 millimetres in diameter; microbleed size appears relatively 
bimodal around 0-5 mm and 5-10 mm, however because studies often differ in specific MRI 
pulse sequences, specific size is considered less important than frequency and - more 
importantly - location (Greenberg et al., 2009).  
In terms of frequency, microbleeds increase in older age and in the presence of 
cardiovascular diseases (Maxwell et al., 2011). In a large review of primary studies that 
examined cerebral microbleeds, Cordonnier et al. (2007) reported a prevalence of 5% in 
healthy older participants (total N = 1411), compared with 33.5% in adults with history of 
ischemic stroke (N = 1075), and 60.4% in participants with history of nontraumatic 




Microbleeds in different locations in the brain appear to reflect different underlying 
pathophysiologies. Microbleeds in strictly lobar regions (e.g. cortex/grey-white matter 
junction; subcortical white matter) are interpreted as reflecting underlying cerebral amyloid 
angiopathy while infratentorial (e.g. basal ganglia; internal/external capsule; thalamus) or 
cerebellar (e.g. brainstem; cerebellum) areas are possibly more reflective of 
hypertensive/ischemic vasculopathy (Viswanathan et al., 2010; Greenberg et al., 2009; 
Cordonnier et al., 2011). As an example, Vernooij et al. (2008) examined a large sample of 
generally healthy older adults (n = 1062, mean age = 69.9, SD = 7.2).  Participants underwent 
detailed MRI, genotyping and medical testing. They found that prevalence of hypertension 
(non; mild; severe) was additively associated with deep or infratentorial microbleeds only 
(severe vs. non-hypertensive OR = 1.66, 95% C.I’s 0.91 to 3.05), but not strictly lobar 
microbleeds. In contrast, the association between APOE ε4 ‘risk’ allele presence (generally 
associated with greater increased amyloid-β depositions and risk of cerebral amyloid 
angiography; vs. ε3/ε3) was stronger for lobar (OR = 1.87, 95% C.I’s = 1.25 to 2.81) 
compared with deep/infratentorial microbleeds (OR = 1.17, 95% C.I’s = 0.70 to 1.93).  
Microbleeds are significantly more prevalent in individuals with AD – primarily but 
not exclusively in lobar regions of the brain (Greenberg et al., 2009). Cordonnier et al. (2011) 
report microbleed frequencies in a collated set of data from 5 small studies that examined 
microbleeds in individuals diagnosed with AD (all sample n’s examined under 80 people 
except for one sample n = 223). They found prevalence rates of 23% (95% C.I’s = 17 to 
31%), much higher than would be expected in relatively healthy older adults.  
Microbleeds may relate to cognitive decline by affecting brain tissue at a specific 
location (i.e. playing a mechanistic role), and/or by may be reflective of underlying 
cerebrovascular disease burden, which is in reality the true mechanism affecting mental 




healthy older adults in terms of cognitive ability and microbleeds (n = 3979, mean age = 60.3, 
SD = 8.7). They analysed microbleed frequency in terms of 0 vs. 1 vs. 2-4 vs. ≥5, and split 
location by strictly lobar vs. deep/intratentorial. Presence (i.e. ≥1) of strictly lobar cerebral 
microbleeds was associated with significantly lower performance on a general factor of 
information processing speed (standardised β = -0.03, 95% C.I’s -0.06 to -0.01) and motor 
speed (standardised β = -0.04, 95% C.I’s -0.08 to -0.01).  Presence of deep/infratentorial 
cerebral microbleeds was associated with lower cognitive ability on various domains only for 
the ≥5 vs. 0 comparison. Only the strictly lobar-speed associations survived correction for 
education and cerebrovascular risk factors such as systolic/diastolic blood pressure, smoking 
history, diabetes total cholesterols, and use of lipid/pressure related drugs; this may suggest 
an independent mechanistic disruption of brain functional connectivity. 
 
6.2.4. APOE, TOMM40 & white matter lesions/cerebral microbleeds 
Previous studies have examined APOE and white matter lesions. Paternoster et al. (2009) 
examined all primary studies reported between 1966 to the end of 2007, including healthy 
and non-healthy individuals. They extracted different white matter hyperintensity statistics 
(e.g. periventricular/deep/overall lesions) and examined burden three ways: 1) by splitting 
participants into high or low lesion burden groups, based on semi-qualitative scores, 2) by 





/ml adjusted for head size. Samples were split into healthy and non-healthy (e.g. 
diagnosed with hypertension), and also collated, as separate analyses. There were 24 studies 
reviewed in total (n = 8564), of which two included non-healthy participants (n = 96). Meta-
analysis was conducted on 18 samples (n = 3465) and showed no significant association 
between APOE ε and membership of the high-lesion group (total OR = 0.97, 95% C.I’s 0.78 




0.15, 95% C.I.’s -0.04 to 0.33). Of the studies that could not be included in the meta-analysis 
because of unavailable data, none showed statistically significant associations (Paternoster et 
al., 2009). It should be noted that of the 24 studies examined, only 8 included relatively 
healthy older adults and of those only 5 were included in the meta-analysis (n = 1176). More 
recent studies in healthy older adults have been conducted since end of 2007. See Table 6.1 
for a collated list of studies in community-dwelling older adults. Observing this table, there is 
a generally inconsistent association between ε4 genotype and white matter lesion burden. No 
studies appeared to correct for multiple testing.  
 A large review of APOE and cerebral microbleeds was conducted by Maxwell et al. 
(2011). They examined 10 primary articles totalling 7,351 adults (3 healthy samples, n = 
5977; 7 with neurological conditions n = 1374). Mean ages ranged from 45 to 76 years. Of 
these 10 studies, 7 assessed microbleeds as dichotomous present vs. absent variables, one 
measured frequency and two were entirely qualitative. The seven with dichotomous 
microbleed data (including healthy and neurological samples) were meta-analysed (n =7272, 
number with ≥1 microbleed = 1156; overall mean age = 66.7 years). When they compared 
ε4+ with ε3/ε3, they found a significant increase in the presence of at least one microbleed 
(OR = 1.22, 95% C.I’s = 1.05 to 1.41, P = 0.01). The association was slightly stronger for 
strictly lobar microbleeds (OR = 1.35, 95% C.I’s = 1.10 to 1.66, P = 0.005) compared with 
not strictly lobar (OR = 1.16, 95% C.I’s = 0.89 to 1.50, P > 0.05) (vs. no microbleeds).  
Notably, only four of seven studies adjusted for cerebrovascular risk factors. To date, four 
large studies have been conducted examining APOE, cerebral microbleeds in healthy older 
adults (examining three samples; See Table 6.2). Observing table 6.2, it is apparent that 
significant associations with ε4 are either a) for the rare ε4/ε4 genotype vs. ε3/ε3, or b) in a 




Table 6.1. Summary of previous studies analysing apolipoprotein-e and white matter lesions in non-demented, community dwelling older adults. 
Report Imaging; measures  Sample (mean age; SD) N Covariates Phenotypic association (direction of  ε4) Notes & limitations 




burden (Peri. + deep). 
Healthy older adults (~52 
years; SD unclear).  
214 Unavailable.  Odds ratio = 0.88 (95% C.I.’s = 0.34 - 
2.28).  
Specific data could not be 
retrieved (covariates etc). 
Kuller et al., 
1998 
Fazekas scale: graded 0-
9 (Peri. + deep).  
Healthy older adults (>65; 
SD unclear).  
3480 Age, sex, race, education, 
clinical disease history. (n.s.) 
Odds ratio = 1.4 (95% C.I’s = 1.1 to 1.9).   
Skoog et al., 
1998* 
Graded dichtotomous 
high/low burden (Peri. + 
deep). 
Healthy older adults (85 to 
88; SD unclear).  
117 None apparent.  Odds ratio = 0.89 (95% C.I.’s = 0.41  to 
1.92).  
Used CT, which is less 
detailed than MRI. 






Healthy/CVD older adult 
twins (72.6; ±3.0**). 
396 Age, education, ICV, 
cardiovascular disease history. 
(Statistically controlled). 
Reported significant effects of ε4 in 
diseased sample only (ε4+ = 12cm
3 
vs. 
e4- = 7 cm
3
; P <0.05). No effects in 
healthy people.  
Sample of twins. Did not 
adjust for relatedness. 
Nebes et al., 
2001* 
Graded dichotomous 
(high/low burden; deep 
only). 
Healthy older adults (73.6; 
±3.4).  
92 Education. (Controlled).  Odds ratio = 1.40 (95% C.I.’s = 0.52 to 
3.72).  
Sample of mixed races. 
Highly educated (mean = 16.3 
years). 
Bigler et al., 
2003* 
Graded dichotomous 
(high/low burden; deep 
only). 
Healthy older adults (~70; 
data could not be retrieved).  
215 Data could not be retrieved. Data could not be retrieved. Report no 
significant effect of APOE.  
Data could not be retrieved. 




* = included in Paternoster et al. (2009) meta-analysis.  Peri. = periventricular white matter lesions, SD = standard deviation, ICV = intracranial volume. ** = weighted estimates.  
De Leeuw et 
al., 2004* 
Continuous volumes 
(deep + perventricular). 
Healthy older adults (72.1; 
±7.3**). 
829 Age, sex, cardiovascular risk 
factors; BMI, peripheral 
arterial disease, diabetes, 
study site. (Controlled). 
Main effect: adjusted mean difference 
for  ε4 carriers = 0.5 milliletres, 95% 
C.I’s = 0.2  to 0.8).  
Significant interaction with 
hypertensive status, where 
ε4+hypertension had greatest 
periventricular lesion load (see 
text). 
Hogh et al., 
2007 
Graded (Scheltens scale; 
peri. + deep). 
Healthy older adults (82.3; 
±0.8). 
75 Cardiovascular risk factors 
such as smoking and diabetes 
(n.s.).   
Significantly increased burden in overall 
white matter: ε4 effect (F = 5.72, P = 
0.02). 
No interaction with risk 
drinking, gender and 
hypertensive status. 




Healthy older adults (58.9; 
±9.09). 
144 Hypertension, age, gender, 
ICV. (Controlled). 
Lobar x genotype interaction: (F [6, 414] 
= 3.29, P = 0.006; data unavailable). 
No ε4 effect. 
Hafsteinsdottir 
et al., 2012 
Continuous overall 
volume. 
Healthy older adults (76.0; 
±5.4**). 
4303 ICV, age, gender, BMI, 
education, mood history. 
(Controlled). 
Significant effect: ε4+ = 0.98 cm
3
 vs. ε4- 
= 0.95 cm3 (P < 0.01). 
Large sample. 
Schuur et al., 
2011 
Continuous  overall 
volume. 
Older hypertensive adults 
with (64.7; ±4.3**). 
139 Age, gender, total ICV. 
(Controlled). 
No significant effects of APOE 
genotype.  
 
Godin et al., 
2009 
Continuous volume: 
cross sectional and 
longitudinal ~4 years 
later. 






Education, total ICV, gender, 
age. (Controlled). 
Baseline: effects of ε4/ε4 vs. ε4/- vs. -/- 
(5.58 vs. 5.34 vs. 8.73 cm
3
; P = 0.004). 
Longitudinal: similar effects for ε4/ε4 vs. 
ε4/- vs. -/- (1.32 vs. 1.48 vs. 3.46 cm3 
change respectively, P = 0.01). 
Significantly greater 










Imaging; measures  
 






(direction of  ε4) 
 
Notes & limitations 
Sveinbjornsdottir 
et al., 2008  
Cerebral microbleeds assessed by 
≥2 independent raters. Presence 
vs. absence (any area). Prevalence 
= 11.1%. 
AGES-Reykjavik 
study; healthy older 
adults (76.0; ±6.0). 
1962 Age, gender, hypertension, 
diabetes, smoking history, self-
reported history of 
stroke/transient ischaemic attach. 
(n.s.). 
Significant effect of ε4/ε4 
genotype (≥1 microbleed in 
22.5%; vs.  ε3/ε3 genotype 
prevalence = 10.9% (n =  1215). 
 
Does not state hardy-Weinberg 
statistics. Homozygosity effect 
only. 
Jeerakathil et al., 
2004 
Cerebral microbleeds assessed by 
≥2 independent raters. Presence 
vs. absence (any area). Prevalence 
= 4.7%. 
Framingham Study 
Original Cohort and 
Offspring Cohort; 
healthy older adults 
(63.9; ±12.0). 
368 Systolic blood pressure, total 
cholesterol, high-density 
lipoprotein, age, smoking status, 
diabetes, gender. (n.s.). 
No significant effect of ε4 (P = 
0.316).  APOE ε4/ε4 
frequencies not reported.  
Only moderate inter-rater 
agreement based on 222 scans 
read (0.33 to 0.57). Does not state 
hardy-Weinberg statistics. 
Vernooij et al., 
2008 
Cerebral microbleeds assessed by 
≥2 independent raters. Presence 
vs. absence (any; deep; 
infrantentorial; lobar). Prevalence 
= 29.1%. 
Rotterdam Study; 
healthy older adults 
(69.6; ±7.2). 
1062 Blood pressure; hypertensive 
status, smoking habits, alcohol 
use, diabetes, serum total/HDL 
cholesterol, use of lipid lowering 
and blood pressure lowering 
medication. (n.s.).  
Significant effect of ε4 allele; 
(odds ratio = 1.87, 95% C.I’s = 
1.25 to 2.81 ; vs ε3/ε3). More 
pronounced effect for lobar only 
(odds ratio = 2.68; 95% C.I’s = 
1.37 to 5.27).  APOE ε4/ε4 
frequencies not reported. 
 
High proportions of 
cardiovascular disease history, 
e.g. 51.5% with mild 
hypertension, 20% with severe 







Poels et al., 
2011a 
Longitudinal onset of new 
microbleeds since above study. 
Presence vs. absence (any; deep; 
infrantentorial; lobar). 
Rotterdam Study; 
healthy older adults 
(68.5; ±6.3). 
831 Age, sex, scan interval (from 
above study). (Controlled). 
Similar cardiovascular covariates 
as above. 
ε4/ε4 group showed significant 
increase in microbleeds (odds 
ratio = 4.43, 95% C.I’s = 1.90 to 
22.89; vs. ε3/ε3). 





In general, it would appear that any association between the APOE ε locus and white matter 
lesion/cerebral microbleed burden is modest (Paternoster et al., 2009; Maxwell et al., 2011). 
However there are important caveats to this based on tables 6.1 and 6.2:  
1 Relatively small sample sizes. For example, in a review of white matter lesion studies, 
Paternoster et al. found that previous population n’s ranged from 29 to 427, excluding one 
study with 944 participants. Of the 18 samples included in meta-analysis, only four had 
>150 participants. Of the more recent studies not reviewed by Paternoster et al., only one 
out of four had >150 participants. A large study of independent data would therefore add 
significantly to the literature.  (In the case of microbleeds, there are only four studies 
conducted, including three independent samples).  
2 Wide age ranges: the mean age of studies examining generally healthy older adults in 
tables 6.1 and 6.2 are relatively wide. Statistically controlling for this variable is unlikely 
to control for the accumulated effects of all subtle age-related changes, and samples with 
homogenous age ranges are preferable (Hofer and Sliwinski, 2001). 
3 Large studies do not consistently adjust for, or consider genetic interactions with, the 
effects of cardiovascular pathology on white matter lesion burden or microbleeds. For 
example, De Leeuw et al. (2004) examined 829 older adults (mean age = 72.1, SD = 7.3) 
with brain MRI and APOE information. They grouped participants according to normo- 
vs. hyper-tensive (systolic blood pressure >160 mmHg, diastolic >95 mmHg) at the first 
scan. White matter lesion burden was rated semi-qualitatively from 0 to 9. Controlling for 
the effects of age, gender, and other intermediate vascular risk factors such as diabetes, 
presence of hypertension was associated with significantly increased subcortical (adjusted 
mean score difference = 1.0, 95% CI’s = 0.8 to 1.2) and periventricular (difference = 0.9, 
95% CI’s = 0.7 to 1.1; both P < 0.05) lesion scores, independent of APOE. They found a 




synergistically associated with greater burden (interaction P = 0.016). An interaction with 
hypertension therefore seems an important aspect to consider. In addition, other large 
studies have reported a significant deleterious effect of hypertension on white matter 
lesion burden in older adults (e.g. van Dijk et al., 2004; N = 1625, mean age = 70.0, SD = 
3.0), although not in the context of APOE. Hypertension may affect blood-brain barrier 
permeability and contribute to microvascular instability (van Dijk et al., 2004).  
It would seem that no previous study has examined the TOMM40 poly-T repeat locus and 
association with white matter lesion or cerebral microbleeds burden. Furthermore, given the 
inconsistent association between APOE and white matter lesions/cerebral microbleeds. A 
large study with homogenous age ranges that takes cardiovascular disease history into 
account would contribute significantly to the literature. 
 
6.2.5. Current study 
This report aims to investigate the APOE ε and TOMM40 poly-T repeat genetic loci in terms 
of white matter hyperintensity burden in a large sample of community-dwelling older adults. 
This will add significant data to the literature in terms of 1) a large set of additional well-
controlled data with a narrow age range, analysed in terms of APOE genotype, 2) novel 
investigation of the TOMM40 poly-T repeat locus, 3) investigating the effects of and 
interactions with an important and relevant cardiovascular disease – hypertension (although 






6.3.1. Sample and procedure 
The LBC1936 recruitment, sample and procedure are detailed in Chapter 2 (‘Methodology’; 
Deary et al., 2007; 2012). In addition, at participants cognitive/sociodemographic/medical 
assessment at the Wellcome Trust Clinical Research Facility (WTCRF) had three standing 
and sitting blood pressure readings taken, with a B026 Omron 705IT monitor (amongst a 
wide range of other physical measures which are not examined here; Deary et al., 2007).  
 
6.3.2. Childhood intelligence 
The Moray House Test no.12 (MHT) completed at around age 11 years is described in 
Chapter 2 (‘Methodology’). MHT scores were adjusted for age in days at time of assessment, 
and standardised to an IQ score with a mean of 100 and a standard deviation of 15 for the 
whole LBC1936 sample.  
 
6.3.3. Genotyping  
The genotyping of the APOE 2/3/4 and TOMM40 523 loci is detailed in Chapter 2 
(‘Methodology’). 
 
6.3.4. Brain MRI: white matter lesions and cerebral microbleeds 
The core brain MRI procedure is described in Chapter 2 (‘Methodology’). The protocol paper 
by Wardlaw et al. (2011) details the imaging methodology, briefly described below.  
White matter lesion volumes were calculated from binary masks generated by an in-
house developed software tool written in MATLAB that applies a technique named 




Hernández et al., 2010). This method and measurement is detailed by Wardlaw et al. (2011). 
Analyses examined white matter lesion volume as a percentage of total intracranial volume 
(ICV); this is marker of general head size. Analyses also examined lesion volume as a 
percentage of total brain tissue volume (TBV); this is a marker of current brain size, and 
therefore takes into account any effects of general age-related brain atrophy on lesion burden 
(Wardlaw et al., 2011; Valdés Hernández et al., 2010). ICV and TBV were measured as 
described in Chapter 5 (‘...Hippocampal volume’), and more specifically the protocol paper 
by Wardlaw et al. (2011). 
 Qualitative and quantitative structural imaging assessments are complementary; 
white matter lesions were scored on the FLAIR and T2W images using the Fazekas scale, 
which codes separately for deep and periventricular lesions (Fazekas et al., 1987). For each 
scale, the left and right hemispheres are scored separately. Further details are provided in the 
protocol paper by Wardlaw et al. (2011). 
Microhaemorrhages were coded for number and distribution using a simplified 
version of the Brain Observer MicroBleed Scale (BOMBS) (Cordonnier et al., 2009), which 
considers microbleeds as being small, homogenous round foci of low singal intensity on T2*-
weighted images of less than 10mm in diameter. This rating scale is used to record the 
number of observed ‘certain’ or ‘uncertain’ microbleeds in the right and left hemispheres, 





6.4. Statistical analysis 
6.4.1. Covariate models & APOE/TOMM40 statistical analysis 
The covariate models and analytic strategies for the APOE and TOMM40 gene loci were 
described in Chapter 2 (‘Methodology’), and briefly recapped in Chapter 4 (‘…White Matter 
Integrity’). All initially-reported P-values are raw (and then FDR-adjustment is applied if 
appropriate), and P-values < 0.05 are considered nominally significant. 
This chapter differs slightly from the analytic protocol described in Chapter 2 
(‘Methodology’), specifically regarding microbleed analyses. In this chapter, for the 
microbleed analysis four statistical models were tested to investigate APOE-ɛ and TOMM40 
523 repeat genetic effects (rather than three, as was done for other imaging/cognitive 
phenotypes in other chapters). First, all models controlled for gender and age in days at 
neuroimaging. Significant associations with ‘any certain/uncertain cerebral microbleeds’ 
were then re-tested as ‘certain’ microbleeds only. As described in Chapter 2 (‘Methodology’), 
any remaining significant associations were then re-tested additionally controlling for (1) age 
11 intelligence, and then (2) the following cardiovascular pathologies; self-reported diagnosis 
of stroke, high cholesterol, high blood pressure, type-2 diabetes, and any other cardiovascular 
disease (Schiepers et al., 2012). Analysis of white matter lesions (in terms of covariate 
models) follows the protocol set in Chapter 2 (‘Methodology’), recapped in Chapter 4 





6.4.2. Hypertension status 
Current hypertensive status was defined according to an average of the second and third 
sitting blood pressure readings around the time of MRI, according to the NeuroCHARGE 
analysis protocol (a large-scale consortia investigating white matter lesions; Debette et al., 
2010; see Appendix A); normotensive (<90 diastolic/140 systolic mmHg with no anti-
hypertensive medication; n = 137), hypertensive (>90/140 mmHg, or use of anti-hypertensive 
medication; n = 598), or severely hypertensive (>100/160 mmHg; n = 122), where 
individuals on hypertensive medication had 5/10 mmHg added to their respective 
systolic/diastolic blood pressure scores in calculating hypertensive group. This hypertensive 
status variable correlated significantly but not perfectly with ‘reported history of high blood 
pressure’, both recorded at age 73 (r = 0.38, one-tailed P <0.001, n = 857). The final results 
reported here reflect the use of the ‘hypertensive status’ variable, however none of the final 
results were different when analyses were re-run with the self-reported ‘history of high blood 
pressure’ variable unless otherwise specified. 
 
6.4.3. ‘BOMBS’ microbleed scale 
The BOMBS microbleed scale allows a rater to note the number of either uncertain or certain 
<5mm or 5-10 mm microbleeds in the cortex/grey-white matter junction, subcortical white 
matter (together ‘strictly lobar’), basal ganglia grey matter, internal/external capsules, 
thalamus (together ‘deep’), brainstem and cerebellum (together ‘infratentorial’) (Cordonnier 
et al., 2009). To make sure that frequencies would be sufficient for meaningful analysis, new 
variables were created; ‘presence/absence of any microbleeds’ (i.e. uncertain + certain), and 
‘presence/absence of certain microbleeds’. This process was repeated for ‘strictly lobar’, and 




microbleeds’ was generally low. Because of this, the author elected against testing for genetic 
effects on specific microbleed variables. 
 
6.5. Results 
6.5.1. Descriptive statistics 
As detailed in Chapter 2 (‘Methodology’), of the 1091 total LBC1936 participants, 866 
attended Waves 1 and 2, and 700 completed neuroimaging at Wave 2. Individuals with MRI 
data were excluded if they had MMSE scores below 24 or not completed at Wave 2, or 
reported dementia. Overall, this left 694 participants, of which 659 and 669 participants had 
successful genotyping for APOE ε and TOMM40 523, respectively. 
APOE had allele frequencies of ε2 = 7.4%, ε3 = 77.0% and ε4 = 15.6%, with 
genotype frequencies of: ε2/ε2 = 1 (0.2%), ε2/ε3 = 80 (12.1%), ε2/ε4 = 15 (2.3%), ε3/ε3 = 
384 (58.3%), ε3/ε4 = 167 (25.3%) and ε4/ε4 = 12 (1.8%). TOMM40 523 had allele 
frequencies of S = 40.9%, L = 15.3% and VL = 43.9%, with genotype frequencies of S/S = 
101 (15.1%), S/L = 97 (14.5%), S/VL = 248 (%), L/L = 15 (2.2%), L/VL = 77 (11.5%) and 
VL/VL = 131 (19.6%). Exact tests confirmed that APOE ε and TOMM40 523 genotypes were 
in Hardy-Weinberg equilibrium (P values = 0.280 and 0.149 respectively).  
 Cardiovascular diseases are common risk factors for cerebrovascular pathology and 
therefore may play a significant role in white matter lesion and microbleed prevalence; the 
distributions of cardiovascular disease history and hypertensive status (based on blood-




Table 6.3. Descriptive statistics for brain imaging and cardiovascular disease history variables, 
grouped by apolipoprotein-e (APOE) and Translocase of outer mitochondrial membrane 40 
(TOMM40) genotypes. 
 





APOE ε genotype 
ε2/ε2 ε2/ε3 ε2/ε4 ε3/ε3   ε3/ε4   ε4/ε4 
History of diabetes (yes; %) 0 (0) 7 (8.8) 2 (13.3) 45 (11.7) 16 (9.6) 1 (8.3) 
History of high cholesterol (yes; %) 1 (100) 24 (30.0) 7 (46.7) 158 (41.1) 80 (47.9) 4 (33.3) 
History of Stroke (yes; %) 0 (0) 1 (1.3) 1 (6.7) 33 (8.6) 8 (4.8) 2 (16.7) 
History of high blood pressure (yes; %) 1 (100) 34 (42.5) 7 (46.7) 191 (49.7) 87 (52.1) 3 (25.0) 
Hypertensive status around MRI (normo-/hyper-/severe-; freq.) 0/1/0 13/58/9 4/11/0 60/270/54 25/118/24 0/2/8/2 
History of other cardiovascular pathology (yes; %) 0 (0) 19 (23.8) 3 (20.0) 104 (27.1) 50 (29.9) 4 (33.3) 
Presence of uncertain/certain microbleeds (yes; %) 0 (0) 12 (15.4) 0 (0) 37 (10.0) 19 (11.6) 4 (33.3) 
Presence of certain microbleeds (yes; %) 0 (0) 8 (10.3) 0 (0) 20 (5.4) 10 (6.1) 2 (16.7) 
Fazekas score: Periventricular Left (0/1/2/3; freq.) 0/0/1/0 3/52/20/4 1/11/1/1 11/249/88/25 3/107/49/7 0/11/1/0 
Fazekas score: Periventricular Right (0/1/2/3; freq.) 0/0/1/0 4/53/17/5 1/10/2/1 10/254/84/25 5/110/43/8 0/11/1/0 
Fazekas score: Periventricular overall (0/1/2/3; freq.) 0/0/1/0 4/50/21/4 1/9/3/1 10/243/95/25 5/104/49/8 0/11/1/0 
Fazekas score: Deep, Left (0/1/2/3; freq.) 0/0/1/0 14/47/15/3 5/8/1/0 70/228/69/6 30/102/26/8 1/9/1/1/ 
Fazekas score: Deep, Right (0/1/2/3; freq.) 0/1/0/0 16/45/17/1 6/7/1/0 71/237/57/8 27/105/26/8 2/9/1/0 
Fazekas score: Deep, Overall (0/1/2/3; freq.) 0/1/0/0 13/47/17/2 6/7/1/0 60/237/69/7 24/107/26/9 2/9/1/0 
White matter lesion alone in brain tissue volume %  













White matter lesion alone in intracranial volume % 















TOMM40 ‘523’ poly-T repeat genotype 
 S/S S/L S/VL L/L L/VL VL/VL 
History of diabetes (yes; %) 8 (7.9) 12 (12.4) 32 (12.9) 1 (6.7) 4 (5.2) 12 (9.2) 
History of high cholesterol (yes; %) 40 (39.6) 49 (50.5) 101 (40.7) 4 (26.7) 31 (40.3) 52 (39.7) 
History of Stroke (yes; %) 3 (3.0) 3 (3.1) 24 (9.7) 1 (6.7) 4 (5.2) 9 (6.9) 
History of high blood pressure (yes; %) 49 (48.5) 44 (45.4) 116 (46.8) 3 (20.0) 41 (53.2) 73 (55.7) 
Hypertensive status around MRI (normo-/hyper-/severe-; freq.) 16/74/11 17/63/17 40/174/34 3/10/2 12/57/8 19/93/19 
History of other cardiovascular pathology (yes; %) 26 (25.7) 24 (24.7) 64 (25.8) 5 (33.3) 25 (32.5) 38 (29.0) 
Presence of uncertain/certain microbleeds (yes; %) 15 (15.6) 14 (14.7) 22 (9.2) 5 (33.3) 6 (8.0) 13 (10.0) 
Presence of certain microbleeds (yes; %) 7 (7.3) 8 (8.4) 15 (6.3) 2 (13.3) 2 (2.7) 9 (6.9) 
Fazekas score: Periventricular Left (0/1/2/3; freq.) 5/62/24/6 4/59/29/3 6/160/61/14 0/11/2/2 1/50/21/5 3/90/27/10 
Fazekas score: Periventricular Right (0/1/2/3; freq.) 5/63/23/6 5/60/26/4 5/163/58/15 0/11/2/2 2/53/17/5 4/92/24/10 
Fazekas score: Periventricular overall (0/1/2/3; freq.) 5/59/27/6 5/57/29/4 5/159/63/14 0/11/2/2 2/48/22/5 4/86/30/10 
Fazekas score: Deep, Left (0/1/2/3; freq.) 21/57/17/2 16/60/18/1 40/152/42/7 1/10/2/2 16/44/11/6 24/76/28/2 
Fazekas score: Deep, Right (0/1/2/3; freq.) 21/59/15/2 15/60/18/2 42/155/39/5 2/10/2/1 14/46/13/4 27/79/21/3 
Fazekas score: Deep, Overall (0/1/2/3; freq.) 18/59/19/1 12/62/19/2 32/161/41/7 2/11/1/1 16/45/11/5 23/75/30/2 
White matter lesion alone in brain tissue volume % 













White matter lesion alone in intracranial volume % 
















6.5.2. White matter lesions  
For the APOE analyses, no significant effects were found for the ɛ4 present vs. absent 
comparison, ε3/ε4 vs. ε3/ε3 comparison or ε2+ vs. ε3/ε3 comparison (see Table 6.4), in terms 
of white matter lesion mm
3
 as a percentage of ICV or TBV, or Fazekas scale scores 
(periventricular or deep).  
For the TOMM40 523 analyses, no significant effects were found for brain imaging 
phenotypes in the whole sample, or when APOE ε3/ε4 or ε3/ε3 genotype subgroups were 




Table 6.4. APOE, TOMM40 and white matter lesions/cerebral microbleeds. 
Note. Age in days at time of testing and gender statistically controlled. Associations significant at P < 0.05 
are printed in bold-face. *Attenuated to P > 0.05 when analysed as ‘certain microbleeds’ only (P = 0.478). 






ɛ4+ vs. ɛ4- 
APOE ε genotype  
ɛ3/ɛ4 vs. ɛ3/ɛ3 
 
ɛ2+ vs. ɛ3/ɛ3 


















Periventricular Left (Fazekas) 1, 641 = 0.01 0.922 0.000 1, 535 = 0.36 0.551 0.001 1, 449 = 0.08 0.777 0.000 
Periventricular Right (Fazekas) 1, 641 = 0.11 0.743 0.000 1, 535 = 0.01 0.939 0.000 1, 449 = 0.46 0.498 0.001 
Periventricular overall (Fazekas) 1, 641 = 0.04 0.845 0.000 1, 535 = 0.00 0.974 0.000 1, 449 = 0.42 0.519 0.001 
Deep Left (Fazekas) 1, 641 = 0.00 0.951 0.000 1, 535 = 0.20 0.653 0.000 1, 449 = 0.16 0.690 0.000 
Deep Right (Fazekas) 1, 641 = 0.30 0.587 0.000 1, 535 = 1.40 0.237 0.003 1, 449 = 0.00 0.987 0.000 
Deep Overall (Fazekas) 1, 641 = 0.00 0.956 0.000 1, 535 = 0.57 0.452 0.001 1, 449 = 0.01 0.933 0.000 
White matter lesion alone in 
brain tissue volume (%) 
1, 633 = 0.61 0.437 0.001 1, 529 = 1.24 0.266 0.002 1, 445 = 0.02 0.894 0.000 
White matter lesion alone in 
intracranial volume (%) 
1, 633 = 0.39 0.534 0.001 1, 529 = 1.04 0.309 0.002 1, 445 = 0.00 0.995 0.000 
≥1 uncertain/certain microbleeds 1, 636 = 0.25 0.618 0.000 1, 531 = 0.19 0.592 0.001 1, 446 = 1.35 0.245 0.003 
≥1 uncertain/certain lobar  
microbleeds 
1, 636 = 0.01 0.929 0.000 1, 531 = 0.05 0.817 0.000 1, 446 = 0.63 0.429 0.001 
≥1  uncertain/certain 
deep/infratentorial  microbleeds 
1, 636 = 2.31 0.129 0.004 1, 531 = 1.47 0.225 0.003 1, 446 = 1.14 0.286 0.003 
  
 Whole sample  
TOMM40 ‘523’ poly-T repeat genotype 
APOE ɛ3/ɛ4 subgroup 
 
APOE ɛ3/ɛ3 subgroup 
















Periventricular Left (Fazekas) 5, 647 = 0.22 0.952 0.002 1, 159 = 0.01 0.938 0.000 2, 361 = 0.38 0.686 0.002 
Periventricular Right(Fazekas) 5, 647 = 0.23 0.951 0.002 1, 159 = 0.38 0.541 0.000 2, 361 = 0.21 0.814 0.001 
Periventricular overall(Fazekas) 5, 647 = 0.12 0.987 0.001 1, 159 = 0.08 0.776 0.001 2, 361 = 0.22 0.800 0.001 
Deep Left (Fazekas) 5, 647 = 0.63 0.679 0.005 1, 159 = 0.06 0.803 0.000 2, 361 = 1.00 0.369 0.006 
Deep Right (Fazekas) 5, 647 = 0.44 0.824 0.003 1, 159 = 0.04 0.839 0.000 2, 361 = 0.23 0.798 0.001 
Deep Overall (Fazekas) 5, 647 = 0.35 0.886 0.003 1, 159 = 0.89 0.348 0.006 2, 361 = 0.63 0.535 0.003 
White matter lesion alone in 
brain tissue volume (%) 
5, 641 = 0.45 0.812 0.004 1, 156 = 1.83 0.178 0.012 2, 359 = 0.03 0.966 0.000 
White matter lesion alone in 
intracranial volume (%) 
5, 641 = 0.37 0.870 0.003 1, 156 = 1.65 0.201 0.010 2, 359 = 0.02 0.978 0.000 
≥1 uncertain/certain microbleeds 5, 642 = 2.77 0.018 0.021* 1, 157 = 1.32 0.253 0.008 2, 359 = 1.68 0.188 0.009 
≥1 uncertain/certain lobar  
microbleeds 
5, 642 = 0.37 0.868 0.003 1, 157 = 1.84 0.177 0.012 2, 359 = 1.05 0.350 0.006 
≥1 uncertain/certain 
deep/infratentorial  microbleeds 




6.5.3. Cerebral microbleeds 
For the APOE analyses, no significant effects were found for the ɛ4 present vs. absent 
comparison, ε3/ε4 vs. ε3/ε3 comparison or ε2+ vs. ε3/ε3 comparison (see Table 6.4).  
For the TOMM40 523 analyses, for the most part no significant effects were found. 
One significant effect was found in the whole sample for ‘presence of any uncertain/certain 
microbleeds’ (F [5, 642] = 2.77, P = 0.018, η
2
 = 0.021). However, when re-analysed as 
‘presence of any certain microbleeds’, this was not statistically significant (F [5, 642] = 0.90, 
P = 0.478, η
2 
= 0.007). There were no significant effects of TOMM40 523 genotype when 




Table 6.5. Hypertensive status (normotensive; hypertensive; severe hypertensive) and white 
matter lesions/cerebral microbleeds. 
Note. Age in days at time of testing and gender statistically controlled. Associations significant at P < 0.05 

























Post-hoc contrasts  
(significant at P < 0.05) 
Periventricular Left (Fazekas) 2, 674 = 6.30 0.002 0.018 Normo<Hyper<Severe 
Periventricular Right(Fazekas) 2, 674 = 5.56 0.004 0.016 Normo<Hyper<Severe 
Periventricular overall(Fazekas) 2, 674 = 5.47 0.004 0.016 Normo<Hyper; Normo<Severe 
Deep Left (Fazekas) 2, 674 = 7.24 0.001 0.021 Normo<Hyper<Severe 
Deep Right (Fazekas) 2, 674 = 5.64 0.004 0.016 Normo<Hyper<Severe 
Deep Overall (Fazekas) 2, 674 = 8.91 <0.001 0.026 Normo<Hyper<Severe 
White matter lesion alone in brain tissue volume (%) 2, 665 = 6.61 0.001 0.019 Normo<Hyper; Normo<Severe 
White matter lesion alone in intracranial volume (%) 2, 665 = 6.54 0.002 0.019 Normo<Hyper<Severe 
≥1uncertain/certain microbleeds 2, 669 = 2.36 0.095 0.007  
≥1 uncertain/certain lobar microbleed 2, 669 = 0.94 0.390 0.003  




Table 6.6. Apolipoprotein-e (APOE) translocase of outer mitochondrial membrane 40 (TOMM40), 
and white matter lesions/cerebral microbleeds: interactions with hypertensive status. 
 
Note. Age in days at time of testing and gender statistically controlled. Associations significant at P < 0.05 
are printed in bold-face.  Fazekas = Fazekas scale scores.  
  
ɛ4+ vs. ɛ4- 
APOE genotype 
ɛ3/ɛ4 vs. ɛ3/ɛ3 
 


































Periventricular Left (Fazekas) 2, 637 = 0.51 0.602 0.002 2, 531 = 0.48 0.687 0.001 2, 445 = 0.93 0.397 0.004 
Periventricular Right (Fazekas) 2, 637 = 1.25 0.288 0.004 2, 531 = 1.25 0.288 0.005 2, 445 = 0.14 0.866 0.001 
Periventricular overall (Fazekas) 2, 637 = 1.01 0.366 0.003 2, 531 = 0.69 0.501 0.003 2, 445 = 0.29 0.746 0.001 
Deep Left (Fazekas) 2, 637 = 0.54 0.584 0.002 2, 531 = 0.32 0.728 0.001 2, 445 = 0.13 0.879 0.001 
Deep Right (Fazekas) 2, 637 = 0.29 0.748 0.001 2, 531 = 0.08 0.925 0.000 2, 445 = 0.06 0.945 0.000 
Deep, Overall (Fazekas) 2, 647 = 0.97 0.379 0.003 2, 531 = 0.35 0.706 0.001 2, 445 = 0.33 0.718 0.001 
White matter lesion alone in brain 
tissue volume (%) 
2, 629 = 0.03 0.971 0.000 2, 525 = 0.27 0.763 0.001 2, 441 = 0.76 0.467 0.003 
White matter lesion alone in 
intracranial volume (%) 
2, 629 = 0.04 0.961 0.000 2, 525 = 0.30 0.738 0.001 2, 441 = 0.84 0.432 0.004 
≥1 uncertain/certain microbleeds 2, 632 = 0.31 0.734 0.001 2, 527 = 0.02 0.981 0.000 2, 442 = 1.12 0.329 0.005 
≥1 uncertain/certain lobar  
microbleeds 
2, 632 = 0.46 0.629 0.001 2, 527 = 0.47 0.625 0.002 2, 442 = 0.79 0.457 0.004 
≥1  uncertain/certain 
deep/infratentorial  microbleeds 
2, 632 = 1.56 0.209 0.005 2, 527 = 1.03 0.357 0.004 2, 442 = 0.72 0.487 0.003 
  
Whole sample 
TOMM40 ‘523’ poly-T repeat genotype 
APOE ɛ3/ɛ4 subgroup 
 
APOE ɛ3/ɛ3 subgroup 
Periventricular Left (Fazekas) 10, 635 = 1.23 0.271 0.019 2, 155 = 0.64 0.531 0.008 4, 355 = 0.33 0.861 0.004 
Periventricular Right (Fazekas) 10, 635 = 1.96 0.036 0.030 2, 155 = 0.94 0.394 0.012 4, 355 = 0.16 0.961 0.002 
Periventricular overall (Fazekas) 10, 635 = 1.60 0.104 0.025 2, 155 = 0.69 0.501 0.009 4, 355 = 0.40 0.811 0.004 
Deep Left (Fazekas) 10, 635 = 1.16 0.316 0.018 2, 155 = 2.97 0.054 0.037 4, 355 = 0.55 0.700 0.006 
Deep Right (Fazekas) 10. 635 = 0.72 0.707 0.011 2, 155 = 1.94 0.147 0.024 4, 355 = 0.36 0.838 0.004 
Deep, Overall (Fazekas) 10, 635 = 0.99 0.455 0.015 2, 155 = 1.55 0.216 0.020 4, 355 = 0.90 0.462 0.010 
White matter lesion alone in brain 
tissue volume (%) 
10, 629 = 1.19 0.292 0.019 2, 152 = 1.18 0.309 0.015 4, 353 = 0.35 0.846 0.004 
White matter lesion alone in 
intracranial volume (%) 
10, 629 = 1.24 0.264 0.019 2, 152 = 1.32 0.269 0.017 4, 353 = 0.36 0.836 0.004 
≥1 uncertain/certain microbleeds 10, 630 = 1.34 0.198 0.021 2, 153 = 0.62 0.615 0.542 4, 353 = 2.04 0.089 0.023 
≥1 uncertain/certain lobar  
microbleeds 
10, 630 = 1.11 0.352 0.017 2, 153 = 1.09 0.338 0.014 4, 353 = 1.99 0.095 0.022 
≥1  uncertain/certain 
deep/infratentorial  microbleeds 




6.5.4. Current hypertensive status: main effects and interactions with 
APOE/TOMM40 genotypes 
First analyses tested for a main effect of hypertensive status (normotensive; hypertensive; 
severely hypertensive, based on readings taken around MRI). Significant effects were found 
for all white matter lesion variables (percentage white matter lesion in ICV and TBV; 
periventricular and deep Fazekas scale left/right/overall scores; all P < 0.01; see Table 6.5). 
Post-hoc contrasts showed that in the majority of cases the ‘Normotensive’ subgroups 
showed significantly less white matter lesion burden than the ‘Hypertensive’ subgroup, which 
in turn showed significantly lower burden than the ‘Severe hypertensive’ subgroup (See 
Table 6.5).  
A series of interaction models were run (genotype*hypertensive status, controlling for 
gender and age). There was one statistically significant interaction: where the TOMM40 523 
genotype interacted with hypertensive status in terms of right periventricular Fazekas scale 
scores, in the whole sample (F [10, 635] = 1.96, P = 0.036, η
2
 = 0.030; see Table 6.6). This 
was mostly driven by the L/L (mean Fazekas score = 1.04, SD = 0.49, n = 2) and L/VL 
genotypes (mean = 1.07, SD = 0.26, n = 8) in the ‘severe hypertensive’ group (all other mean 
scores ranged = 0.68 – 0.88). Additional analysis was performed where this was re-analysed 
with ‘self-reported history of high blood pressure; yes/no’, and this interaction attenuated to 
non-significance (F [5, 641] = 0.64, P = 0.673, η
2
 = 0.005). Because the significant 
interaction was due to a very small group of individuals, it was not examined further. There 
was no evidence of any other statistically significant interaction with hypertensive status for 






6.6.1. Overview  
The current study investigated the effects of the APOE ε and TOMM40 rs10524523 (‘523)’ 
poly-T repeat gene loci, on white matter lesion and cerebral microbleed burden as assessed 
by brain MRI in the LBC1936. This study also investigated interactions with hypertensive 
status assessed by blood pressure readings taken around the time of MRI, because evidence 
suggested that this was an important variable, relevant to white matter lesion burden in 
particular (van Dijk et al., 2004; De Leeuw et al., 2004). 
In terms of white matter lesions, this study reports no significant main effects of 
variation at either gene locus, with lesions analysed either volumetrically - as white matter 
lesion volume as a percentage of either intracranial volume (i.e. peak brain size), or total 
brain volume (i.e. current brain size) – or as semi-qualitative Fazekas scale ‘periventricular’ 
or ‘deep’ lesion scores. TOMM40 523 genotype significantly interacted with hypertensive 
status in terms of right periventricular Fazekas scale scores, however there are reasons to 
doubt this association. First, no other white matter variables showed a significant interaction 
and it is hard to see why this specific variable would be particularly sensitive to this (vs. 
right/overall periventricular scores); second, the interaction was not significant when re-
analysed as ‘self-reported history of high blood pressure’, taken around the same time as the 
MRI (and which would be expected to show relatively similar results as the normo-/hyper-
/severely hyper-tensive variable); and finally, the interaction was due to a very small group of 
individuals in the L/L and L/VL genotypes with severe hypertension. It should also be noted 
that this is in the context of a large number of tests of association, increasing the risk of type 
1 error; generally, it is unlikely that the interaction reflects a genuine mechanism in this 




In terms of cerebral microbleeds, APOE genotype was not associated with microbleed 
prevalence, whether analysed overall, strictly lobar or deep/infratentorial. TOMM40 523 
genotype was associated with significant differences in 'presence of ≥1 uncertain/certain 
micro bleeds', in the whole sample. However this association attenuated to non-significance 
when re-analysed as ‘certain microbleeds’ only; i.e. there was no association when uncertain 
cerebral microbleeds were excluded, making it unlikely that this effect is genuine. 
 
6.6.2. Interpretation: APOE ε genotype  
A recent large scale review by Paternoster et al. concluded that there was no significant 
association between APOE and white matter lesion burden in a pooled analysis of 
healthy/clinical samples of varying ages. Few of those studies - or those conducted 
subsequently - examine community dwelling older adults, and therefore may not be directly 
relevant to non-pathological ageing as investigated here. Examining studies of generally 
healthy older adults (see Table 6.1) indicates a modest and inconsistent association. The 
current study, in a large sample of generally healthy older adults, adds significant data to the 
literature and aligns with Paternoster et al. in observing no significant APOE/white matter 
lesion association. Previous associations may reflect type 1 error (particularly in less reliable, 
smaller samples), or failure to control for the effects of cardiovascular disease history. Other 
studies also report broader age ranges that reported here, and this may contribute to the risk 
of type 1 error; controlling for age is unlikely to eliminate all of the effects of various age 
related processes that influence white matter lesion burden (Hofer and Sliwinski, 2001).  
The current study contrasts with several previous reports in showing no significant 
association between APOE ε4 and cerebral microbleeds. However of those studies two report 
deleterious effects for the rare ε4/ε4 genotype only (vs. ε3/ε3; Sveinsbjornsdottir et al., 2008; 




present dataset: namely, Vernooij et al. (2008) report slightly increased prevalence of mild 
hypertension in the Rotterdam Study of older adults (52%) – compared with the current 
sample (49%; self-reported high blood pressure), and a relatively higher rate of  participants 
having ever smoked (72%, vs. 53% in the final present sample). This prevalence perhaps 
results in greater differentiation according to genotype, although it is unlikely to account for 
the whole effect. 
A key strength of this study is its use of the BOMBS instrument, because it allows 
raters to note cerebral microbleeds as either ‘certain’ or ‘uncertain’ (examples of mimics 
include basal ganglia calcification, cortical vessels or partial volume artefacts; Cordonnier et 
al., 2009). It would be interesting to find if any previously reported significant APOE-
microbleed associations are affected when analysed to incorporate uncertain microbleeds.     
 
6.6.3. Interpretation: TOMM40 ‘523’ poly-T repeat genotype 
The author is not aware of the TOMM40 523 locus having being analysed in terms of white 
matter lesions or cerebral microbleeds in any previous study. Firstly, here this study reports 
no direct significant association with white matter lesion burden. Previous analyses showed 
that in this sample - using MRI data taken at the same visit - TOMM40 523 genotype was 
associated with white matter tact integrity assessed with diffusion tensor MRI tractography in 
the LBC1936, most notably in the left ventral cingulum tract, and a general factor of white 
matter integrity constructed using principal components analysis (See Chapter 4). The lack of 
association here highlights that quantitative tractography assesses white matter microstructure 
rather than gross tissue death, and would therefore be expected to be the more sensitive brain 
white matter metric. However, the pathology underlying white matter lesions/brain 
microbleeds may be distinct from that underlying loss of microstructural integrity, meaning 




The significant association between TOMM40 523 and presence of any 
uncertain/certain microbleeds attenuated when only certain microbleeds were examined. This 
indicates that the effect is unlikely to be genuine, or is perhaps the early signs of genuine 
pathology which may be more clearly apparent in future longitudinal MRI scans conducted in 
the LBC1936.  
 
6.6.4. Limitations and future research  
There is evidence that the prevalence of white matter lesions and microbleeds increase 
significantly with age (Christiansen et al., 1994). For example, Raz et al. (2012) examined 
144 healthy adults of a range of ages (mean age = 58.89, SD = 9.09; range = 44 to 77 years). 
Participants underwent MRI. Independent of the effects of gender and hypertension, they 
found a significant effect of age on overall white matter lesion volumes (F [1, 140] = 53.14, P 
<0.001). Poels et al. (2011a) reported that the APOE ε4/ε4 allele in 831 older adults (mean 
age = 68.5, SD = 6.3; vs. ε3/ε3) was associated with an increase of micro bleeds over 3.4 
years (range 2.3 to 4.5) (OR = 4.43, 95% C.I’s = 1.44 to 13.64). It is possible that the current 
sample of non-demented, generally healthy older adults (aged around 73 years) have not 
undergone sufficient change show significant differentiation according to genotype. The 
sample reported  on here (mean age 72.7 years) is undergoing repeat MRI around three years 
later (i.e. around the year 2012); future studies may investigate APOE and TOMM40 
genotypes in terms of longitudinal increase in white matter lesion or cerebral microbleed 
burden. As discussed above, future studies in independent samples should also use the 
BOMBS because it allows raters to distinguish between certain and uncertain microbleeds 






The current study investigated the effects of variation in the APOE ε and TOMM40 ‘523’ 
gene loci, in terms of white matter lesion burden and cerebral microbleeds. Previous studies 
have shown inconsistent and modest associations between APOE and these brain imaging 
phenotypes. In a large study of generally healthy, community dwelling older adults, present 
analyses ultimately found no association between APOE or TOMM40 and these phenotypes. 
The present findings align well with recent reviews (Paternoster et al., 2009; Maxwell et al., 
2011) that suggest there is unlikely to be a particularly strong or consistent association 
between APOE and these phenotypes in large, well-controlled community dwelling samples. 
Reasons for discrepancies with previous reports may relate to mean age differences, failure to 
control for type 1 error e.g. with Bonferroni, and failure to account for cardiovascular disease 
history. Future studies of APOE and cerebral microbleeds should utilise the BOMBS to 














Chapter 7: APOE ε genotype, TOMM40 poly-T repeat length and 
cognitive ageing via brain white matter tract integrity 
 
A version of this chapter is in preparation for submission for publication: Lyall, D.M., Harris, 
S.E., Royle, N.A., Bastin, M.E., Valdés Hernández, M. del C., Muñoz Maniega, S., Murray, 
C., Lutz, M.W., Saunders, A.M., Roses, A.D., Starr, J.M., Porteous, D.J., Wardlaw, J.M. & 






Specific variations in the APOE ε and TOMM40 ‘523’ poly-T repeat gene loci have been 
associated with significantly increased risk of Alzheimer’s disease (AD). This study 
investigated the independent effects of these loci on human cognitive ageing, and the extent 
to which nominally significant gene-cognitive associations were mediated by previously 
reported genetic associations with white matter tract integrity in this sample. Most 
participants in the Lothian Birth Cohort 1936 completed a reasoning-type intelligence test at 
age 11. As part of a longitudinal study of cognitive ageing, they underwent genotyping for 
APOE ε2/ε3/ε4 status and TOMM40 523 poly-T repeat length, detailed cognitive/physical 
assessments and structural brain MRI at a mean age of 72.70 years (standard deviation = 
0.74). Data were available from 758-814 subjects for cognitive analysis, and 522-543 for 
mediation analysis. 
APOE genotype was significantly associated with performance on several different 
tests of cognitive ability, including general factors of intelligence, information processing 
speed, and memory (raw P values all < 0.05), independent of childhood IQ and 
cardiovascular disease history. Formal tests of mediation showed that several significant 
APOE-cognitive ageing associations - particularly those related to tests of information 
processing speed - were significantly, but not entirely mediated by white matter tract 
integrity. TOMM40 523 genotype was significantly associated with scores on two specific 
tasks, but these associations did not survive statistical correction for APOE ε genotype or 
cardiovascular disease history. A range of brain imaging phenotypes are likely to form the 
anatomical basis for significant associations between APOE genotype and cognitive ageing, 




7.2. Introduction  
Alzheimer’s disease (AD) is a progressive neurodegenerative disease characterised by 
cognitive impairment (Albert et al., 2011). Requisite for the diagnosis of AD is severe 
cognitive decline that interferes with independent daily life (e.g. the ability to recall and 
understand information, make reasoned judgements or complete relatively complex tasks; 
Alzheimer’s Association, 2011).  
 There is evidence from large studies that whereas AD is associated with severe and 
broad cognitive decline, specific mental domains may be particularly susceptible to the early 
stages of the dementing process. Chen et al. (2001) were interested in how the degree of 
specific longitudinal cognitive decline - across two years from 3.5 to 1.5 years prior to 
diagnosis - predicted the onset of AD. They examined the Monongahela Valley Independent 
Elders Survey, a large sample of older adults with repeat cognitive testing. Participants (n = 
1422) were assessed every two years (over ten years) for the diagnosis of AD. Of those that 
were diagnosed with AD over the ten years, Chen et al. examined those with complete 
cognitive data taken around 3.5 and 1.5 years (±1 year) before AD symptoms were first 
observed. This left 551 older adults overall (mean control group n = 483, age = 72.6, standard 
deviation [SD] = 4.4; converted-to-AD group n = 68, age = 76.6, SD = 5.3 at baseline). The 
controls showed no significant declines across two years on any of a broad battery of 15 
cognitive tests of different domains, adjusted for age, gender and education. The variables 
that most strongly predicted conversion to AD were decline in Trail Making Test-B (odds 
ratio [OR] = 3.72), reflecting processing speed and set-shifting (Lezak et al., 2004) and 
Word-List delayed recall (OR = 3.63), reflecting verbal memory (Lezak et al., 2004). The 
decline was not uniform across tests; for example Boston Naming Test (crystal intelligence) 
performance and Verbal Fluency (semantic memory) performance were not significantly 




memory-related cognitive abilities are particularly sensitive to AD-related pathology (Chen et 
al., 2001). It is important to understand the mechanisms and neural basis for non-pathological 
cognitive decline prior to dementia; the primary hypothesis tested in this chapter was that 
specific aspects of cognitive ability may be particularly susceptible to risk factors for AD.   
Two genetic risk factors for AD are in the apolipoprotein-e (APOE) and translocase of 
outer mitochondrial membrane 40 (TOMM40) gene loci (Roses et al., 2010). A large number 
of previous studies have investigated the effects of APOE on cognitive ability in later life, 
including data from the Lothian Birth Cohort 1936 (LBC1936) around age 70, both 
unadjusted and adjusted for childhood intelligence (i.e. reflecting lifetime cognitive change or 
‘cognitive ageing’; Deary et al., 2004). Here, this study examined cognitive ability at the 
older age of around 73 years, and examined whether significant raw associations with 
APOE/TOMM40 are mediated by previously reported significant associations between 
APOE/TOMM40 and white matter microstructural integrity, assessed with diffusion tensor 
magnetic resonance imaging (DT-MRI; see Chapter 4).  
Having described the APOE ε and TOMM40 ‘523’ poly-T repeat gene loci in Chapter 
1 (‘Introduction’) and Chapter 2 (‘Methodology’), the following sections describe the genes 
in terms of their relation to cognitive ability in older adults. 
 
7.2.1. APOE ε, TOMM40 523 & cognitive ability 
A large number of previous studies have investigated associations between APOE genotype 
and cognitive ability in non-demented adults. Wisdom et al. (2011) conducted a meta-
analysis of 77 studies, excluding samples with any disorders that may affect cognitive ability 
such as dementia or Parkinson’s disease (final N = 40,942; calculated mean age = 67.7, SD = 
11.86; published between January 2003 and August 2008) that investigated cognitively intact, 




statistical information to allow for calculation of effect sizes (e.g. means/SD etc).  They 
calculated an effect size, Hedge’s g, reflecting the difference between ε4 presence vs. ε4 
absence divided by the pooled standard deviation, and therefore corrected for any bias 
associated with small sample sizes. For analytic purposes, they then constructed a ‘d’ effect 
size metric that weighted standardized differences between the groups in terms of sample 
sizes. They grouped cognitive tests into eight domains – attention, episodic memory, 
executive function, global ability (e.g. full-scale IQ), perceptual (i.e. information processing) 
speed, primary (i.e. working) memory, verbal ability (i.e. crystal intelligence) and 
visuospatial ability. Of a total 227 effect sizes across 8 cognitive domains, significant 
deleterious effects of the ε4 allele were found for episodic memory (d = -0.14, standardised r 
coefficient = -0.07), global cognitive function (d = -0.05, r = 0.03), executive function (d = -
0.06, r = -0.03) and perceptual speed (d = -0.07, r = -0.06; all P < 0.05). There were no 
effects on verbal ability, primary memory, attention or visuospatial functioning (all P > 0.05). 
When Wisdom et al. modelled the effects of age on effect sizes (relative to ε4 presence vs. ε4 
absence), they found that increasing sample age significantly predicted greater effect sizes for 
episodic memory and global cognitive ability only (exact data not provided). These results 
are similar to those reported by Small et al. (2004), who examined similar studies of APOE 
and non-demented older adults, published from January 1993 to February 2004 (38 
independent studies, total N = 20,765). They reported significant deleterious effects of the ε4 
allele on episodic memory (d = -0.14, r = -0.07, P <0.01), global cognitive ability (d = -0.05, 
r = -0.03, P <0.05), executive functioning (d = -0.06, r = -0.03, P <0.01) and perceptual 
speed (d = -0.07, r = -0.04, P <0.05) only. Wisdom et al. note that studies do not consistently 
correct for important covariates such as gender, education or cardiovascular disease history. 
Despite this, the high number of papers examined by Wisdom et al. and Small et al. indicate a 




The largest single report on APOE and cognitive ageing involved a large consortium 
including samples of generally healthy, community-dwelling older adults with a metric of 
prior cognitive ability (Davies et al., 2012; detailed in Chapter 1; Introduction). Davies et al. 
conducted a genome-wide association study on cognitive ageing based on five large 
discovery cohorts of community-dwelling, non-demented older adults, totalling 3802 
participants. Significant associations were re-tested in two replication cohorts (total N = 
1367). The different samples each constructed general factors of cognitive ability with 
different tests of fluid intelligence, using principal components analysis (PCA). Each score 
was then adjusted for premorbid ability; either with measures of childhood intelligence or 
with growth curve models based on data from up to four time points, including ability at 10 
years prior. Old age ability adjusted for prior ability was considered ‘cognitive ageing’. 
Participants in the discovery groups received genotyping for APOE ε and, in two cohorts, 
TOMM40 523, in addition to GWAS data. When GWAS data for cognitive ageing were 
meta-analysed, one single nucleotide polymorphism (SNP) achieved genome-wide 
significance, adjusted for multiple testing (rs2075650 in TOMM40, un-standardised β = -1.30, 
standard error = 0.27, P = 2.47 x 10
-8
), with similar results in the smaller replication groups. 
However the SNP genotyping array used for GWAS (Illumina610-Quadv1 chip; Illumina, 
San Diego, CA, USA) does not cover the APOE/TOMM40 region well, and the significant 
association with rs2075650 may reflect linkage with a more causal variant. Davies et al. 
(2012) therefore tested for the effect of APOE ε genotype. They found that possession of the 
APOE ε4 genotype was associated with significantly worse cognitive ageing (un-standardised 
β = -0.22, standard error = 0.04, P = 2.18 x 10
-8
). When rs2075650 was added to the model, 
it did not reach significance (P > 0.05). No significant effects of TOMM40 523 genotype 




 Luciano et al. (2009a) examined cognitive ageing in the LBC1936 in detail. As 
described in previous chapters, this sample of older adults completed a test of general 
intelligence at age 11 – the Moray House Test no. 12 (MHT) – and returned for detailed 
testing in older age (mean age = 69.9; SD = 0.8; n = 1013). They found a significant 
deleterious effect of the ε4 allele on Matrix Reasoning (F [1, 1006] = 4.85, P = 0.03), Symbol 
Search (F [1, 1000] = 5.30, P = 0.02), Choice Reaction Time (RT) standard deviation (F [1, 
992] = 4.64, P = 0.03), and a general factor of cognitive ability constructed with PCA (F [1, 
981] = 4.24, P = 0.04). They did not find any association with on age 70 MHT scores, Verbal 
Fluency, Letter-Number Sequencing, Backward Digit Span, Block Design, Digit Symbol, 
Simple RT, or a general factor of Processing Speed. Furthermore, they found that the 
significant associations survived correction for - and were therefore independent of - age 11 
intelligence. In a separate report by Luciano et al. (2009b), the same participants were 
examined in terms of several immediate and delayed memory tasks at age 70 (n = 1013; 
Logical Memory; Verbal Paired Associates; Spatial Span). They found a significant 
deleterious effect of ε4 allele presence for Logical Memory immediate scores (F [1, 983] = 
4.32, P = 0.04; adjusted or age and gender only), Spatial Span forwards scores additionally 
adjusted for MHT scores at age 11 years (F [1, 949] = 4.15, P = 0.04) and age 70 years (F [1, 
983] = 4.50, P = 0.03). This indicates significant association independent of early life as well 
as concurrent general cognitive ability.  Luciano et al. (2009a) noted significant main effects 
of age on all tasks, despite a relatively small age range (P <0.001; except for Simple/Choice 
RT). This may suggest more pronounced effects of APOE genotype now that participants 






TOMM40 523 genotype and cognitive ability has been examined in three studies 
(Johnson et al., 2011; Caselli et al., 2012; Hayden et al., 2012). These reports are displayed in 
Table 7.1 and indicate a generally inconsistent association between TOMM40 523 poly-T 




Table 7.1. Previous studies analysing translocase of outer mitochondrial membrane 40 (TOMM40) genotype and cognitive ability in community 
dwelling older adults. 
 
Report Cognitive measures  Sample (mean age; SD) n Covariates Genotype effects Notes & limitations 
Johnson et al. 2011 Performance and 
Verbal IQ,  
Auditory Verbal 
Learning Test  
scores 
Healthy older adults  
(55.4 ±6.00; APOE 3/3 
genotype only*)  
117 Age, intracranial 
volume, gender 
(controlled), 
family history of 
AD, hypertension 
(n.s.). 
No significant effects of TOMM40 on 
performance or verbal IQ; significant 
deleterious effect of the 523 VL/VL genotype 
(vs. S/S) on total AVLT scores (49.62 vs. 
55.13 out of 75; Cohen’s d = 0.72, P < 0.05) 
 
A sample of individuals with the 
‘neutral’ APOE ε3/ε3 genotype 
Caselli et al., 2012 Auditory Verbal 
Learning Test  
scores 
Healthy older adults, 
longitudinally assessed 
 Every 1-2 years (57.8; ± 
12.2*)  
639 Age, gender, 
education 
(controlled).  
Significant difference in memory change between 
S/S and VL/VL (deleterious) groups (in APOE 
ε3/ε3genotype only: P = 0.04).  
 
VL/VL is deleterious in that it 
shows no test-retest benefit, 
unlike other genotypes 
Hayden et al., 2012 Broad cognitive 
battery of memory, 
attention, language 
and exeutive 
function (17 tasks) 
Healthy older adults (80.6 ± 
6.0), then APOE ε3ε3 
genotype only (n = 82)  





No significant effects of 523 in whole sample. 
Significant deleterious effect of VL allele (Paired 
Associates Learning and Verbal Recall Memory 
scores, Rapid Visual Information Processing 
latency, Digit Span forwards/backwards total; all P 
<0.05, with S/VL > S/S & VL/VL (APOE 3/3 
subgroup only) 
Deleterious effect of S allele in 
‘neutral’ APOE genotype only. 
S/VL performed much better than 
S/S and VL/VL, who performed 
similarly. No associations 
survived bonferroni correction. 
No markers of prior ability 




7.2.2. APOE, TOMM40 and cognitive ageing: mediated by white matter tract 
integrity?   
It is important to understand the anatomical brain substrates of cognitive ageing. Penke et al. 
(2012) investigated the role of white matter integrity using different metrics, one of which 
was fractional anisotropy (FA). They reported that a general factor of fractional anisotropy 
(gFA) constructed with principal components analysis (PCA) was significantly associated with 
general factors of processing speed (gspeed; standardized β = -0.19) and general cognitive 
ability (g; standardized β = 0.13) in LBC1936, explaining around 10% of the variance in 
general cognitive ability. Few studies have examined the brain imaging phenotypes 
underpinning the deleterious effects of genetic variation on cognitive ability in old age. In 
Chapter 2 (‘ADRB2’; see also Lyall et al., 2013), mediation analysis was conducted in the 
LBC1936, where a gene-cognitive ageing association was significantly mediated by integrity 
in a specific white matter tract. Specifically, variation in the rs1042714 SNP (in the ADRB2 
gene) was associated with performance on the Digit Symbol Coding test (standardised β = -
0.09, P = 0.010), and integrity of the left arcuate fasciculus tract (assessed by FA; 
standardised β = -0.11, P = 0.007). It was reported that the SNP-cognitive ageing association 
was mediated by left arcuate fasciculus FA (bootstrapping point estimate coefficient = -0.207, 
95% C.I’s = -0.52 to -0.04; Lyall et al. 2013). 
This PhD thesis has tested for genetic associations with white matter microstructural 
integrity, hippocampal volumes (independent of generalized brain atrophy and head size), 
brain white matter lesions and cerebral microbleeds. Those studies showed significant 
nominal raw effects of APOE ε and TOMM40 523 genotypes on white matter microstructure 





7.2.3. The current study 
The APOE ε and TOMM40 523 poly-T repeat gene loci have been associated with increased 
risk of AD. Previous studies have investigated the effects of APOE on cognitive ability in 
older adults; however, there are relatively few studies that examine TOMM40 523 genotype, 
and the author is not aware of any studies that have formally investigated the specific 
structural brain MRI phenotypes that mediate APOE-cognitive associations.  
This study aims to: 1) assess the effects of APOE/TOMM40 523 genotypes on 
cognitive abilities in older people, at first unadjusted and then adjusted for age 11 intelligence 
(i.e. reflecting cognitive ageing); and 2) determine the extent to which any such significant 
associations are mediated by previously-reported associations with white matter tract 
integrity, assessed with DT-MRI (see Chapter 4).  
 
7.3. Methods 
7.3.1. Sample and procedure 
The LBC1936 recruitment, sample and procedure are detailed in Chapter 2 (‘Methodology’; 
Deary et al., 2007; 2012).  
 
7.3.2. Genotyping  






7.3.3. Childhood intelligence 
The Moray House Test no.12 (MHT) completed at around age 11 years is described in 
Chapter 2 (‘Methodology’). MHT scores were adjusted for age in days at time of assessment, 
and standardised to an IQ score with a mean of 100 and a standard deviation of 15 for the 
whole LBC1936 sample.  
 
7.3.4. Assessment of cognitive domains at age ~73 (‘Wave 2’)  
The tests are described in Chapter 2 (‘Methodology’; Deary et al., 2007). In brief, the 
cognitive domains assessed were as follows. Working memory was assessed with Digit Span 
Backwards and Letter Number Sequencing from the WAIS-III
UK 
(Wechsler 1998a). 
Processing speed was assessed using: Digit Symbol Coding and Symbol Search from the 
WAIS-III
UK
; Simple reaction time (RT), and Four-Choice RT via a self-contained device 
(Cox et al. 1993); and a psychophysical visual discrimination task called Inspection Time 
(Deary et al. 2007). Verbal declarative memory was assessed with the Verbal Paired 





; Wechsler 1998b). Visuospatial ability and memory were assessed with 




 respectively. Abstract 
reasoning was assessed using Matrix Reasoning from the WAIS-III
UK
. 
Data reduction was applied to the test scores using PCA, as described in Chapter 2 
(‘Methodology’). The first unrotated principal component score in each domain for general 
intelligence (g), information processing speed (gspeed) and memory (gmemory) accounted for 50-
54% of the respective variance, and all individual variables had high loadings on their 






7.3.5. Diffusion MRI and tractography  
The core brain MRI procedure is described in Chapter 2 (‘Methodology’), and the diffusion-
tensor procedure and processing is described in Chapter 3 (‘ADRB2…’; but see Wardlaw et 
al., 2011 for specific details). To permit principal components analysis (PCA) on the 
tractography data, participants with up to two missing values from specific tracts had data 
replaced with the mean value for that tract. PCA was conducted on tract-averaged water 
diffusion parameters for twelve pathways, giving a clear single-factor model for FA (gfa) that 
accounted for 38.8% of the overall variance. The ventral cingulum was not included in the 
PCA because the rostral and ventral cingula are subdivisions of the same tract. General white 
matter integrity factors have previously been found to be associated with cognitive abilities in 
this sample (Penke et al., 2012; Penke et al., 2010a).  
 
7.4. Statistical Analysis 
7.4.1. Covariate models & APOE/TOMM40 statistical analysis 
The covariate models and analytic strategies for the APOE and TOMM40 gene loci were 
described in Chapter 2 (‘Methodology’). For ease, this is recapped in Table 7.2 also. All 
initially-reported P-values are raw (and then FDR-adjustment is applied), and P-values < 




Table 7.2. Final analytic strategies for APOE ε and TOMM40 ‘523’ poly-T repeat 
gene loci for Chapters 4-7. 
 
 APOE ε TOMM40 ‘523’ 
Gene locus: rs7412 + rs429358 









ε4 present (vs. ε4 absent) 
Overall effect of genotype? 
(S/S; S/L; VL/L; L/L; VL/VL) 






ε3/ε4 (vs. ε3/ε3) 
S/S; S/L*; L*/L* 







ε2 present (vs. ε3/ε3) 
S/S; S/L*; L*/L* 







Model 1: Age + Gender 
Model 2: Age + Gender + Age 11 IQ 
Model 3: Age + Gender + Age 11 IQ + Cardiovascular disease history 
 
Note. The term ‘ε4 present’ includes participants with ε3/ε4; ε2/ε4; ε4/ε4 genotypes pooled 
together, while ‘ε4 absent’ includes all other genotypes. ‘ε2’ present includes participants 
with ε2/ε3 and ε3/ε3 genotypes only. TOMM40 523 L* = L and VL alleles pooled.  
 
 
7.4.2. Mediation analysis 
Mediation analysis was used to test the indirect effect of the predictor variable 
(APOE/TOMM40) upon the outcome (cognitive function), through the hypothesised mediator 
(white matter integrity). Mediation analysis was run using the INDIRECT bootstrapping 
macro (Preacher and Hayes, 2008), and detailed in Chapter 3 ‘(ADRB2…’). Briefly, in a 




indirect via variable M. Path A represents the effect of X on M, while path B represents the 
effect of M on Y, partialling out the effect of X.  The direct effect of X on Y is represented by 
path C. The indirect effect can then be quantified as the combined product of paths A and B. 
The bias-corrected bootstrapping point estimate coefficients that are reported here each 
reflect this indirect product (Preacher and Hayes, 2008). Bootstrapping point estimate 
coefficients are un-standardised and averaged over 5000 bootstrap estimates (Preacher and 
Hayes, 2008). The indirect point estimate coefficients (commonly simply ‘effects’) were 
considered statistically significant if the 95% confidence intervals (C.I’s) did not cross 0.00 
(Preacher & Hayes, 2008) 
 
7.5. Results 
7.5.1. Descriptive statistics 
As detailed in Chapter 2 (‘Methodology’), of the 1091 total LBC1936 participants, 866 
attended Waves 1 and 2. Individuals who had MMSE scores below 24, did not complete the 
MMSE at Wave 2 or had a history of dementia were excluded from analysis. Overall, this left 
859 participants, of which 811 and 823 participants had successful genotyping for APOE and 
TOMM40, respectively.   
APOE had allele frequencies of 2 = 7.3%, 3 = 76.9% and 4 = 15.8%, with 
genotype frequencies of: 2/2 = 3 (0.4%), 2/3 = 95 (11.7%), 2/4 = 18 (2.2%), 3/3 = 
472 (58.2%), 3/4 = 208 (25.6%), and 4/4 = 15 (1.8%) (total n = 811). TOMM40 523 had 
allele frequencies of S = 41.0%, L = 15.4% and VL = 43.6%, with genotype frequencies of 
S/S = 125 (15.2%), S/L = 123 (14.9%), S/VL = 302 (36.7%), L/L = 18 (2.2%), L/VL = 95 




TOMM40 were in Hardy-Weinberg equilibrium (P-values = 0.44 and 0.06, respectively). 
Specific GLM data (F/P value/η
2
) are presented in Tables 7.3 to 7.8.  
 
APOE, TOMM40 and cognitive ability - not adjusted for childhood intelligence (Model 1) 
Significant deleterious effects of the APOE ε4 allele (vs. absence) were found on three tasks: 
specifically Symbol Search, Inspection Time Total, and Spatial Span (‘Step 1’). For the ε3/ε3 
vs. ε3/ε4 comparison a significant effect was found for Inspection Time Total only (‘Step 2’). 
For the ε2+ (vs. ε3/ε3) comparison, a significant protective effect of ε2 possession was found 
for Inspection Time Total (all P < 0.05; ‘Step 3’; see Table 7.3). 
For TOMM40, no significant effects were found in the whole sample (‘Step 1’) or 
ε3/ε3 genotype subgroup (‘Step 3’). A single significant protective effect of the S allele was 
found in APOE ε3/ε4 genotype subgroup only, for Letter-Number Sequencing (P < 0.05; 

































4 allele presence (vs. absence) 
 
 3/4 ( vs. 3/3) 
 
APOE 2/3 & 2/2  (vs. 3/3) 















(1, 757) = 0.75 0.386  0.001 (1, 633) = 0.52 0.473 0.001 (1, 529) = 1.73 0.189 0.003 
General factor: intelligence (g) 
 
(1, 797) = 0.19 0.166 0.002 (1, 667) = 1.58 0.210 0.002 (1, 559) = 0.66 0.417 0.001 
Digit Span Backwards 
 
(1, 807) = 0.03 0.862 0.000 (1, 676) = 0.21 0.649 0.000 (1, 566) = 2.92 0.088 0.005 
Matrix Reasoning 
 
(1, 806) = 1.40 0.237 0.002 (1, 675) = 1.84 0.175 0.003 (1, 565) = 0.08 0.782 0.000 
Block Design 
 
(1, 805) = 1.77 0.184 0.002 (1, 674) = 1.96 0.162 0.003 (1, 564) = 1.84 0.176 0.003 
Letter-Number Sequencing 
 
(1, 806) = 0.10 0.747 0.000 (1, 675) = 0.00 0.954 0.000 (1, 565) = 0.57 0.449 0.001 
General factor: processing speed (gSpeed) 
 
(1, 765) = 2.53 0.112 0.003 (1, 639) = 0.62 0.431 0.001 (1, 543) = 1.51 0.220   0.003 
Digit Symbol Coding 
 
(1, 804) = 0.67 0.414 0.001 (1, 673) = 0.02 0.896 0.000 (1, 564) = 1.08 0.298 0.002 
Symbol Search 
 
(1, 802) = 3.92 0.048 0.005 (1, 671) = 0.20 0.153 0.003 (1, 562) = 0.00 0.960 0.000 
Simple Reaction time (seconds) 
 
(1, 798) = 0.01 0.914 0.000 (1, 668) = 0.50 0.478 0.001 (1, 559) = 0.26 0.107 0.005 
Four Choice Reaction Time (seconds) 
 
(1, 802) = 0.10 0.748  0.000 (1, 672) = 0.20 0.652 0.000 (1, 564) = 0.15 0.230 0.003 
Inspection Time Total  
 
(1, 799) = 8.42 0.004 0.011 (1, 651) = 3.96 0.047  0.006 (1, 552) = 0.59 0.015 0.011 
General factor: memory (gMemory)   
 
(1, 788) = 1.94 0.165 0.002 (1, 659) = 1.90 0.169 0.003 (1, 552) = 0.04 0.848 0.000 
Logical Memory  
 
(1, 805) = 0.32 0.075 0.004 (1, 674) = 2.48 0.116 0.004 (1, 565) = 0.41 0.523  0.001 
Verbal Paired Associates  
 
(1, 790) = 0.27 0.603 0.000 (1, 661) = 0.32 0.570 0.000 (1, 553) = 0.25 0.615  0.000 
Spatial Span 
 



































3/4 carriers only   
Step 2 
3/3 carriers only   















5, 763 = 0.31 0.908 0.002 (1, 188) = 0.00 0.985 0.000 (2, 427) = 0.88 0.417 0.004 
General factor: intelligence (g) 
 
5, 805 = 0.49 0.784 0.003 (1, 198) = 0.70 0.405 0.004 (2, 449) = 0.72 0.489 0.003 
Digit Span Backwards 
 
5, 815 = 0.10 0.992 0.001 (1, 200) = 0.07 0.788 0.000 (2, 458) = 0.53 0.591 0.002 
Matrix Reasoning 
 
5, 814 = 0.59 0.707 0.004 (1, 200) = 1.65 0.201 0.008 (2, 457) = 0.43 0.654 0.002 
Block Design 
 
5, 813 = 0.74 0.597 0.005 (1, 200) = 0.35 0.556 0.002 (2, 455) = 1.20 0.301 0.005 
Letter-Number Sequencing 
 
5, 814 = 1.07 0.378 0.007 (1, 200) = 4.48 0.035 0.022 (2, 457) = 1.28 0.278 0.006 
General factor: processing speed (gSpeed) 
 
5, 773 = 0.42 0.839 0.003 (1, 185) = 0.16 0.691 0.001 (2, 437) = 0.06 0.944 0.000 
Digit Symbol Coding 
 
5, 812 = 0.73 0.603 0.004 (1, 199) = 0.32 0.570 0.002 (2, 456) = 0.99 0.371 0.004 
Symbol Search 
 
5, 810 = 0.83 0.526 0.005 (1, 199) = 0.01 0.916 0.000 (2, 454) = 0.59 0.554 0.003 
Simple Reaction time (seconds) 
 
5, 806 = 0.45 0.816 0.003 (1, 198) = 0.28 0.596 0.001 (2, 452) = 0.97 0.382 0.004 
Four Choice Reaction Time (seconds) 
 
5, 810 = 0.38 0.860 0.002 (1, 198) = 0.95 0.332 0.005 (2, 456) = 0.25 0.783 0.001 
Inspection Time Total  
 
5, 787 = 1.79 0.113 0.011 (1, 189) = 1.57 0.211 0.008 (2, 445) = 0.36 0.700 0.002 
General factor: memory (gMemory)   
 
5, 796 = 1.27 0.276 0.008 (1, 195) = 0.16 0.691 0.001 (2, 446) = 0.43 0.650 0.002 
Logical Memory  
 
5, 813 = 1.50 0.189 0.009 (1, 199) = 0.09 0.767 0.000 (2, 457) = 0.53 0.587 0.002 
Verbal Paired Associates 
 
5, 798 = 0.68 0.640 0.004 (1, 196) = 0.02 0.899 0.000 (2, 447) = 1.01 0.365 0.004 
Spatial Span 
 




7.5.2. APOE, TOMM40 and cognitive ability - adjusted for childhood intelligence 
(Models 2 & 3) 
Significant deleterious effects of APOE ε4 allele presence (vs. absence) were found for nine 
out of a possible fifteen age 73 cognitive ageing variables (see Table 7.5). Specifically these 
were g, Matrix Reasoning, gspeed, Digit Symbol Coding, Symbol Search, Inspection Time 
Total, gmemory, Logical Memory total, and Spatial Span (all P < 0.05; ‘Step 1’; Table 7.5) Each 
significant association survived correction for cardiovascular disease history (P < 0.05; see 
Table 7.7). 
For the ε3/ε4 vs. ε3/ε3 comparison, significant deleterious effects of ε3/ε4 were found 
for: g, Matrix Reasoning, Block Design, Symbol Search, Inspection Time Total, gmemory, 
Logical Memory total and Spatial Span (all P < 0.05; see Table 7.5; i.e. similar to above 
except for Digit Symbol Coding and gspeed which were not significant here, and Block Design 
which was significant here). All associations survived correction for cardiovascular disease 
history (All P < 0.05; ‘Step 2’; see Table 7.7) except for Symbol Search (P > 0.05). 
For the ε2+ (vs. ε3/ε3) comparison, a significant protective effect of ε2 allele 
possession was found for Inspection Time Total (P < 0.05; Table 7.5). This survived 
correction for cardiovascular disease history (P < 0.05; ‘Step 3’; see Table 7.7). 
For TOMM40 523, two significant protective associations with S allele possession 
were found: in the whole sample for Spatial Span (‘Step 1’), and for Letter-Number 
Sequencing in the APOE ε3/ε4 genotype subgroup only (both P < 0.05; ‘Step 2’; see Table 
7.6). The significant association with Spatial Span scores did not remain significant when 
corrected for possession of the APOE ε4 allele (F [5, 730] = 1.62, P = 0.151, η
2
 = 0.011). The 
significant association with Letter-Number Sequencing attenuated to (marginal) non-




Table 7.7). Because of this, associations between TOMM40 and cognitive ageing were not 
examined further.  
 
7.5.3. Correction for multiple testing with False Discovery Rate 
When tests of main effect were corrected for multiple testing with the FDR, all significant 
associations attenuated to non-significance (all FDR-adjusted P values > 0.05). Further 


































4 allele presence (vs. absence)  3/4 ( vs. 3/3) APOE 2/3 & 2/2  (vs. 3/3) 












General factor: intelligence (g) 
 
(1, 746) = 8.04  0.005 0.011 (1, 622) = 7.32 0.007 0.012 (1, 519) = 0.08 0.773 0.000 
Digit Span Backwards 
 
(1, 755) = 0.53 0.468 0.001 (1, 631)  = 1.12 0.291 0.002 (1, 527) = 2.52 0.113 0.005 
Matrix Reasoning 
 
(1, 754) = 4.19 0.041 0.006 (1, 630) = 5.54 0.019 0.009 (1, 526) = 0.02 0.890 0.000 
Block Design 
 
(1, 753) = 3.70 0.055  0.005 (1, 629) = 4.68 0.031 0.007 (1, 525) = 1.91 0.168 0.004 
Letter-Number Sequencing 
 
(1, 754) = 0.70 0.403 0.001 (1, 630) = 0.43 0.513 0.001 (1, 526) = 0.66 0.418 0.001 
General factor: processing speed (gSpeed) 
 
(1, 716) = 5.80 0.016 0.008 (1, 597) = 2.44 0.119 0.004 (1, 506) = 2.06 0.152 0.004 
Digit Symbol Coding 
 
(1, 753) = 3.92 0.048 0.005 (1, 629) = 1.61 0.205 0.003 (1, 525) = 1.44 0.231 0.003 
Symbol Search 
 
(1, 750) = 6.04 0.014 0.008 (1, 626) = 3.86 0.050 0.006 (1, 523) = 0.04 0.849 0.000 
Simple Reaction time (seconds) 
 
(1, 747) = 0.04 0.845 0.000 (1, 624) = 0.22 0.638 0.000 (1, 521) = 3.69 0.055 0.007 
Four Choice Reaction Time (seconds) 
 
(1, 751) = 0.30 0.587 0.000 (1, 628) = 0.03 0.866 0.000 (1, 525) = 1.47 0.226 0.003 
Inspection Time Total  
 
(1, 729) = 11.10 0.001 0.015 (1, 608) = 6.34 0.012 0.010 (1, 514) = 5.96 0.015 0.011 
General factor: memory (gMemory)   
 
(1, 739) = 5.43 0.020 0.007 (1, 617) = 5.61 0.018 0.009 (1, 515) = 0.38 0.536 0.001 
Logical Memory  
 
(1, 753) = 6.23 0.013 0.008 (1, 629) = 5.10 0.024 0.008 (1, 526) = 1.20 0.274 0.002 
Verbal Paired Associates  
 
(1, 741 = 1.03 0.311 0.001 (1, 619) = 1.36 0.245 0.002 (1, 516) = 0.45 0.501 0.001 
Spatial Span 
 

































3/4 carriers only   
Step 2 
3/3 carriers only   












General factor: intelligence (g) 
 
5, 753 = 1.52 0.182 0.010 (1, 186) = 1.04 0.309 0.006 (2, 418) = 0.92 0.401 0.004 
Digit Span Backwards 
 
5, 762 = 0.08 0.995 0.001 (1, 187) = 0.07 0.786 0.000 (2, 426) = 0.74 0.476 0.003 
Matrix Reasoning 
 
5, 761 = 0.73 0.602 0.005 (1, 187) = 1.02 0.314 0.005 (2, 425) = 0.56 0.572 0.003 
Block Design 
 
5, 760 = 1.39 0.228 0.009 (1, 187) = 0.25 0.618 0.001 (2, 424) = 1.31 0.277 0.006 
Letter-Number Sequencing 
 
5, 761 = 1.19 0.312 0.008 (1, 187) = 4.51 0.035 0.024 (2, 425) = 1.39 0.250 0.007 
General factor: processing speed (gSpeed) 
 
5, 723 = 0.93 0.463 0.006 (1, 173) = 0.31 0.578 0.002 (2, 407) = 0.30 0.739 0.001 
Digit Symbol Coding 
 
5, 760 = 0.93 0.459 0.006 (1, 187) = 0.31 0.578 0.002 (2, 424) = 0.89 0.410 0.004 
Symbol Search 
 
5, 757 = 1.18 0.316 0.008 (1, 186) = 0.00 0.951 0.000 (2, 422) = 0.37 0.692 0.002 
Simple Reaction time (seconds) 
 
5, 754 = 0.55 0.741 0.004 (1, 185) = 0.42 0.518 0.002 (2, 421) = 1.25 0.287 0.006 
Four Choice Reaction Time (seconds) 
 
5, 758 = 0.35 0.880 0.002 (1, 186) = 0.84 0.462 0.004 (2, 424) = 0.44 0.646 0.002 
Inspection Time Total  
 
5, 736 = 2.13 0.060 0.014 (1, 177) = 2.26 0.135 0.013 (2, 414) = 0.20 0.820 0.001 
General factor: memory (gMemory)   
 
5, 746 = 2.11 0.063 0.014 (1, 183) = 0.17 0.685 0.001 (2, 416) = 0.79 0.457 0.004 
Logical Memory  
 
5, 760 = 2.13 0.060 0.014 (1, 186) = 0.27 0.601 0.001 (2, 425) = 2.33 0.099 0.011 
Verbal Paired Associates 
 
5, 748 = 0.95 0.449 0.006 (1, 184) = 0.02 0.891 0.000 (2, 417) = 1.09 0.337 0.005 
Spatial Span 
 




Table 7.7. Significant associations between APOE & TOMM40 and cognitive ageing 
in Tables 7.4 and 7.5 – adjusted for cardiovascular disease history (in addition to 
age, gender, and age 11 IQ) 
 
 




ɛ4+ vs. ɛ4- 
APOE ε genotype  
ɛ3/ɛ4 vs. ɛ3/ɛ3 
 
  ɛ2+ vs. ɛ3/ɛ3 
























General factor:  
intelligence (g) 
 
1, 741 = 8.47 0.004 0.011 1, 617 = 7.78 0.005 0.012 - 
Matrix Reasoning 
 
1, 749 = 4.41 0.036 0.006 1, 625 = 5.74 0.017 0.009 - 
Block Design 
 
- 1, 624 = 5.36 0.021 0.009 - 




1, 711 = 6.36 
 




1, 748 = 4.27 0.039 0.006 - - 
Symbol Search 
 




1, 724 = 11.36 0.001 0.015 1, 603 = 6.58 0.011 0.011 1, 509 = 4.93 0.027 0.010 
General factor:  
memory (gMemory)   
 
1, 745 = 5.36 0.021 0.007 1, 612 = 5.41 0.020 0.009 - 
Logical Memory  
 
1, 748 = 6.22 0.013 0.008 1, 624 = 5.02 0.025 0.008 - 
Spatial Span 
 
1, 746 = 6.03 0.014 0.008 1, 622 = 5.31 0.022 0.008 - 
 
  
 Whole sample 
TOMM40 ‘523’ genotype  
APOE ɛ3/ɛ4 subgroup 
 
APOE ɛ3/ɛ3 subgroup 






























Table 7.8. Inter-correlations between cognitive ageing and white matter tract 
variables that are each significantly associated with APOE ε genotype.  
 
 






General factor: intelligence (g) 
 
0.02 (0.347) 0.20 (<0.001) 
Matrix Reasoning 
 
-0.01 (0.411) 0.10 (0.008) 
Block Design 
 
0.06 (0.077) 0.16 (<0.001) 
General factor: processing speed (gSpeed) 
 
0.04 (0.196) 0.17 (<0.001) 
Digit Symbol Coding 
 
0.03 (0.276) 0.18 (<0.001) 
Symbol Search -0.03 (0.240) 0.11 (0.004) 
Inspection Time Total  0.07 (0.042) 0.14 (<0.001) 
General factor: memory (gMemory)   
 
0.01 (0.441) 0.08 (0.024) 
Logical Memory total 
 
0.02 (0.328) 0.05 (0.131) 
Spatial Span -0.02 (0.334) 0.09 (0.015) 
 
Note. Pearson semi-partial correlations controlling for age, gender and age 11 IQ. Figures 
reflect ‘r’ correlations. FA = fractional anisotropy. Significant correlations in bold reflect a 
significant correlation (P < 0.05) where both variables are also associated with APOE 




Mediation: inter-correlations between white matter tract integrity & cognitive ageing 
Analyses next examined the mediation of genetic-cognitive ageing associations, via white 
matter tract integrity metrics. First I examined inter-correlations between white matter tract 
variables which showed significant association with APOE genotype in Chapter 4, and 
cognitive ageing variables which were significantly associated with APOE here after 
correction for cardiovascular disease history (see Tables 7.7 & 7.8). No significant 
associations were found between TOMM40 and cognitive ageing, corrected for 
cardiovascular disease history or APOE genotype. As can be seen in Table 7.8, several semi-
partial correlations between white matter tract FA and cognitive ability were statistically 
significant, controlling for age, gender and age 11 IQ, where both variables were also 
associated with APOE genotype (detailed below).  
There were significant correlations between variables that were associated with 
APOE: for right ventral cingulum FA with Inspection Time Total (r = 0.07, P = 0.042), and 
for left inferior longitudinal fasiculus with g (r = 0.20, P < 0.001), Matrix Reasoning (r = 
0.10, P = 0.008), Block Design (r = 0.16, P < 0.001), gspeed (r = 0.17, P  <0.001), Digit 
Symbol Coding (r = 0.18, P < 0.001), Symbol Search (r = 0.11, P = 0.004), Inspection Time 
Total, r = 0.14, P <0.001), gmemory (r = 0.08, P = 0.024) and Spatial Span (r = 0.09, P = 
0.015). 
 
7.5.4. Mediation: APOE/TOMM40 → white matter tract integrity → cognitive ageing 
Brain imaging and cognitive variables that showed nominally significant associations with 
APOE genotypes, and that significantly inter-correlated, were examined further for 
mediation. Analyses tested exploratory mediation based on the above correlations, with the 




Bootstrapping statistics indicated that right ventral cingulum FA did not significantly 
mediate the association between APOE and Inspection Time Total scores (indirect effect = -
0.16, 95% C.I’s = -0.57 to 0.02).  
Bootstrapping statistics indicated that left inferior longitudinal fasciculus FA 
significantly mediated the association between APOE and g (indirect effect = -0.02, 95% 
C.I’s = -0.05 to -0.00) and Block Design (indirect effect = -0.25, 95% C.I’s = -0.63 to -0.06), 
gspeed (indirect effect = -0.03, 95% C.I’s = -0.07 to -0.01), Digit Symbol Coding (indirect 
effect = -0.30, 95% C.I’s = -0.79 to -0.05), Inspection Time Total (indirect effect = -0.30, 
95%, C.I’s = -0.76 to -0.06), but not Matrix Reasoning (indirect effect = -0.06, 95% C.I’s = -
0.20 to 0.17), Symbol Search (indirect effect = -0.08, 95% C.I’s = -0.30 to 0.21), gmemory 
(indirect effect = <-0.00, 95% C.I’s = -0.22 to 0.21) or Spatial Span (indirect effect = -0.04, 
95% C.I.’s = -0.12 to 0.01). Cases of statistically significant mediation are displayed in 























(n = 538) 
 
APOE  
ε4 ‘risk’ allele 
Digit Symbol 
Coding 
(n = 543) 
 
gspeed 
(n = 522) 
Block Design 
(n = 542) 
β = ~0.12
a 
, P < 0.01 
Note: All associations are standardized β values; 
a
Specific 
association betas varied here because each mediation test used 
listwise exclusion criteria and therefore had very slightly 
different sample N’s. *P < 0.05; **P <0.01; ***P < 0.001. 
Figures in (brackets) represent associations after adjustment 

























The current study investigated the effects of the APOE ε and TOMM40 rs10524523 (‘523)’ 
poly-T repeat gene loci, on cognitive ability around the age of 73 years, both unadjusted and 
adjusted for age 11 IQ (‘cognitive ageing’; Deary et al., 2004). Analyses also formally tested 
whether significant raw nominal associations were mediated by previously reported 
associations with white matter tract microstructural integrity in this sample (see Chapter 4; 
‘…White matter integrity’).  
In terms of cognitive ageing, this report found significant deleterious effects of APOE 
ε4 allele possession on several cognitive tasks, independent of age, gender, childhood IQ and 
cardiovascular disease history; namely, tests of non-verbal reasoning (Matrix Reasoning), 
visuospatial ability (Block Design, Spatial Span), processing speed (Digit Symbol Coding, 
Symbol Search, Inspection Time Total), and memory (Logical Memory total). Accordingly 
this study also found significant nominal effects on general factors of intelligence, processing 
speed and memory, constructed with PCA. This study also reports significant protective 
effects of the TOMM40 523 ‘Short’ allele on Spatial Span scores in the whole sample, but 
this did not survive statistical correction for APOE ε genotype, and Letter-Number 
Sequencing in the APOE ε3/ε4 genotype group, but this did not survive correction for 
cardiovascular disease history. Formal tests of mediation (with bootstrapping; Preacher and 
Hayes, 2008) showed that the left inferior longitudinal fasciculus significantly mediated 
associations between APOE ε4 and g, Digit Symbol Coding, gspeed, Inspection Time Total and 
Block Design scores. This tract did not completely mediate these significant associations; the 
gene-cognitive associations did not attenuate markedly.  
All associations with cognitive ability attenuated when corrected for type 1 error with 




intelligence, memory and processing speed that were constructed with PCA. Although FDR 
is less affected by inter-correlated test statistics compared with other type 1 error adjustment 
procedures (such as Bonferroni; Benjamini and Yekutieli, 2001), this can still make 
correction for multiple testing overly conservative (Williams and Haines, 2011). All 
significant raw gene-cognitive associations are interpreted cautiously in this context. These 
inter-correlations also highlight that the genetic associations with cognitive variables are not 
independent and may partly reflect a degree of shared variance between these tasks (as 
indicated by g).  
 
7.6.2. Interpretation: APOE ε genotype 
A large number of previous studies have examined APOE and cognitive ageing, synthesised 
into a large meta-analysis by Wisdom et al. (2011). On the basis of a large number of studies 
into APOE and non-impaired adult cognitive functioning, they found the strongest effects of 
ε4 allele presence on episodic memory (e.g. WMS-III scores), information processing speed 
(e.g. Digit Symbol Coding), executive function (e.g. Trail-Making Test-B) and global 
cognitive ability (e.g. full-scale IQ). The domains of crystallised intelligence (e.g. Boston 
Naming Test), attention (e.g. Trail-Making Test-A), visuospatial (e.g. Block Design) and 
working memory (e.g. Digit Span) did not show significant effects, based on several samples 
(range = 13 to 56 independent samples). Our results in the current sample (aged around 73 
years) align almost perfectly with this.  
Luciano et al (2009a; 2009b; as described above) reported relatively specific, 
circumscribed effects of APOE genotype on cognitive ability - adjusted for age 11 
intelligence – in the LBC1936 sample at age 70 years. In comparison, the current study 
reports much more broad deleterious significant (raw unadjusted) effects of the ε4 allele on 




could reflect either 1) greater type 1 error in the slightly smaller age 73 sample, or 2) that 
APOE has a stronger influence on cognitive ability at older ages; these explanations are 
explored below in order. 
 It is possible that the sample reported here; around 860 participants with a mean age 
around 73, is meaningfully different – other than being older - from the sample reported on 
by Luciano et al. (2009a; 2009b), where roughly 1000 participants were around 70 years old. 
However both studies had very similar exclusion criteria, e.g. MMSE cut-offs below 24 
(indicative of dementia), removal of outliers around 3 standard deviations from the mean. 
However Chapter 3 (‘ADRB2….’; published as Lyall et al., 2013) showed that the LBC1936 
participants who attended both wave one (70 years) and wave two (73 years) had 
significantly higher age 11 MHT scores compared with participants that attended wave one 
only (mean scores = 50.16 vs. 47.62, t = -2.89, P = 0.004). This indicates a degree of 
selection bias, in the sense that the more cognitively impaired individuals did not return for 
testing at age 73; however, in that case one would expect a restriction of range in cognitive 
scores, which would typically result in a lower likelihood of spurious results. For these 
reasons, spurious results here (vs. Luciano et al. 2009a; 2009b) are unlikely.  
 The different findings by Luciano et al. (2009a; 2009b) and the current study may 
reflect that APOE affects age-related processes that impact on cognitive ability more into 
older age. These processes could include the maintenance and repair of myelin, neuronal 
membrane and synaptic connections, among others (Reivang et al., 2013). As an example, 
Schiepers et al. (2012) found that APOE associated with significant cognitive change across 
later life in the Lothian Birth Cohort 1921, (LBC1921), a sample of community-dwelling 
older adults. They examined 187 participants assessed at ages 79, 83 and 87 on Verbal 
Fluency, Logical Memory and Raven’s Progressive Matrices (a reasoning test). They found 




ε4 allele was associated with worse Logical Memory (parameter estimate = -0.50, 95% C.I’s 
= -0.93 to -0.07) and Raven’s Progressive Matrices scores (parameter estimate = -0.27, 95% 
C.I’s = -0.52 to -0.02), adjusted for age 11 IQ and cardiovascular disease history. The age-
related effects of APOE may be through influencing risk of cardiovascular disease (which can 
contribute to cerebrovascular pathology), amyloid beta clearance and neuronal/myelin 
survival (Smith, 2002; Morris et al., 2010). The first explanation is unlikely to explain the 
results here because the majority of significant associations survived correction for 
cardiovascular disease history (although self-reported history – as used here - may not be 
accurate). It is not possible to distinguish or elucidate the influence of other explanations 
without further relevant data (this is explored below in ‘future research’).   
 The current study is relatively novel in demonstrating that significant associations 
between APOE and cognitive ageing are formally mediated by white matter tract integrity, 
possibly reflecting the fact that relatively few studies have the requisite genetic, imaging and 
cognitive data (Salthouse, 2010). This is important because it helps to elucidate the neural 
substrates underpinning the association between APOE and cognitive ageing. Previous 
chapters have shown that APOE is not significantly associated with hippocampal volume, 
white matter lesions or cerebral microbleeds in LBC1936. This report found that the 
associations between APOE and g, Digit Symbol Coding, gspeed, Inspection Time Total and 
Block Design did not attenuate (to non-significance; P > 0.05) when variation in left inferior 
longitudinal fasciculus FA was controlled for, with Boostrapping.   
It is plausible that the left inferior longitudinal fasciculus at least partly mediates 
specific APOE-cognitive ageing associations. The inferior longitudinal fasciculus is an 
occipito-temporal tract (Catani and de Schatten, 2008). Our findings fit in well with a large, 
relatively similar study by Ryan et al. (2011), who examined whether correlations between 




126; mean age ranges = 71.6, 69.2 and 67.0 for non-carriers, ε4 carriers and ε4/ε4 
homozygotes). They constructed general ‘executive’ and ‘memory’ composites based on a 
range of standard WAIS-III and WMS-III tests, plus the California Verbal Learning and the 
Wisconsin Card Sorting tests. They found significant differences in correlation strengths for 
APOE ε4+ and ε4- groups, between frontal lobe FA with executive scores (r = 0.46 vs. 0.04) 
and memory scores (r = 0.43 vs. 0.14), and for temporal stem FA with executive scores (r = 
0.50 vs. 0.04) and memory scores (r = 0.57 vs. 0.14; all P < 0.05). Westlye et al. (2012a) 
posited that the stronger correlations between white matter integrity and cognitive ability in 
APOE ε4 carriers may reflect a “computational bottleneck” whereby lowered integrity limits 
the amount of information that can be transmitted between brain structures, strengthening the 
FA-cognitive correlation (Westlye et al., 2012a; pp. 514). This provides a reasonable 
biological explanation for the mediating role of the inferior longitudinal fasciculus and 
performance on specific cognitive tasks. It is also possible that the integrity of this tract 
correlates significantly with the actual mechanistic brain imaging phenotype, which was not 
examined here (Salthouse, 2010). Our findings suggest that a large scale, hypothesis-free 
examination of APOE and cognitive ageing – with a range of brain imaging phenotypes – is 
required.  
 
7.6.3. Interpretation: TOMM40 ‘523’ poly-T repeat genotype 
The author is aware of three previous independent studies of TOMM40 523 genotype and 
cognitive ability, by Caselli et al. (2012), Johnson et al. (2011), and Hayden et al. (2012). 
Caselli et al. examined 639 non-demented older adults that had been recruited between ages 
21 and 97 years (mean ages of genotype groups ranged from 57.8 to 60.9 years), and 
undergone repeat testing at least once since (mean duration of follow-up  = 6.1 years ± 3.1). 




genotype subgroup on Auditory Verbal Learning Test delayed scores. They reported a 
significant deleterious effect of the VL/VL group in comparison with S/S, whereby the 
former did not show a test-retest improvement over follow-up (P = 0.04; in APOE ε3/ε3 
subgroup). They did not find an additive VL allele effect, however. Johnson et al. (2011) 
examined 117 older adults with the ε3/ε3 genotype, controlling for age, gender, family 
history of AD and hypertension. They compared participants on AVLT scores. They reported 
a significant deleterious effect of the VL/VL genotype compared with S/S on total correct 
scores (means scores = 55.13 vs. 49.63, P = <0.05). Johnson et al. however reported no 
effects of TOMM40 523 genotype on verbal or performance IQ scores on the WAIS-III. 
Hayden et al. (2012) examined 82 older adults with the APOE ε3/ε3 genotype (mean age = 
80.6, SD = 6.0) in terms of TOMM40 523 genotype and a broad battery of memory and 
intelligence tests. Controlling for age, gender and education, they found a significant 
deleterious effect of the S/VL genotype (vs. S/S and VL/VL genotypes) on Paired Associates 
Learning and Verbal Recall memory scores, Rapid Visual Information Processing latencies, 
and Digit Span scores (P value range = 0.016 to 0.48). They had no metric of prior cognitive 
ability, however.  
 The above findings contrast with the current study in that here the present results 
showed no significant effects of TOMM40 523 genotype, independent of APOE or 
cardiovascular disease history. This suggests that previous studies may to an extent report 
type 1 errors; note the relatively marginal significance reported by Caselli et al. (2012), and 





7.6.4. Future research and limitations 
Future studies may investigate the effects of APOE and TOMM40 genotypes on longitudinal 
cognitive change in this sample. The current study examined cognitive ability at around age 
73. Participants also have similar data at age 70 (Luciano et al. 2009a/2009b reported 
generally modest cross-sectional effects of APOE genotype on cognitive data) and are 
currently undergoing repeat testing (around age 76). Tests of association with APOE or 
TOMM40 genotypes may be more sensitive to later-life cognitive change compared with 
cross-sectional abilities. Schiepers et al. (2012; described above) for example showed 
significant cognitive change in the LBC1921 longitudinally across older age (79-to-83-to-87 
years).  
This study reported generally modest mediation of significant APOE-cognitive ageing 
associations via white matter tract integrity. In this regard, future studies may investigate the 
role of other brain imaging phenotypes that were not examined in this thesis. Interesting 
phenotypes could include subcortical brain structures such as the amygdala, or 
dorsolateral/orbitofrontal cortical volumes for example (Pievani et al., 2009).  
This chapter took a ‘causal-step’ approach of examining associations between 
APOE/TOMM40 with brain imaging and cognitive ageing phenotypes (Hayes, 2009). This 
dictates that: 
1. The total effects of APOE/TOMM40 on brain imaging and cognitive variables must each 
be statistically significant (P < 0.05).  
2. The association between imaging and cognitive variables must remain statistically 
significant controlling for APOE/TOMM40. 
3. Having corrected for variation in the mediating imaging variables, the association 




mediated’ model; i.e. P > 0.05) or attenuate in strength, but not necessarily to non-
significance (‘partial’ mediated model; still P < 0.05; MacKinnon et al., 2002). 
This report examined variables that were statistically significantly inter-correlated at P < 
0.05, and where mediation would therefore be most likely. A limitation of this ‘causal steps’ 
approach is that each hypothesis test carries a possibility of type 1 or type 2 error. Rather, 
Hayes (2009) suggests hypothesis-driven testing of indirect effects, regardless of the 
statistical significance of the mediator’s association with the independent and dependent 
variables; it is possible that significant APOE-cognitive ageing associations occur via very 
small effects on a large, distributed range of brain imaging phenotypes. Future studies should 
consider a large-scale, hypothesis free examination of APOE genotype, different brain 
imaging phenotypes and cognitive ageing variables.  
 
7.6.5. Summary 
The current study investigated the independent effects of the APOE ε and TOMM40 523 
poly-T repeat gene loci on cognitive ageing, and the extent to which nominally significant 
gene-cognitive associations were mediated by previously reported genetic associations with 
white matter tract integrity in the LBC1936 (around the age of 73 years).  
APOE ε - but not TOMM40 523 - genotype was significantly associated with 
performance on several different measures of cognitive ability, including general factors of 
intelligence, information processing speed and memory, and more specifically Block Design, 
Digit Symbol Coding, Symbol Search, Inspection Time Total, Spatial Span and Logical 
Memory total scores (raw P values all < 0.05). These significant associations were 
independent of age 11 IQ and cardiovascular disease history.  
Formal tests of mediation showed that several APOE-cognitive ageing associations 




the associations themselves did not attenuate markedly when FA of this tract was statistically 
controlled for. A range of brain structural imaging phenotypes - including matter 
microstructural integrity - may form the anatomical basis for significant associations between 























8.1. Review of background and findings 
The APOE ε locus has previously been statistically significantly associated with increased 
risk of Alzheimer’s disease (AD), and this association has been replicated in a number of 
independent samples (e.g. Corder et al., 1994; Farrer et al., 1997; Genin et al., 2011). 
However the association between APOE ε4 allele presence and AD is not completely 
penetrant; it accounts for around 4-5% of the variation contributing to liability for AD. This 
suggests it may be modified by other variables, including other genetic loci (Lee et al 2013). 
More recently, variation in the TOMM40 ‘523’ poly-T repeat locus has been reported to 
significantly influence age of AD onset independently of APOE genotype, although the 
statistical significance and directions of these associations have varied (Roses et al., 2010; 
Crenshaw et al., 2013). 
Using the Lothian Birth Cohort 1936 (aged around 73 years; LBC1936), the analyses 
in this PhD thesis had three main aims. The first two aims were to quantify the independent 
effects of the APOE ε status and TOMM40 523 loci on specific structural brain magnetic 
resonance imaging (MRI) phenotypes; namely white matter microstructural integrity, 
hippocampal volumes, white matter lesions, and cerebral microbleeds. The subsequent third 
aim was to formally investigate the anatomical substrates of genetic associations with 
cognitive ageing. 
There were several previous studies of APOE ε and brain structural/cognitive 
phenotypes in community-dwelling, generally healthy older adults, but few-to-none for 
TOMM40 523.  Specifically, studies reported deleterious effects of the APOE ε4 allele; 
however, directions varied for TOMM40 523 in terms of showing either deleterious or 
protective effects of the ‘Short’ allele (vs. Long and Very-long alleles). Reflecting that, this 




ε4 allele (vs. ε3/ε3 or ε4-absent groups), but with no specific direction for TOMM40 523 
genotype.  
In the context of a relatively large number of tests of association (and hence increased 
risk of type 1 error), results showed that possession of APOE ε4 or TOMM40 523 Short allele 
variants (vs. absence) were independently significantly associated with the microstructural 
integrity of specific white matter tracts, but not white matter lesions, hippocampal volume or 
cerebral microbleeds. These significant associations were 1) statistically independent in the 
sense that effects of TOMM40 523 survived correction for APOE ε4 presence, and 2) 
biologically independent in the sense that the TOMM40 523 effect was statistically significant 
in a subgroup of participants with the APOE ε3/ε4 genotype (i.e. cannot be attributed to 
variation in APOE genotype; Roses et al., 2010).  APOE ε4 - but generally not TOMM40 523 
- was significantly associated with worse cognitive ageing, and these associations were 
partially mediated by the integrity of specific white matter tracts. The reported significant 
associations with white matter integrity and cognitive ageing survived correction for 
cardiovascular disease history. This indicates that it is less likely that effects of 
APOE/TOMM40 on age 73 brain variables are secondary to associations with cerebrovascular 
pathologies such as stroke.  
The majority of associations were non-significant when corrected for multiple testing 
with the False Discovery Rate (FDR; Pike, 2011). Type 1 error correction could be 
considered overly conservative when testing significantly inter-correlated brain 
imaging/cognitive phenotypes because each test is not independent (Nyholt, 2001). FDR is 
less affected by inter-correlated test statistics compared with other adjustment procedures 
(Benjamini and Yekutieli, 2001). All significant raw associations are interpreted cautiously in 





8.2. Relation to predictions  
The study presented in Chapter 4 found significant deleterious independent effects of APOE 
ε4 and TOMM40 523 on specific white matter tract integrity variables, and a significant 
deleterious effect of APOE ε4 on a large proportion of cognitive ageing variables. (‘Cognitive 
ageing’ reflects test scores at age 73 adjusted for age 11 IQ; Deary et al., 2004). Those 
findings aside, generally the a priori predictions were not met: other than Chapter 4 there was 
no effect of APOE ε on the majority of imaging phenotypes, or TOMM40 523 on 
imaging/cognitive phenotypes. Analyses therefore generally failed to support previous claims 
drawn from smaller studies. 
 
8.3. Integration with previous reports 
Specific common gene loci typically account for only small amounts of variation in complex 
brain-related phenotypes (e.g. cognitive abilities). Single candidate loci often fail to replicate 
across studies for different reasons including insufficient power, study design/analytic 
strategy and low prior probability of true biological association (Hattersley and McCarthy, 
2005).  
Previous studies have investigated APOE and the imaging phenotypes described, and 
in some instances describe statistically significant associations where in the present analyses 
they were null (Chapters 5-7) or more specific and restricted effects than previously reported 
(Chapter 4; Gold et al., 2012). In several cases previous reports had observable limitations, 
and there are general and study-specific reasons why these reports may have shown spurious 
results: 
1. Chapters 4-7 observed that previous studies of APOE/TOMM40 do not always control for 




several reports examine samples with wide age ranges. First, this is important because 
APOE in particular has been significantly associated with greater risk of cardiovascular 
and more specifically cerebrovascular diseases, which could directly contribute to brain 
changes (Ward et al., 2009). In this LBC1936 sample, there were no significant genotype-
phenotype associations which attenuated to non-significance when corrected for 
cardiovascular disease history; however this may not be the case in independent samples. 
Second, this is important because while studies typically statistically adjust for the effects 
of age, the correlation between age and brain phenotypes is unlikely to be completely 
unique and rather may be via several processes associated with chronological age; it is 
therefore unlikely that statistically controlling for age would completely capture this  
(Hofer and Sliwinski, 2001). These factors could result in spurious results because several 
brain imaging/cognitive phenotypes show change with age and in the presence of 
cardiovascular/cerebrovascular diseases; effects of APOE or TOMM40 523 could occur 
via these variables if not adequately controlled (Wardlaw et al., 2011). 
2. The majority of studies were also relatively small (i.e. N < 150, typically) and therefore 
less likely to be reliable because they are less representative of the general population 
(Wacholder et al., 2004). This is particularly applicable to previous studies of APOE and 
white matter microstructural integrity (Chapter 4), where only Westlye et al. (2012b) 
reported on a sample N over 150. A practical example is in Chapter 3 (Lyall et al., 2013; 
‘ADRB2…’). In 162 members of the LBC1936 that had by that time undergone diffusion 
tensor-MRI (simply ‘DTI’), Penke et al. (2010b) reported a significant effect of the 
rs1042714 SNP in the ADRB2 gene (β = 0.16, P = 0.043). When examined again in the 
larger, full LBC sample (Chapter 3), the association had attenuated to non-significance (β 




3. In the case of APOE and hippocampal volume (Chapter 5), two large previous studies that 
reported significant associations (Den Heijer et al., 2002; Lemaitre et al., 2005) did not 
statistically adjusted for general brain volumetric atrophy. This is important because 
MacLullich et al. (2002) described significant inter-correlations between subcortical brain 
structural and general brain tissue volumes; this means it is possible that previous 
significant associations were between APOE and general brain atrophy rather than 
hippocampal volume specifically. Furthermore, Den Heijer et al. (2002) examined 
hippocampal volume as a ratio proportion of intracranial volume (maximal head size). 
This approach is limited because any significant effect of APOE on hippocampal volume 
could reflect an effect on intracranial volume only, because this would also affect the 
‘ratio’ score. Indeed, further analysis in Chapter 5 showed that 1) APOE genotype 
significantly associated with the ‘ratio’ variable, but with not hippocampal volume 
statistically adjusted for intracranial volume as a model covariate, and 2) the 




4. In the case of APOE and cerebral microbleeds (Chapter 6), previous large (significant, 
positive) studies have not differentiated between ‘certain’ and ‘uncertain’ microbleeds as 
was done here. These studies may be including brain microbleed mimics which do not 
necessarily reflect deleterious processes, such as cortical vessels or flow voids 
(Cordonnier et al., 2011). 
In the case of APOE and white matter lesions (Chapter 6), the null association corresponds 
well with a large meta-analysis (Paternoster et al., 2009) suggesting a truly null association, 
when large amounts of data are collated. 
There have been previous studies of TOMM40 523 genotype, cognitive ability, and 




(Johnson et al., 2011; Hayden et al., 2012), or very marginal statistical significance, 
uncorrected for multiple testing (Caselli et al., 2012). The findings in the LBC1936 regarding 
TOMM40 523 are therefore not contradicting a considerable literature.  
 
8.4. Contribution to the literature 
8.4.1. Anatomical basis of APOE-cognitive ageing associations 
In Chapter 7, it was reported that integrity of a specific white matter tract – the left inferior 
longitudinal fasciculus – significantly mediated part of the association between APOE and 
specific cognitive abilities, particularly related to information processing speed (e.g. Digit 
Symbol Coding and Inspection Time Total tasks). Few studies have investigated the 
anatomical substrates of genetic contributions to cognitive ageing with mediation (as detailed 
below). Specifically, this thesis contributes to understanding of the anatomical basis of 
APOE-cognitive ageing associations.  
 Large samples of healthy adults with genetic, brain imaging and cognitive data are 
rare, and as such there are few studies that examine mediation or structure-ability correlations 
(e.g. Honea et al. 2009; Salthouse, 2010). To the author’s knowledge, the largest previous 
study was conducted by Espeseth et al. (2006), who examined 230 older adults with an age 
range of 53 to 75 years. Participants completed the Wechsler Abbreviated Scale of 
Intelligence, California Verbal Learning Test, a cued visual discrimination test of reaction 
time, and underwent detailed brain MRI. Carriers of APOE ε4 showed significantly slower 
average reaction times (F [1, 222] = 6.32, P = 0.013), and lower white matter volume 
although this did not attain statistical significance (F [1, 93] = 2.71, P = 0.100; vs. non-
carriers). They tested the extent to which white matter volume mediated the APOE-cognitive 




effect of white matter volume (F [1, 92] = 4.05, P < 0.05), but not APOE genotype. This 
attenuation indicates that the association between APOE and reaction time was partly 
dependent and at least in part mediated by white matter – although Espeseth et al. did not 
formally test this. The current sample adds significant data to this – in terms of participant 
sample size and range of cognitive/brain imaging phenotypes examined. 
White matter tracts form the basis for connected brain networks, providing a direct 
plausible foundation for cognitive functioning (Penke et al., 2012). Lower tract integrity may 
result in a processing ‘bottleneck’ that hinders efficient information processing (Westlye et 
al., 2012a). The inferior longitudinal fasciculus is an occipito-temporal tract (Catani and 
Thiebaut de Schotten, 2008). The inferior longitudinal fasciculus tract may mediate the 
transfer of visual signals from visual areas to anterior temporal regions (Catani et al., 2003), 
although understanding of its relevance to specific cognitive abilities - independent from 
other white matter tracts - is limited (Ashtari, 2012).  
A study by Penke et al. in a subset of the LBC1936 sample (2010a) showed that a 
general factor of white matter integrity (constructed with principal components analysis; 
‘gFA’) was significantly associated with a general factor of information processing speed 
(gspeed; r = -0.24, P = 0.007; n = 132), and explained 10% of the variance in general cognitive 
ability (‘g’; n = 420, Penke et al., 2012). Penke et al. (2012) noted that no single tract showed 
significant associations with general cognitive ability beyond what was explained by the 
general factor gFA, reflecting that a large proportion of variance in white matter integrity is 
shared, emphasising that tracts probably function together, and warning against placing too 
much emphasis on associations found with only one or a few tracts.  
As discussed in Chapter 4, it is unclear why APOE genotype would be significantly 
associated with the left inferior longitudinal fasciculus in particular, over and beyond other 




ability however this is not necessarily at the tract-specific level. The reported mediation may 
be either mechanistic in some way, or reflect a secondary correlation with a brain marker that 
is linked to this tract. It is possible that the effects of APOE on cognitive ageing are very 
subtle and mediated via a large range of brain imaging phenotypes. It should also be noted 
that – taking the thesis as a whole - Chapter 7 reflects the end point of a large number of tests 
of association (including APOE/TOMM40 and imaging/cognitive phenotypes, and their inter-
correlations), each of which will have a natural possibility of type 1 or type 2 error (Hayes, 
2009). Chapter 7 tested for mediation only in cases of significant nominal three-way 
associations between genetic/imaging/cognitive variables at P < 0.05, where mediation would 
be most likely. A hypothesis free approach to investigating the anatomical substrates of 
APOE’s contributions to cognitive ageing - where simply the indirect ‘effects’ (reflecting the 
extent of statistical mediation) are examined regardless of the strength or significance of 
genotypic/phenotypic associations – may be fruitful (Hayes, 2009). Overall it is likely that a 
range of brain imaging variables – including white matter microstructural integrity - partly 
mediate associations between APOE and cognitive ageing. 
 
8.4.2. A large amount of homogenous data that addresses several previous 
methodical issues 
A number of previous reports have examined APOE and structural brain imaging phenotypes 
with MRI, and the majority of these studies are in relatively small samples (i.e. N < 150; 
Gold et al., 2012). The smaller studies are less likely to be reliable (Flint and Munafo, 2012). 
Chapters 4-7 therefore provide a relatively large amount of new data in community-dwelling 
older adults. There is reason to believe the data here are of generally high quality relative to 
previous reports in terms of testing a relatively large imaging/cognition/genetics sample with 




of childhood intelligence, as detailed in each chapter and above in ‘Integration with…’. Also 
detailed above (in ‘Integration with…’) are several study-specific limitations to some larger 
previous reports, which have been addressed here. Thus, the high-quality data presented here 
contribute significantly to the literature in terms of addressing previous methodological 
issues.  
Chapter 4 examined white matter tract integrity using a different methodology to that 
used previously. Previous studies of APOE and white matter integrity used Tract-based 
spatial statistics (TBSS). Chapter 4 in contrast used probabilistic neighbourhood 
tractography, an approach for automatic and reproducible tract segmentation, as implemented 
in the TractoR package for fibre tracking analysis (Clayden et al., 2011;
 
Tractography with R 
website, 2012). This method segments the same fasciculus-of-interest in different individuals 
by identifying the best-matched tract from a group of ‘candidate’ tracts that most closely 
resembles a predefined reference tract in terms of both length and shape. This approach has 
advantages over tract-based spatial statistics in that each tract is segmented in native rather 
than standard space, therefore providing a better representation of specific tract anatomy in 
each individual (Bastin et al., 2013) preserving the individual variance of interest. The tracts 
are also visually inspected and corrected/rejected where processing has failed. It is also 
optimised for older subject’s brains which commonly show pathological changes. This 
contributes to the APOE/white matter microstructure literature by adding a large amount of 
high quality data, with an imaging analysis methodology with several possible advantages 





8.4.3. TOMM40 poly-T repeat genotype is independently associated with white 
matter tract integrity but not cognitive ageing, hippocampal volume, white matter 
lesions or cerebral microbleeds 
The APOE locus has a well replicated association with AD, and it is important to understand 
modifiers of that risk which may extend to non-pathological cognitive ageing – in this case 
TOMM40 523 poly T repeat length genotype. Previous studies have varied in terms of 
showing a statistically significant - or null - association between TOMM40 523 and AD 
disease risk, or age of onset (Roses et al., 2013; Jun et al., 2012). The exact direction of 
association has varied in terms of the Short allele showing a deleterious (e.g. Cruchaga et al., 
2011) or protective effect (e.g. Roses et al., 2010).  
In a relatively large imaging genetics sample, we found deleterious effects of the 
TOMM40 523 Short allele on white matter tract microstructural integrity independent of 
APOE genotype; but ultimately not hippocampal volume, white matter lesions, microbleed or 
(generally) cognitive ageing phenotypes. This may reflect two points:  
1) There may be a degree of brain plasticity which enables carriers of the TOMM40 
523 Short allele to have significantly worse white matter integrity (as reported in Chapter 4), 
but preserved cognitive ability (…Chapter 7). As an illustrative example, Bendlin et al. 
(2008) examined 36 adults (mean age = 28.37, SD = 9.78) that had traumatic brain injuries 
(TBI; confirmed with computerised topography on the same day), and compared them with 
19 age-and gender-matched controls. Participants underwent detailed cognitive and brain 
imaging assessments around 2 months after injury, and around 1 year later. Controlling for 
age, gender and intracranial volumes where applicable, they found that the TBI group had 
significantly lower fractional anisotropy (FA) and higher mean diffusivity (MD) reflecting 
worse integrity in several white matter tracts (exact statistics not shown), and lower cognitive 




Learning test and Digit Symbol Coding). At follow-up assessment, they found that the TBI 
group showed significantly greater declines in FA/increases in MD in several tracts (possibly 
reflecting Wallerian degeneration after the initial TBI insult; Bendlin et al., 2008). However 
several regions showed significant decreases in MD (reflecting improved integrity); namely 
the internal capsule, superior/inferior longitudinal fasciculi, corona radiate, and the anterior 
thalamic radiation. Similarly, performance on several cognitive tasks improved over the two 
time points on most tasks (e.g. Digit Symbol Coding standardized mean score = 7.7, SD = 
2.9, vs. 44.4, SD = 12.9, P <0.05). This could indicate a degree of plasticity in how brain 
architecture subserves cognitive ability, meaning that the integrity of specific white matter 
tracts may not have an absolutely direct association with non-pathological cognitive ageing 
(Bendlin et al., 2008). 
2) White matter microstructure assessed with DTI may be more sensitive to genetic 
variables than other imaging or cognitive phenotypes examined in this thesis. For example, in 
the above report by Bendlin et al., at Timepoint  2 (around 1 year after TBI) white matter 
volume assessed with T1-weighted images was far less sensitive to showing significant 
differences between TBI/control groups, compared with FA/MD as assessed by DTI (which 
was more sensitive). Specifically, significant differences (P < 0.05) were found in 1.79% of 
FA voxels and 3.91% of MD voxels, compared with 0.04% of total T1 white matter voxels. 
DTI white matter metrics may be a more sensitive phenotype to insult (or ‘risk’ genotypic 
variants) compared with gross white matter loss or structural volumetric atrophy (Paorpaoli et 
al., 2001).  
The findings in this thesis progress understanding of TOMM40 523 and 
cognitive/brain imaging phenotypes by demonstrating significant associations specifically 
with white matter integrity, but not other structural brain or cognitive ageing phenotypes. 




underlying association between TOMM40 523 and AD, in healthy older brains with no 
evidence of the disease. Future studies in independent samples will help to elucidate – and 
replicate – similar effects of TOMM40 523, independent from APOE.  
 
8.5. Implications  
8.5.1. Future candidate gene studies should be carefully controlled; standardised 
criteria may be required 
Imaging genetics is based on the premise that genetic variation will contribute more directly 
to phenotypic variation at the biological and brain structural/functional level, compared with 
at the level of complex behavioural traits such as cognitive ability (Flint and Munafo, 2012). 
It is unlikely that single common genetic variants account for more than small amounts of 
variance in cognitive ability (see Davies et al., 2011; Munafo et al., 2006). Studies of specific 
genetic variants often do not replicate consistently (Munafo et al., 2006) and it would be 
beneficial to limit inter-study heterogeneity. An important implication of Chapters 4-7 is that 
imaging genetic research may benefit from more specific universal guidelines in terms of 
methodology and analysis.  
Journals are increasingly setting guidelines for candidate gene studies. For example 
Hewitt (2012) describes guidelines for the journal Behavior Genetics: the study must be 
adequately powered; any novel findings must meet the equivalent of genome-wide 
significance taking into account multiple testing and valid covariates. Further broad 
recommendations are described by Little et al. (‘STREGA’ criteria; 2009); studies should 
define laboratory methods; how any biases were addressed; software; Hardy-Weinberg 
statistics; multiple testing correction; numbers of individuals that failed genotyping; relevant 




(2011) provide a detailed checklist for considering the quality of imaging genetics papers, 
including consideration of; study size; imaging variables clearly defined (e.g. microbleed 
presence vs. absence); number of independent imaging raters; inter/intra-observer 
agreement?; blinding of imaging/genetics staff to participant information. Maxwell et al. 
rated ten studies of candidate genes and microbleeds, out of a maximum possible score of ten. 
The average score was 4.8, with a range of one to nine. Maxwell et al. note that in many 
cases studies simply did not report these. This implies significant inter-study heterogeneity 
that could be addressed a priori and that certain details should be stated as standard across 
studies. This is important because single common gene variants account for only small 
amounts of variance and therefore may be sensitive to differences in data collection/analysis 
(Hattersley & McCarthy, 2005). Relatively standardised reporting would make it easier to 
synthesise the state of the literature (Maxwell et al., 2011; Wardlaw et al., in press).  
 
8.5.2. Should TOMM40 poly-T repeat genotype be considered as standard in studies 
of APOE ε?  
The significance of the TOMM40 523 poly-T repeat is an area of on-going epidemiological 
and biological research. Roses et al. (2010) noted that while the APOE ε4 allele is in very 
strong linkage with the TOMM40 523 Long allele (specifically around 98%), with ε3 linked 
to either Short or Very-long. Beyond the obvious question of what effect each allele has on 
brain-related phenotypes such as cognitive ageing or brain structure, TOMM40 523 genotype 
may add additional noise to studies of APOE ε. Specifically, the TOMM40 523 Short allele 
(vs. Very-long) may modify the effect of APOE ε3 for some phenotypes (e.g. Chapter 4, 
‘…white matter integrity’) and this may partly account for any inconsistencies in reports of 




relative to APOE ε2 or ε3 alleles - are not clear. Future reports should consider controlling for 
this – perhaps by ensuring frequencies are relatively similar across studies. 
 
8.5.3. The effect of APOE ε4 does not appear to reflect the TOMM40 ‘Long’ allele  
The TOMM40 523 ‘Long’ allele is in significant linkage with the APOE ε4 allele (Linnertz et 
al., 2012; Chapter 2; ‘Methodology’). There is biological rationale for why variations in these 
gene loci may contribute to phenotypic differences, respectively via lipid transport and 
mitochondrial translocase processes (Hardy, 2006; Swerdlow et al., 2010). Roses et al. (2010) 
argue that significant associations between APOE ε4 and brain-related phenotypes may be 
reflective of the TOMM40 523 L allele (Roses et al., 2010). However in Chapter 7 we found a 
clear divergence where APOE ε but generally not TOMM40 523 genotype was associated 
with cognitive ageing at age 73. This suggests that APOE ε4 is not simply reflecting a causal 
role of TOMM40 523 in this sample (although note that APOE ε may simply be in linkage 
with a true ‘causal’ variant).  
 
8.6. Thesis strengths  
8.6.1. The Lothian Birth Cohort 1936 dataset 
The LBC1936 sample has childhood cognitive ability, genetic, sociodemographic, medical, 
and detailed cognitive and brain imaging information; it is rare in having the requisite data to 
examine the brain imaging substrates of genetic contributions to cognitive ageing (Salthouse, 
2010). The sample has a narrow age range (mean age = ~73 years, SD = ~0.7) and is 
relatively large for a brain imaging study which makes it more likely to be reliable compared 




genetic variation compared with cognitive ability because they are not as affected by state-
dependent variables such as fatigue (Penke et al., 2010b).  
The current sample is drawn from community-dwelling older people who are 
relatively healthy (Wardlaw et al., 2011; Deary et al., 2007; 2012). As detailed in Chapters 3 
and 6, this sample primarily consisted of community-dwelling older adults that varied in 
terms of overall health (e.g. prevalence of Stroke or Hypertension). Cardiovascular disease 
prevalence frequencies are comparable to other large studies of ageing, such as the Rotterdam 
Study of Cognitive Ageing (Vernooij et al., 2008; See Chapter 6, Table 7.3). The APOE ε and 
TOMM40 523 genotypes were both in Hardy-Weinberg equilibrium, indicating relatively 
similar frequencies to what would be predicted in a general population (see Chapter 2 for 
relevant statistics). It is worth noting, however, that the LBC1936 sample is slightly restricted 
in range, towards the upper-end of general intelligence and socio-economic status (Deary et 
al., 2012; also see below).  
 
8.7. Thesis limitations 
There are possible general- and chapter-specific limitations to the empirical chapters in this 
thesis, and these are examined here in that order.  
 
8.7.1. A lack of age-related differentiation? 
The brain imaging and cognitive phenotypes investigated here fundamentally show age-
related change (e.g. Raz et al., 2012; Wisdom et al., 2011). It is possible that the current 
sample of non-demented, generally healthy older adults, around 73 years old, have not 
undergone sufficient age-related change to show significant differentiation according to 




makes this seem unlikely: APOE genotype was significantly associated with a range 
cognitive test scores at age 73, but less so at age 70 when examined in separate reports by 
Luciano et al. (2009a; 2009b). However it may still be the case that effects of the 
APOE/TOMM40 523 gene loci are more pronounced at older ages, and this could be 
examined when cognitive/imaging data on the LBC1936 participants aged  ~76 years are 
available (i.e. when repeat longitudinal testing is completed).  
 
8.7.2. Selection bias 
Non-random selection bias occurs when a sample of participants vary from being truly 
random for a specific reason (Berk, 1983). This could be important if this reason was relevant 
to cognitive ability. Generally, the LBC1936 sample is slightly restricted in range in certain 
ways. Firstly, the sample is generally of restricted social class (mean = 2.4, SD = 0.9; 
generally ‘Managerial & Technical’ to ‘Skilled’ occupations; Deary et al., 2012). Secondly, 
the LBC1936 sample is of a relatively higher childhood intelligence (mean MHT score = 
49.0, SD = 11.8, N = 1091), compared with the general population (mean score = 36.7, SD = 
16.1; Cohens d = 0.87; ‘large effect’; Deary et al., 2012). These restrictions of range could 





8.7.3. Lack of intermediate longitudinal data 
The current study primarily examines cognitive and genetic phenotypic variables in the 
LBC1936 as assessed around age 73 (‘Wave 2’). In certain analyses, these variables are 
statistically adjusted for age 11 intelligence as assessed with the Moray House test (no.12), in 
order to better reflect ‘cognitive ageing’. This childhood intelligence measure is a rare and 
valuable piece of information, reflective of cognitive ability before the effects of age-related 
changes due to stroke, injuries etc (Deary et al., 2007).  
 APOE moderates lipid metabolism, including the development and maintenance of 
myelin (that characterizes white matter), and of neuronal membrane (Bu, 2009). This means 
that APOE could play a role in brain development from age 11 to early adulthood, and 
significant associations with cognitive ageing are at least partly reflective of this. Further 
intelligence data from around adolescence would inform this possibility. 
 
8.7.4. Correction for multiple testing 
A large number of tests of association were performed in this thesis and this increases the risk 
of type 1 error, as inherent with multiple testing. However, the association tests were 
primarily not independent because brain/cognitive variables were often statistically 
significantly inter-correlated at P < 0.05; this can make correction for multiple testing overly 
conservative (Nyholt, 2001; Williams and Haines). As such, this thesis corrected for multiple 
testing with the FDR (which is less conservative than Bonferroni correction; Benjamini and 
Hochberg, 1995), but cautiously considered nominally significant results further, with the 
caveat that many attenuated when adjusted for FDR. This was to avoid type 2 errors. These 




samples; this would help to determine the extent to which the nominally, raw significant 
results reported in this thesis are spurious, if this is the case (Williams and Haines, 2011).  
 
8.7.5. Specific MRI imaging analytic limitations 
Chapter 4 used probabilistic tractography to examine white matter tract integrity. While 
having advantages (described above), it does not allow a hypothesis-free voxelwise 
examination of white matter integrity in the entire brain. This is important because previous 
studies have reported significant deleterious effect of APOE ε4 possession in regions of the 
brain that were not assessed here, e.g. the fornix (Smith et al., 2010). This is not a critical 
limitation because it does not detract from the key conclusion that nominally significant raw 
effects were weaker and more specific that would be expected on the basis of previous, 
smaller papers (see Gold et al., 2012 for a review).  
 
8.8. Future research 
8.8.1. Instrumental variables 
This thesis reported significant effects of APOE/TOMM40 523 genotypes on some imaging 
and cognitive phenotypes but not others. APOE plays a role in moderating lipid metabolism 
which is relevant to amyloid beta plaque levels (Cramer et al., 2012). TOMM40 encodes for a 
translocase of outer-mitochondrial membrane complex, and poly-T repeat length may be 
important for TOMM40 gene expression (Bekris et al., 2011) and mitochondrial function 
(Billing et al., 2011). Associations with cognitive decline/AD may be mediated by these 
intermediate variables. Chapters 4-7 are therefore slightly limited in that it there are not 
concurrent in vivo measures of relevant intermediate variables such as amyloid-beta 




‘ΔΨm’, reflecting depolarization of transmembrane potential; Hedskog et al., 2012). These 
data would help to elucidate the instrumental mechanisms through which these gene variants 
actually affect the brain and cognitive function (Smith and Ebrahim, 2003).  
 
8.8.2. Longitudinal imaging of the LBC1936 
There are possible limitations to cross-sectional analyses of brain structure and cognitive 
ability. There is a large amount of natural inter-individual variation in healthy human brain 
morphology, and this could either artificially affect the sensitivity of detecting morphological 
differences across groups (Scahill et al., 2003). Examining within-participant longitudinal 
age-related changes in brain structure is less susceptible to natural inter-individual 
morphological variation. As a hypothetical example, two healthy older individuals may 
fundamentally have significantly differently sized subcortical volumes, but this may not in 
itself reflect any deleterious processes. A significantly greater rate of longitudinal relative 
change in older age, however, may be reflective of deleterious processes distinct from normal 
healthy age-related brain changes (Resnick et al., 2003). (Whilst most studies correct from 
general head size with intracranial volume, this is not a perfect correction for inter-individual 
variation in brain morphology; Scahill et al., 2003).  
The LBC1936 sample is currently undergoing repeat MRI scanning around age 76 
years, using an identical protocol to that at around age 73 (see Wardlaw et al., 2011). Future 
research may investigate the role of ‘risk’ genotypes on rates of age-related change in brain 







8.8.3. APOE, TOMM40 and further brain MRI phenotypes 
A number of brain imaging phenotypes were examined in this thesis, and each of these were 
considered informative or relevant for different reasons. There are other brain imaging 
phenotypes that may be important anatomical substrates of genetic associations with 
cognitive ageing.  
As an example, functional brain imaging may be an important mediating variable. 
Trachtenberg et al. (2012) examined the effects of APOE on functional connectivity with 
functional MRI, which measures regional cerebral blood flow with a metric called blood 
oxygen level dependent (BOLD). They examined 76 healthy adults (age range 32 to 55 
years). Participants encoded images of houses for a memory task, and were excluded from 
analysis if their post-scanning score was below 2 standard deviations. Controlling for age, 
gender and family history of dementia, Trachtenberg et al. found that APOE ε4 carriers 
showed significant increases in activation during the encoding task in four clusters, 
particularly in parieto-temporal brain regions (vs. the ε3/ε3 genotype; significant Z scores 
ranged from 2.3 to 4.9). This highlights that different imaging methods are required to 
elucidate the anatomical substrates of genetic contributions to cognitive ageing. Other 
research could investigate white matter integrity using different methods such as TBSS (see 





8.8.4. What else modifies the effects of APOE?  
There may be variables that moderate the effects of APOE and/or TOMM40. These could be 
genetic or environmental, and are detailed below in turn. 
Other genetic variants may partly moderate the effects of APOE or TOMM40 523. For 
example, Hamilton et al. (2011) investigated several genes that previous GWAS studies had 
suggested may contribute to AD risk (e.g. Lambert et al., 2010). Hamilton et al. examined 
their effects on cognitive ability in the LBC1936 at around 70 years of age (N= 1039) and 
LBC1921 at around age 79 years (N = 453). These genetic variants were in the APP, PS1, 
PS2, BIN1, CLU, CR1 and PICALM genes, and in the genomic region surrounding the 
BLOC1S3/EXOC3L2/MARK4 genes on chromosome 19. They conducted analyses in APOE 
ε4+ and ε4- groups. Controlling for age, gender and childhood intelligence, they tested the 
effects of specific SNPs on different cognitive abilities. They found a significant effect of the 
TRAPPC6a locus based on three SNPs with Matrix Reasoning performance in the APOE ε4- 
group, in both LBC1936 and 1921samples (SNPs rs7247764/rs28555639/rs1246041; overall 
β = -0.20, P = <0.001). They also found significant associations for haplotypes based on 
SNPs in the APP gene, with Logical Memory total scores (rs2829997/rs440666/rs2014146; β 
= 1.3, P = 0.004, and rs1783025/rs380417/rs1787438; β = 0.72, P = <0.001) in the APOE 
ε4+ group of LBC1936 only.   
 There is also evidence that important environmental variables may moderate the 
effects of APOE/TOMM40 523. For example Haan et al. (1999) examined 5888 members of 
the Cardiovascular Health Study, a sample of adults that underwent repeat cognitive testing 
on the Digit Symbol Coding task at least twice during nine years follow-up (baseline age 
range = 65-85, no means provided). Participants were genotyped for APOE ε and were also 
assessed in detail for clinical or subclinical cardiovascular disease (e.g. with blood pressure 




significant decline on the Digit Symbol Coding task (unstandardized β = -2.00, P < 0.05). 
However several cardiovascular/cerebrovascular risk factors were also associated with 
decline such as diagnosis of diabetes mellitus, or high fasting plasma glucose, 2 hour glucose 
tolerance, systolic blood pressure, or high common/internal carotid artery thickness (all P < 
0.001). They reported a significant interaction whereby individuals with low ankle arm blood 
pressure (<0.90 mmHg) and at least one APOE ε4 allele had 8.3 times greater decline that 
subjects with neither risk factor, compared with 2.94 (ε4 only) or 3.66 (low blood pressure 
only). These findings could possibly reflect the deleterious effects of APOE ε4 on brain repair 
mechanisms, resulting in a synergistically greater effect of cerebrovascular risk factors on 
cognitive change (Lee et al., 2008). Future studies could investigate the role of other 
modifying environmental variables in terms of APOE or TOMM40 in this sample.  
 
8.8.5. The biological interaction between TOMM40 and APOE 
Greater understanding is required into the biological significance of the APOE ε and 
TOMM40 poly-T repeat loci and their interaction. In one case, Bekris et al. (2011; N = 32) 
conducted functional analysis of different poly-T repeat haplotypes on reporter assay 
expression levels in SHSY5Y, HepG2 and U118 neuronal cell lines. Results indicated that 
specific TOMM40 523 haplotypes were associated with lower TOMM40 – but not APOE – 
gene expression in SHSY5Y neuronal cell lines only, indicating a role for this locus in 
TOMM40 promoter silencer/enhancer activity, but that the direction of its effect on 
expression depends on the cell type and specific haplotype content.  
Chapter 4 reported nominally significant deleterious effects of the TOMM40 523 
Short allele in specific brain MRI white matter tracts, particularly in a subgroup of 
participants with the APOE ε3/ε4 genotype. That report did not have the relevant data to 




Further study of TOMM40 poly-T repeat function and significance is therefore required in 
samples with relevant AD diagnostic (e.g. MMSE score), APOE protein/genotype, regional 
brain imaging and mitochondrial function data. For example, a study could examine 1) 
colocalization patterns between ApoE and Tomm40 proteins and/or 2) whether 
APOE/TOMM40 genotypes show significant association/interact in affecting metrics of 
mitochondrial function and morphology (similar to Hedskog et al., 2012; Amy Reeve, 
Newcastle University Institute for Ageing and Health – personal communication). 
 
8.9. Overview 
This PhD thesis investigated the effects of variation at two specific linked gene loci that have 
been associated with significantly increased risk of AD – APOE ε and the TOMM40 523 
poly-T repeat. Chapters 4-6 found significant, raw nominal deleterious independent effects of 
APOE ε4 and TOMM40 523 Short alleles on specific measures of white matter 
microstructural integrity but not hippocampal volumes, white matter lesions, or cerebral 
microbleeds. Chapter 7 showed that APOE ε but generally not TOMM40 523 was 
significantly associated with cognitive ability at age 73 adjusted for age 11 intelligence (i.e. 
cognitive ageing; Deary et al., 2004), and these associations were partially – but not 
completely - mediated by specific white matter tracts. Several findings became non-
significant when corrected for multiple testing, but this may be overly conservative when 








8.9.1. What contributions do the analyses in this PhD thesis make?  
The findings in this PhD thesis contribute a significant amount of data to the literature on 
these genetic/imaging variables in generally healthy, community dwelling older adults. In 
certain cases, no significant association was found between APOE and imaging phenotypes 
where - previously - significant associations had been reported in independent studies. (This 
applies to TOMM40 523 to a lesser extent, on which far less previous research has been 
conducted). There are several possible reasons for discrepancies. Several prior reports 
examined relatively small samples; these are less likely to be reliable and may report spurious 
results. Several studies reported wide age ranges, and failed to consider important covariates 
such as cardiovascular disease history. There were also study-specific limitations e.g. failure 
to control for general brain atrophy.  
 These findings help to elucidate the effects of the TOMM40 523 poly T repeat on 
brain imaging and cognitive phenotypes, independent of APOE ε. The significant effect of 
TOMM40 523 on white matter tract integrity - but not other imaging/cognitive phenotypes - 
suggests that TOMM40 523 genotype should be considered in future studies of APOE ε, but 
also that it is generally not as influential as APOE ε4. The finding that TOMM40 523 
significantly affected white matter tract integrity - but not cognitive ageing – also possibly 
suggests that this imaging phenotype is more sensitive to genetic effects compared with the 
other imaging phenotypes examined in this thesis - at least in this sample, around the age of 
73 years.   
 Finally, the findings in this PhD help elucidate the anatomical substrates of genetic 
associations with cognitive ageing – namely partly but not entirely via white matter tract 
integrity. This research contributes to understanding of how risk factors for AD affect 




Future research should investigate, on the basis of these findings: 1) the extent to 
which other relevant brain imaging phenotypes mediate APOE-cognitive ageing associations; 
2) the functional significance of APOE/TOMM40 loci in terms of protein colocalization and 
mitochondrial function; 3) the role of other environmental/genetic variables in moderating 
APOE/TOMM40 genetic effects.  
 
8.9.2. Conclusion 
On the basis of the available data in the LBC1936 (around the age of 73 years), the APOE ε 
and - to a lesser extent - TOMM40 523 gene loci are significant moderators of specific 
structural brain and cognitive ageing phenotypes in generally healthy, community-dwelling 
older adults. However in the case of several phenotypes such as cross-sectional hippocampal 
volume, previous independent reports may have overstated associations for various reasons. 
The genetic contributions of the APOE locus to cognitive ageing appear partially – but not 
entirely - mediated by white matter tract integrity in this sample; in this regard, future studies 
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Appendix A – Neurocharge protocol for hypertensive status 
 
----- Forwarded message from lorna.lopez@ed.ac.uk ----- 
    Date: Fri, 04 Jan 2013 14:49:01 +0000 
    From: Lorna Lopez <lorna.lopez@ed.ac.uk> 
 Subject: Re: Couple of questions 





2) John Starr advised the following for me when dealing with LBC blood pressure 
measurements 
 
LBC1936: unweighted mean of the second and third readings of sitting blood pressure, 
except for three individuals where the mean of the first and second readings were used as a 
third reading was not available 
 
In LBC1936, blood pressure was measured three times in a sitting position using the B026 
Omron 705IT monitor. 
 
LBC1921: blood pressure was measured once in a sitting position. 
 
There is also information available on which individuals are on antihypertensive medication 
as this is important to consider. "The blood pressure traits were adjusted for medication as 
suggested: For all individuals taking antihypertensive or blood pressure lowering medication, 
add [10]mmHg to the measured SBP value, and add [5]mmHg to the measured DBP value.  
For individuals not taking such medication, the imputed values are left equal to the measured 
values. " 
 
I will forward this to you. 
 
Let me know if you have any questions, 
 
Lorna 
 
